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 Legionella pneumophila is an aquatic organism capable of intracellular 
replication within a wide range of protozoan hosts and within human 
macrophages where it causes Legionnaires’ Disease.  L. pneumophila 
manipulates a variety of host cell processes by translocating, into the host cell 
cytosol, more than 300 effector proteins via the type IVB secretion system 
(T4SS).  The AnkB effector from the AA100/130b strain (AnkB-AA100) contains a 
C-terminal CaaX motif that rapidly becomes farnesylated upon translocation into 
the host cell and anchored to the cytosolic face of the Legionella-containing 
vacuole (LCV) membrane, which is essential for intracellular replication.  We 
show that a homolog of AnkB from the Paris strain (AnkB-Paris) has a frameshift 
mutation that truncates the C-terminus eliminating the CaaX motif, but creating a 
unique KNKYAP sequence that resembles a eukaryotic di-lysine ER retention 
motif (KxKxx).  AnkB-Paris localizes to the cytosolic face of the LCV membrane 
most likely through the ER retention motif.  Phylogenetic analyses indicate that 
the AnkB-Paris allele is common among environmental isolates and is positively 
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selected specifically for the di-lysine motif.  Ectopic expression of AnkB-Paris 
results in a perinuclear distribution and trans-rescues the ankB mutant of the 
AA100/130b strain for intravacuolar replication.  The trans-rescue is dependent 
on an intact di-lysine ER-retention motif, which most likely enables anchoring of 
AnkB to the ER-derived LCV membrane.  AnkB contains a N-terminal eukaryotic 
F-box domain that recruits the cellular ubiquitylation machinery by interacting 
with the host Skp1 protein resulting in decoration of the LCV with 
polyubiquitylated proteins.  Proteins targeted for ubiquitylation during infection 
are likely bound by ankyrin domains in the C-terminus of AnkB.  Based on the 
crystal structure, we identified four residues within the ankyrin domains likely 
involved in binding specific substrate proteins.  Mutation of these residues did not 
affect protein folding but resulted in loss of accumulation of ubiquitylated proteins 
around the LCV and a severe defect in intracellular replication, similar to the 
ankB null mutant.  Overall, we identified a di-lysine ER retention motif in the C-
terminus of AnkB-Paris and 4 substrate binding residues within the 3 ankyrin 
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1. History and Etiology of Legionnaires’ Disease 
 Legionnaires’ disease was first described in the aftermath of an outbreak 
of a severe pneumonia in 221 people at a convention of the American Legion in 
Philadelphia that ultimately claimed 34 lives [1, 2].  Many of the people who 
became ill had visited the Bellevue Stratford Hotel in Philadelphia, however, 
some affected individuals had merely walked passed the hotel [3].  Nevertheless, 
there was a strong association between staying at the hotel and development of 
the pneumonia.  It is apropos that the epidemic occurred on the centennial of 
Koch’s discovery of the bacterium responsible for anthrax, since the identification 
of the causative agent of Legionnaires’ disease closely followed Koch’s 
postulates.  The postulates state that to establish the cause of an infectious 
disease, the organism must be present in diseased but not healthy hosts [4].  It 
must be isolated in pure culture from diseased individuals and reproduce the 
disease when inoculated into a healthy host [4].  Finally, it must be re-isolated in 
pure culture from the diseased experimental host [4].  After an extensive 
epidemiological investigation, a small filamentous gram-negative rod was 
isolated from infected patients.  The causative agent was later identified and 
classified into the new family Legionellaceae as Legionella pneumophila [5].    
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L. pneumophila is a gram-negative, motile, non-spore-forming bacillus.  
Although the bacterium is found free-living and biofilm-associated, it primarily 
persists in freshwater environments by infecting and replicating within several 
protozoans including members of Acanthamoeba, Hartmannella, Naegleria, and 
Tetrahymena [6].  L. pneumophila has a biphasic lifecycle that alternates 
between a nonmotile replicative phase and a flagellated transmissive phase [7, 
8].   
More than 50 species and 70 serogroups in the genus have been 
described with almost 50% of the species causing disease in humans [9].  
Among the various isolates of L. pneumophila, serogroup 1 accounts for 85% of 
cases in the USA.  In Australia and New Zealand, 30% of cases of Legionnaires’ 
disease are caused by L. longbeachae, which is found mostly in soil [5].     
2. Epidemiology and Clinical Manifestations 
The worldwide incidence of Legionnaires’ disease is difficult to determine 
due to differences in awareness levels, diagnosis, and reporting throughout the 
world [10].  The data are better in countries where it is a reportable disease such 
as the USA, New Zealand, Australia, Japan, Canada, and Europe where the 
incidence ranges from 2-14 per million people [11].  L. pneumophila is thought to 
account for 2-9% of community-acquired pneumonia with most cases occurring 
during the warmer and wetter months of the year [10].  In the USA, the reported 
incidence has increased from 3.9 to 11.5 cases per million people during the 
period from 2000-2009 [12].  Still, the disease is thought to be largely 
underreported even in countries with surveillance programs.  For example, a 
 3 
 
German study of community-acquired pneumonia that utilized a standard 
protocol to rigorously diagnose Legionella pneumonia found a prevalence of 180-
360 cases per million people [10].   
Risk factors for Legionnaires’ disease include age >50 years, male 
gender, smoking, chronic lung disease, diabetes, and end-stage renal disease 
[10, 13].  Additional risk factors include immunosuppression, hematologic 
malignancies, lung cancer, and treatment with chemotherapy.  Persons infected 
with human immunodeficiency virus (HIV) may be at greater risk according to 
CDC surveillance data, however, clinical studies in HIV cohorts have failed to 
verify this [14-16].   
Clinically, L. pneumophila causes two distinct illnesses.  Pontiac fever is a 
self-limiting flu-like illness with symptoms of fever, headache, malaise, and 
myalgia [17].  This manifestation of L. pneumophila infection was first described 
in 1968 as an epidemic that occurred in a county health department building in 
Pontiac, Michigan [17].  At the time, the causative agent was not identified.  
However, after the description of Legionnaires’ disease in 1976, the cause of 
Pontiac fever was retrospectively identified as L. pneumophila.  The other clinical 
syndrome caused by L. pneumophila is the multisystem disease involving 
pneumonia known as Legionnaires’ disease, which mimics other types of 
pneumonia with fever, cough, dyspnea, headache, myalgia, and delirium [13, 18].  
The similarity to other types of pneumonia and the empiric nature of treatment for 
community-acquired pneumonia likely contribute to under-reporting of cases of 
Legionnaires’ disease.  However, gastrointestinal or neurological symptoms 
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suggest Legionella as the cause of the pneumonia [10].  Nevertheless, 
Legionnaires’ disease is difficult to distinguish clinically from other pneumonias.  
Diagnosis of Legionnaires’ disease can be achieved using several 
modalities, including culture of the organism, immunofluorescence microscopy, 
urine antigen testing, and nucleic acid based assays.  Diagnosis by culture 
remains the gold standard for diagnosis, but can suffer from low sensitivity due to 
inadequate sample collection and, potentially, poor survival of the bacteria within 
respiratory secretions [13].  Urine antigen testing is a commonly used test due to 
its ease of sample collection and fast turnaround time.  This test employs 
monoclonal antibodies to detect lipopolysaccharide (LPS) antigens shed by the 
organism [9].  The diagnostic utility of this test is limited by its ability to detect 
only serogroup 1 and by the fact that about 8% of patients do not shed LPS in 
their urine [10].  In addition, the results cannot be used in epidemiologic 
investigations that endeavor to trace the source of the contagion.  The 
community acquired pneumonia guidelines published by the Infectious Disease 
Society of America (IDSA) recommend blood and sputum cultures as well as 
urinary antigen testing for L. pneumophila and S. pneumoniae in patients with 
severe community acquired pneumonia (CAP) [19].  Ultimately, this would seem 
a prudent approach in most cases. 
The mortality rate of Legionnaires’ disease is estimated to be 10-40% with 
the number of fatalities likely decreasing.  One study found that mortality rates 
dropped from 34% to 12% between 1980-1998 [20].  This may be due to newer 
antibiotic therapies, which are the mainstay of treatment for Legionnaires’ 
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disease, or more aggressive treatment of community acquired pneumonia.  
Prompt treatment is important since delayed initiation of antibiotics may increase 
mortality associated with Legionella pneumonia [21].  The empiric antibiotic 
therapy for CAP recommended by the IDSA will be effective in patients infected 
with Legionella.  The bacteria are susceptible to macrolides including 
erythromycin and azithromycin as well as fluoroquinolones such as levofloxacin 
[13].  Legionella are naturally resistant to beta-lactam antibiotics, which is an 
important consideration, since clinicians do not always follow IDSA guidelines 
particularly in an outpatient setting.     
3. Microbial Ecology and Transmission  
Freshwater is the major habitat for L. pneumophila and the bacteria have 
been isolated from these environments throughout the world [22].  The organism 
is relatively sensitive to drying, pH extremes, and temperatures much above or 
below the preferred 25-42°C [23].  Within these aquatic environments, Legionella 
bacteria invade into, and persist within, free living protozoan hosts, including at 
least 14 species of amoebae, two species of ciliated protozoa, and a slime mold 
[13].  The intracellular environment of these hosts provides a nutrient-rich and 
sheltered environment for replication [24].  In addition to their persistence in 
natural bodies of water, Legionella bacteria can also survive and replicate in 
man-made bodies of water. 
L. pneumophila has been isolated from air conditioning systems, cooling 
towers, hot tubs, showers, and dental water lines [25-28].  Legionnaires’ disease 
outbreaks are strongly associated with these man-made aquatic environments.  
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The increased presence of man-made water systems in the latter half of the 20th 
century is what led to the initial outbreak and description of Legionnaires’ disease 
[29].  These man-made aquatic environments may provide a habitat more 
favorable to Legionella proliferation, as bacterial counts within these 
environments can exceed those found in rivers, lakes, and ponds.  Yamamoto 
and colleagues found that bacterial counts within cooling tower water samples 
correlated positively with increases in water temperature, pH, and levels of 
protozoans [30].  Several methods for disinfection of these reservoirs have been 
utilized including physical, thermal, and chemical treatments [31].  It is generally 
recommended that treatment and maintenance plans be in place for these water 
systems, however, the are no definitive recommendations [31].  When water from 
these man-made reservoirs is aerosolized, it can be inhaled by people in close 
association and cause the disease.    
4. Metabolism 
Early work using chemically defined media revealed L. pneumophila could 
only grow on amino acids and did not utilize glucose or starch [32, 33].  Pyruvate 
and α-ketoglutarate both stimulated growth, however, addition of glucose or 
starch did not impact growth rate.  George et al., found that L. pneumophila is 
auxotrophic for arginine, cysteine, isoleucine, leucine, threonine, valine, 
methionine, and phenylalanine or tyrosine [32, 34-36].  The sole sources of 
carbon and energy were serine and, to a lesser degree, threonine.  Later, it was 
determined that L. pneumophila can utilize glucose as well as glycerol for 
synthesis of histidine and mannose at certain times [37].  The bacteria have two 
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growth phases within cells, a replicative and a transmissive phase.  From the 
perspective of gene expression, these phases correspond closely with in vitro 
grown bacteria in exponential (E) and post-exponential (PE) states, respectively 
[38]. It is now appreciated that L. pneumophila alters its basic metabolism in each 
of these phases [13]. 
During its replicative phase, L. pneumophila uses serine as its major 
carbon source for amino acid and protein synthesis and also as its major energy 
source [37].  Serine is converted to pyruvate, which is then converted to acetyl-
CoA.  The acetyl-CoA can drive energy production via the tricarboxylic acid 
(TCA) cycle and also serves as a substrate for synthesis of the energy storage 
compound poly-3-hydroxybutyrate (PHB) [38, 39].  The replicative form is 
nonmotile, contains little to no PHB, and is minimally infectious [13].  As nutrients 
within the host cell are depleted, the alarmone, 3’,5’-bispyrophosphate (ppGpp), 
accumulates within the bacterial cell and causes an increase in the stationary-
phase σ factor RpoS [40].  During stationary phase, the PHB is broken down and 
used as the major source of carbon and energy [41, 42].  RpoS expression 
causes the bacteria to transition into the transmissive phase, which is 
characterized by osmotic resistance, sodium sensitivity, motility, accumulation of 
PHB granules, and high infectivity [13, 41].  These infectivity traits include egress 
from the spent host cell, extracellular survival, invasion of a new host, and 
lysosome evasion [38].  Thus, L. pneumophila is an asaccharolytic organism that 




5. Intracellular Life Cycle 
The life cycle of L. pneumophila has been described in multiple host cell 
types ranging from protozoans, including Acanthameoba castellanii, 
Hartmannella vermiformis, and Dictyostelium discoideum, to various mammalian 
cells, including mouse bone marrow-derived macrophages, human mononuclear-
derived macrophages (hMDM), HeLa, A549, and CHO-K1 cells [29].  While some 
host cell specific differences exist, most of the fundamental life cycle is the same 
in all of these eukaryotic cells [29].  Preliminary studies on entry indicated that 
the bacteria enter the host cell by coiling phagocytosis, however, they can also 
enter by traditional phagocytosis [43].  Unlike most bacteria whose phagosomes 
fuse with lysosomes, phagosomes containing Legionella do not become acidic or 
fuse with lysosomes [44].  Instead, they remodel the phagosome into a 
replicative niche called the Legionella containing vesicle (LCV) [18].  During the 
first hour, the LCV becomes surrounded by rough ER-derived vesicles and 
mitochondria [45-48].  The vacuoles acquire ER markers such as BiP, but do not 
accumulate endocytic or lysosomal markers such as LAMP-1, cathepsin D, and 
Rab5 [46, 47, 49].  Since amoebae feed on bacteria, it is likely that L. 
pneumophila evolved to become an intracellular pathogen due to selective 
pressure to avoid the lysosomal pathway.   
6. T4SS and Manipulation of Host Cell Processes 
Control over host cell processes is achieved by virtue of the type IVB 
secretion system (T4SS), which is a protein translocation machine designed to 
inject bacterial effector proteins into the host cell that modulate host cell functions 
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and promote formation of a replicative niche [29].  This virulence system was co-
discovered by two groups and is now known as the dot/icm system for defect in 
organelle trafficking or intracellular multiplication, respectively [50, 51].  This 
system is essential for L. pneumophila survival and proliferation within phagocytic 
cells as mutations that impair translocation of all T4SS effector proteins render 
the bacteria unable to replicate [52].  In addition, the system is also involved in 
bacterial entry into host cells, establishing the LCV, manipulation of various 
cellular processes, and exit from the host cell [29, 53, 54].  Host cell processes 
that are affected during an infection include vesicle trafficking, protein translation, 
apoptosis, and ubiquitination pathways [29]. 
L. pneumophila encodes at least 330 effector proteins, which is nearly 5 
times more than other intracellular pathogens including Salmonella enterica.  In 
fact, the bacterium dedicates nearly 10% of its proteome to effectors [52].  
Knocking out any single effector protein rarely results in a bacterial strain 
defective for intracellular replication.  Functional redundancy is the widely 
accepted explanation for the large number of effectors and the absence of a 
growth defect in strains lacking any one effector [55].  Evidence for this, in part, 
comes from work in the Isberg laboratory [56].  A strain lacking 5 large regions of 
the genome including 31% of the known effectors of the T4SS was not defective 
for in vitro growth and only minimally defective for growth in mouse 
macrophages.  However, deletion of just one of the regions caused reduced 
growth in amoebae.  In addition, the importance of each of the 5 regions differed 
depending on the species of amoebae that was infected.  Interestingly, deletion 
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of a region five, which contained ankB, resulted in a growth defect in vitro.  The 
strain variations observed in L. pneumophila reflect its highly plastic genome that 
has evolved to adapt to multiple host cells.  Many effectors contain eukaryotic 
protein domains and Legionella has evolved by acquiring genetic material 
through horizontal gene transfer from its host cells [57].  Therefore, the functional 
redundancy exists to expand Legionella’s host range to be a generalist pathogen 
to ensure survival in diverse hosts in the aquatic environment.     
Many effector proteins contain eukaryotic domains to facilitate 
manipulation of host cell processes [58].  These domains are mixed and matched 
in different combinations to make new effectors.  One comprehensive study of 
effectors in 38 Legionella species found 608 Legionella effector ortholog groups, 
but only seven effectors were conserved as “core effectors” and found in all 
species [59].  The authors identified numerous new effector domains as well as 
novel domain combinations.        
7. Genome Plasticity 
Members of the Legionella genus are capable of infecting protozoans in 
many freshwater environments throughout the world and they have a very broad 
host range [29].  Protozoans that serve as hosts are diverse and include 
amoeba, slime molds, and ciliates.  In response to the need to parasitize many 
different protozoa, the genome of Legionella, and L. pneumophila in particular, is 
highly plastic [60].   
An analysis of the genomes of 6 L. pneumophila strains (Paris, Lens, 
Philadelphia, Corby, Alcoy, and AA100/130b) revealed that, although the GC 
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content was consistent at 38% for all strains, there was significant heterogeneity 
among them [60].  The total size of the genomes ranged from 3.345 mega bases 
(Mb) in Lens to 3.576 Mb in Corby, while the number of genes ranged from 2980 
in Lens to 3288 in AA100/130b [60].  The number of genes specific to a given 
strain varied from 144 in Corby to 386 in AA100/130b, which translates to 
between 6 and 11% of the genes as strain specific [60].  Intriguingly, a large 
percentage of genes are dispensable for growth of the Philadelphia strain in 
bacterial culture.  Deleting 27% of all protein encoding genes from various places 
in the chromosome did not result in a growth defect in vitro [56].  Together, these 
regions represent 49% of the known Dot/Icm translocated effectors [56].  In 
addition, they had a lower GC content than the rest of the genome suggesting 
acquisition by horizontal gene transfer [56].  These data indicate that the genome 
of L. pneumophila is highly adaptable and that genome plasticity, particularly of 
the effectors, has played a major role in shaping the different strains [60]. 
In support of the idea of genome plasticity, the effector repertoires also 
differ between strains within the same species.  Cazalet et al., compared the 
genome sequences of L. pneumophila from strains Paris and Lens [61].  They 
identified 10% of Lens genes and 14% of Paris genes as strain-specific.  The 
Paris strain contains 10 eukaryotic-like genes, including several with ankyrin 
domains, that are not found in the Lens strain [61].  Likewise, the Lens strain 
contains 3 eukaryotic-like genes not found in the Paris strain [61].  This diversity 
is remarkable especially when one considers that these differences occur 
between members of the same serotype and species [61].  It is possible that this 
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plasticity exists to allow L. pneumophila to parasitize the multitude of protozoan 
hosts it may encounter and, thereby, to adapt to virtually any aquatic 
environment. 
Burstein et al., analyzed the genome sequence of 38 Legionella species, 
including L. pneumophila, and compared the repertoire of effectors contained 
within each [59].  The genome size varied significantly from 2.37 Mb in L. 
adelaidensis up to 4.82 Mb in L. santicrucis [59].  The percentage of guanine and 
cytosine nucleotides in the genome (GC content) was also highly variable and 
ranged from 36.7% to 51.1% [59].  The number of putative effector genes varied 
greatly from 52 in L. adelaidensis to 247 in L. waltersii [59].  Interestingly, the 
genome size is not necessarily predictive of the number of effectors, since 
species with very different size genomes can have similar numbers of effectors 
[59].  Their analysis identified a total of 5,885 predicted effectors among all the 
species with very little overlap and only 7 core effectors common to all [59].  
These core effectors seemed to evolve over a long period of time suggesting 
they are fundamental to Legionella pathogenesis.  The effectors unique to a 
given species also had low GC content suggestive of recent acquisition by 
horizontal gene transfer from ameobal or protozoal hosts which have a lower GC 
content than L. pneumophila [59].  L. pneumophila had the most species-specific 
effectors and the most dynamic complement of effectors [59].  This suggests that 
L. pneumophila is particularly prone to horizontal gene transfer and may explain 
why most infections in humans are due to L. pneumophila.  Overall, the genomes 
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of Legionella spp. are highly variable in relation to size and GC content, as well 
as the number of effectors and their predicted function. 
Identification of the function of individual L. pneumophila effectors using a 
genetic approach has been challenging because most single gene knock-outs do 
not result in a growth defect due to the high degree of functional redundancy 
among the effectors [62, 63].  Ghosh and colleagues describe five types of 
redundancy [62].  In molecular redundancy, two or more effectors target the 
same host protein using the same mechanism.  Target redundancy occurs when 
multiple effectors target the same host protein but by distinct molecular 
mechanisms.  In pathway redundancy, effectors alter a single host pathway but 
each target different components.  Cellular process redundancy occurs when 
multiple effectors target analogous or complementary host pathways that control 
the same host cell process.  Finally, system redundancy is where effectors target 
multiple host cell processes to accomplish a single goal.  Modulating cell death is 
an example of this type of redundancy, since L. pneumophila can alter apoptosis, 
necrosis, pyroptosis, or autophagy.  The presence of so many types of 
redundancies suggests that L. pneumophila has evolved over a long period of 
time and become highly sophisticated as an intracellular pathogen.  L. 
pneumophila has the highest rate of gain and loss of effectors among Legionella 
spp., making it particularly malleable [59].  By frequently shifting its effector 
repertoire, L. pneumophila may have had the best chance at making the jump 




8. Ankyrin Domain-Containing Proteins in L. pneumophila 
The majority of ankyrin domain-containing proteins are found in eukaryotic 
organisms where they are some of the most common protein domains.  The 
domain was first described in yeast and Drosophila but is named after the human 
protein responsible for attachment of the cytoskeleton to the plasma membrane 
[64].  Ankyrin domain proteins are involved in numerous cellular processes 
including cell-cell signaling, development, cytoskeleton anchoring, transcription, 
and cell cycle regulation [65].     
The ankyrin repeat (ANK) is a 33-residue motif that forms a helix-loop-
helix conformation and is involved in protein-protein interactions [66].  The 
helices are arranged anti-parallel with the loop projecting out to make interactions 
with adjacent loops forming a β-sheet structure [65].  This basic structure can be 
repeated from 1 to 33 domains, although most proteins contain six or fewer 
repeats [65].  Key residues that define the motif and stabilize the first α-helix 
include the TPLH sequence at positions 4 through 7.  The V/I-V-X-L/V-L-L motif 
(X is any hydrophilic amino acid) contributes to the second α-helix and stabilizes 
adjacent ANK repeats [65, 67].  The substrate binding surface of the ankyrin 
domain is composed of the β-hairpin/loop region as well as the inner short 
helices [67].  These interaction surfaces were determined from co-crystal 
structures of six ankyrin repeat proteins and determine the specificity of the 
protein-protein interaction. 
Proteins containing ANK domains are also found among bacteria, 
archaea, and many viral genomes [65].  Fifteen ank genes have been identified 
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in four sequenced L. pneumophila genomes with 11 shared among all four 
(ankB, ankC, ankD, ankF, ankG, ankh, ankl, ankJ, ankK, ankN, ankQ) [64].  
Ankyrin repeat genes in L. pneumophila were likely acquired through horizontal 
gene transfer from amoebal or protozoal hosts and appear to be novel without 
significant homology to known ank genes [57, 68].  L. pneumophila effectors 
containing ANK domains are diverse in that they can be combined with F-box 
domains, leucine-rich repeats, cysteine peptidase domains, and 
glycosyltransferase domains to name a few [59].  Eight of the 11 ANK effectors 
are translocated through the T4SS based on adenylate cyclase fusion assays 
[69].  Three of the 11 effectors, ankB, ankH, and ankJ, are essential for 
intracellular growth in human macrophages and amoebae [70, 71].  While the 
functions of AnkH and AnkJ are unknown, AnkB is responsible for recruiting 
polyubiquitylated proteins to the LCV during infection in macrophages and 
amoebae. 
9. Protein Ubiquitylation  
Ubiquitylation is a post-translational modification of proteins that involves 
the covalent attachment of the 76-amino acid ubiquitin protein.  The process 
occurs only in eukaryotic cells and is highly conserved from amoebae to 
mammals [72, 73].  Lysine residues on the target protein are the most common 
site of attachment, however, ubiquitin can also be conjugated on other residues 
including cysteine or the free α-amino group of an N-terminal residue [72].  
Additional ubiquitin molecules can be added to other residues in the substrate 
protein resulting in multi-monoubiquitylation [74-77].  In polyubiquitylation, 
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additional ubiquitin molecules are added onto the first ubiquitin molecule via one 
of seven lysines (K6, K11, K27, K29, K33, K48, and K63) creating a polymeric 
ubiquitin chain [74, 77].  Homogenous ubiquitin chains are named based on 
which K residue within ubiquitin contains the additional ubiquitin molecules [74, 
77].  The nature of the polyubiquitin linkage determines the fate of the 
ubiquitylated protein.  Typically, linkage of a single ubiquitin moiety alters protein 
localization or activity, whereas addition of multiple moieties, particularly on K48, 
targets the protein for degradation by the 26S proteasome [72, 78, 79].  In 
contrast to targeting K48-linked proteins for degradation via the proteasome, K63-
linked proteins can promote lysosomal degradation of plasma membrane 
proteins [74].  In addition, K63-linkages can promote protein-protein interactions.  
In canonical NF-κB activation, K63-linked ubiquitin chains are generated on the 
IL-1β receptor and recruit the TAK1-TAB1-TAB2/3 complex and the IKK complex, 
which allows TAK1 to phosphorylate IKK2 [80].  Ubiquitination of ribosomal 
proteins, for example, can stabilize interactions and promote translation [81].  In 
addition, K63-linked proteins can serve as a scaffold to recruit DNA repair 
enzymes and cell cycle checkpoint proteins to sites of DNA damage [82].   
Ubiquitylation is a three-step process that begins with an E1 activating 
enzyme that covalently attaches ubiquitin to itself via a high energy thioester 
linkage [72].  The activated ubiquitin is then transferred to the active site of an E2 
ubiquitin conjugating enzyme.  Finally, the E2-ubiquitin interacts with an E3 
ubiquitin ligase complex that transfers ubiquitin to a specific substrate.  E3 
ubiquitin ligases can be either HECT, RING, or RING-IBR-RING (RBR) type [83, 
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84].  RING-type E3 ligases consist of either a single U-box domain protein or as 
part of a complex, such as the SKP1-CUL1-F-box (SCF) complex [78, 83].  The 
SCF complex is composed of a RING-box 1 protein (RBX1), cullin 1 (CUL1), S-
phase kinase associated protein 1 (SKP1), and an F-box domain containing 
protein [85, 86].  The F-box domain protein also contains a protein-protein 
interaction domain such as WD40 or leucine-rich repeat (LRR) domain, which 
directs the E3 ubiquitin ligase complex to specific substrates [87].  This makes F-
box proteins modular in nature, and they contain a domain for interacting with the 
cellular ubiquitylation machinery and a domain for interacting with substrate 
proteins. 
E3 ligases of the SCF family recognize substrates by multiple 
mechanisms including by binding specific degron motifs within the targeted 
proteins, by altered protein localization, and by domain-based recognition [88, 
89].  Canonical degrons are short defined motifs in target proteins that are 
recognized by the F-box protein only after they have been phosphorylated by 
specific kinases.  For example, the FBXW1 protein binds the degron Asp-Ser-
Gly-X-X-Ser (where X is any amino acid and both Ser are phosphorylated) [88, 
90].  This provides specificity to the E3 and restricts degradation to cellular 
conditions under which the protein kinase is active.  Recognition of substrates by 
F-box proteins can be restricted to certain subcellular compartments [91].  The 
FBXL20 protein contains a CaaX motif, which undergoes isoprenylation directing 
it to membranes [92].  FBXL20 can only target its substrate protein for 
degradation when it is localized to membranes, which provides control of 
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recognition by restricting access of the E3 to its substrate [92].  Finally, F-box 
proteins can recognize substrates by binding specific domains [93].  The FBXO4 
protein binds TRF1 via an intermolecular beta sheet as opposed to a short 
degron [94].  L. pneumophila encodes multiple F-box proteins which have the 
potential to interface with host cell processes and drastically alter the 
ubiquitylation state of the cell. 
10. Manipulation of Host Ubiquitylation Pathways 
During infection of macrophages and amoebae, the LCV acquires an 
aggregate of polyubiquitinated proteins.  L. pneumophila strain Philadelphia-1 
encodes five F-box proteins including LegU1, LicA, AnkB, PpgA, and Lpg2525.  
Ensminger and Isberg characterized the E3 ubiquitin ligase activity of these 
proteins [95].  All 5 of the effectors are delivered by the T4SS during infection.  
Three of these F-box proteins (LegU1, AnkB, and LicA) associate with 
components of the host ubiquitylation machinery [95].  LegU1 and AnkB were 
shown to interact with host SKP1 and CUL1 in a manner dependent upon an 
intact F-box domain [95].  LegU1 can bind to the host protein BAT3 when 
ectopically expressed in HEK-293T cells and can direct its ubiquitylation in vitro.  
The fact that Legionella encodes multiple F-box proteins and that these proteins 
interface with the host ubiquitylation machinery, and target host proteins for 
ubiquitylation, suggests that this process should be critical for intracellular 
growth.  However, legU1, ankB, and lpg2160 were all shown to be dispensable 
for intracellular growth of the Philadelphia strain in both murine macrophages and 
amoebae [95].  In addition, a triple F-box mutant (legU1, ankB, and licA) in the 
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Philadelphia-1 strain background still accumulated polyubiquitinated proteins 
around its LCV [96].  Although this may seem to argue against the importance of 
manipulating the ubiquitylation machinery, it may simply be explained by 
functional redundancy and highlight the importance of this process for 
intracellular growth in various hosts.  If manipulating the ubiquitylation machinery 
is crucial for infection, one might expect L. pneumophila to have acquired 
multiple F-box proteins from the many hosts it has encountered over time.   
The importance of each of the F-box proteins in Legionella depends on 
the strain.  Different strains encode different compliments of F-box proteins.  For 
example, the Paris and Lens strains have three genes that encode F-box 
proteins, whereas the Philadelphia strain encodes five [97].  The F-box effector, 
AnkB, is essential for accumulation of polyubiquitinated proteins around the LCV 
during infection in some strains.  In the Paris strain, the percentage of LCVs 
associated with ubiquitin is reduced by about half in ankB mutant infected cells 
compared with WT infected cells in the macrophage-like THP-1 cell line [98].  In 
the AA100/130b strain, the percentage of LCVs surrounded by ubiquitin dropped 
from 88% in WT infected hMDMs to 30% in ankB mutant infected cells [99].  In 
both the AA100/130b and Paris strains, AnkB is essential for intracellular growth 
in macrophages (hMDMs and U937 for AA100/130b and THP-1 for Paris) and 
amoebae [71, 98].  However, AnkB is not essential in the Philadelphia strain for 
robust intracellular growth within mouse macrophages [95].  These results 
indicate that among F-box proteins, there is a high degree of functional 
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redundancy and that AnkB may make the largest contribution to manipulation of 
host ubiquitin pathways in certain strains. 
In addition to F-box proteins, L. pneumophila also utilizes several other 
means to promote ubiquitylation of proteins.  First, the LubX effector contains an 
eukaryotic U-box domain and has E3 ubiquitin ligase activity [100].  Interestingly, 
it ubiquitylates another L. pneumophila effector, SidH, and is designated as a 
metaeffector or an effector that regulates other effectors [100].  Second, the SidC 
and SdcA effectors also possess E3 ligase activity and use a mechanism that 
involves the CHD catalytic triad [101].  The targets of these proteins are 
unknown, however, they are involved in recruiting ER vesicles and 
polyubiquitylated proteins to the LCV [73].  Finally, L. pneumophila also employs 
a novel ubiquitylation strategy that uses NAD as an energy source and is 
independent of E1 and E2 enzymes [102].  An ADP-ribosyl group from NAD is 
added to a ubiquitin molecule resulting in an activated intermediate.  This 
intermediate is attacked by a Ser residue in a substrate protein resulting in the 
covalent addition of ubiquitin to the substrate through a phosophor-ribosyl 
linkage.  The SidE family of effectors contains a mono-ADP-ribosyltransferase 
(mART) motif that catalyzes the ubiquitylation of host Rab33b and Rab1 by this 
mechanism [103].  Thus, L. pneumophila utilizes diverse strategies to manipulate 
the host ubiquitylation machinery to promote its replication within eukaryotic cells. 
11. Manipulation of Host Prenylation 
Protein prenylation is a eukaryotic post-translational modification of 
proteins that facilitates anchoring to membranes [104-106].  The process 
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involves covalent attachment of either a 15 carbon farnesyl or 20 carbon 
geranylgeranyl moiety onto a conserved cysteine residue within the CaaX motif, 
where “a” is an aliphatic amino acid and “X” is any amino acid [104, 106-108].  
The first step is attachment of the farnesyl group by farnesyltransferase (FTase) 
or geranylgeranyl group by geranylgeranyltransferase (GGTase) to the cysteine 
within the CaaX motif [109].  The prenylated protein is further processed by the 
activity of the Ras-converting enzyme I (Rce1) which removes the -aaX tripeptide 
from the C-terminus [109].  Finally, the isoprenylcysteine carboxyl 
methyltransferase (Icmt) enzyme methylates the prenylated cysteine residue 
[109].  The modified protein can be anchored to the plasma membrane or other 
subcellular membranes including the LCV membrane [104, 109, 110]. 
In two studies, eleven genes encoding proteins containing a eukaryotic 
CaaX motif were identified among four L. pneumophila strains (Philadelphia, 
Paris, Lens, and Corby) with five being conserved in all 4 strains [111, 112].  
When ectopically expressed in mammalian cells, six of these displayed a plasma 
membrane localization indicative of prenylation.  When the cysteine residue 
within the CaaX motif was mutated to alanine, all the proteins redistributed to the 
cytoplasm.  In addition, the LCV accumulated prenylated proteins during infection 
in a dot/icm-dependent manner.  It is likely that these prenylated proteins are 
either dot/icm translocated effectors or host proteins recruited to the LCV in a 
dot/icm-dependent manner.  Therefore, L. pneumophila hijacks the protein 
prenylation machinery to lipidate and anchor specific CaaX motif-containing 
effectors to the surface of the LCV. 
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  There is evidence that prenylation of L. pneumophila effectors is critical 
for intracellular replication.  The AnkB effector from strain AA100/130b is a CaaX 
motif containing effector that has been characterized in more detail [110].  
Ectopically expressed AnkB localizes to the plasma membrane in a CaaX motif-
dependent manner [110].  In addition to the CaaX motif, host cell FTase activity 
is required for the membrane localization of ectopically expressed AnkB [110].  
The CaaX motif and host cell FTase activity are also required for localization of 
AnkB to the cytosolic face of the LCV membrane during infection in hMDMs and 
amoebae [110].  Importantly, farnesylation of AnkB is essential for intracellular 
replication within macrophages and amoebae as well as intrapulmonary 
proliferation in a mouse model of Legionnaires’ disease [110].  Even though 
farnesylation of AnkB is essential for its biological function, a naturally occurring 
variant of AnkB in the Paris strain (AnkB Paris) lacks this motif altogether.  This 
ankB allele contains a mutation at nucleotide 450 that truncates the C-terminus 
eliminating the CaaX motif and creating a new KNKYAP sequence.  This 
sequence matches the eukaryotic di-lysine motif consensus, KXKXX, found in 
the C-terminus of proteins, which is responsible for trafficking proteins from the 
Golgi to the ER [113-115].  This will be discussed further in chapter 2.   
12.  AnkB  
AnkB is a 172-amino acid protein that contains a eukaryotic F-box domain, 
which interacts with the host E3 SCF ubiquitin ligase complex, thus mimicking 
host F-box proteins [71, 99].  AnkB also contains three eukaryotic-like ANK 
domains, that likely bind specific substrates, and a C-terminal eukaryotic CaaX 
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motif [110].  AnkB is the only effector known to be required for intracellular 
replication in both amoeba and human cells, and in a mouse model of 
intrapulmonary proliferation [71, 98, 99, 116].  It’s importance during infection is 
strain specific, as knockouts made in the AA100/130b or Paris strain result in a 
replication defect, however, a knockout made in the Philadelphia strain does not 
[71, 95, 98].  The Philadelphia strain encodes five F-box proteins and the 
AA100/130b strain encodes two, while the Paris strain encodes three [95, 98, 
117].  Thus, it is possible that the Philadelphia strain does not depend upon AnkB 
because it contains F-box proteins that can functionally compensate for the loss 
of AnkB, while the Paris and AA100/130b strains do not.  
A model for AnkB function is shown in Figure 1.  Upon contact with a 
suitable host cell, AnkB is translocated through the T4SS into the host cell 
cytoplasm where it rapidly becomes farnesylated on its C-terminal CaaX motif 
[110, 118].  Farnesylation of AnkB confers hydrophobicity allowing it to insert into 
the cytosolic face of the LCV membrane [110].  AnkB recruits the host 
ubiquitylation machinery by binding to the Skp1 component of the host SCF E3 
ubiquitin ligase complex via its F-box domain [99].  As a result, polyubiquitinated 
proteins accumulate around the LCV during infection [119].  These proteins are 
polyubiquitylated on K48 which targets them for degradation by the 26S 
proteasome generating a high level of cellular amino acids that drives bacterial 
replication [120].     
Evidence for the role of K48-linked polyubiquitylated proteins in generating 
amino acids for intracellular growth comes from data showing that inhibition of 
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the proteasome with MG132 prevents replication of WT bacteria in hMDMs [120].  
Importantly, this defect could be completely rescued by supplementation with a 
5-fold excess of amino acids, which suggests that the sole purpose of 
manipulating the ubiquitylation machinery is to generate a surplus of free amino 
acids [120].  It was shown that AnkB has a prominent role in this process.  
Replication of the ankB mutant can be rescued by addition of a 5-fold excess of 
amino acids or by specific single amino acids such as serine and cysteine, which 
are converted by the bacteria to pyruvate that feeds the TCA cycle [120].  
Importantly, some non-essential amino acids also rescue the ankB mutant.  
Interestingly, addition of pyruvate or citrate can also rescue the ankB mutant for 
intracellular replication [120].  The fact that the ankB mutant can be rescued by 
addition of pyruvate or citrate indicates that sufficient amino acid levels are 
present within the host cell, and that higher levels of amino acids are required 
specifically as sources of energy to feed the TCA cycle [120].  RelA, an indicator 
of amino acid starvation, is upregulated in the ankB mutant during an infection 
[121].  Importantly, induction of RelA was reversed, and intracellular replication of 
the ankB mutant was rescued, by addition of a 5-fold excess of amino acids 
[120].  Overall, the ankB mutant undergoes a starvation response within 
amoebas and hMDMs, which is consistent with a nutritional role for AnkB.  These 
data indicate that the K48-linked polyubiquitylated proteins surrounding the LCV 
are assembled by AnkB and are degraded by the proteasome, which results in a 
surplus of free amino acids that are taken up by the bacteria and shunted 
through the TCA cycle to generate ATP to drive replication.    
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While AnkB seems to be a nutritional virulence factor that recruits 
polyubiquitylated proteins to the LCV in order to generate amino acids for 
replication, the specific substrates of AnkB are currently unknown and their 
identification could reveal novel roles.  It seems unlikely that AnkB would 
indiscriminately target proteins for degradation, since ankyrin domains typically 
mediate specific protein-protein interactions [66].  Identification of AnkB 
substrates could reveal that it also has a role in modulating certain host pathways 
by targeting specific proteins for degradation.  Alternatively, AnkB may target 
specific host proteins rich in amino acids for which L. pneumophila is auxotrophic 



















Fig. 1.  Model of AnkB Function.  AnkB is translocated via the Dot/Icm system 
where it rapidly becomes farnesylated by the host enzymes FTα, RCE1, and 
ICMT.  This allows it to insert into the cytosolic face of the LCV membrane where 
it interacts with the host ubiquitylation machinery and directs the K48-linked 
polyubiquitylation of specific host proteins.  These proteins are degraded by the 
proteasome into peptide fragments which are further processed into free amino 





AnkB of the AA100/130b strain (AnkB AA100) is farnesylated and inserts 
into the cytoplasmic face of the LCV membrane, a process which is essential for 
recruiting polyubiquitylated proteins to the vacuole and for full virulence of L. 
pneumophila [110].  Substitution of the farnesylated cysteine to alanine blocks 
farnesylation of AnkB and causes a loss of LCV polyubiquitin accumulation and 
results in a replication defect identical to the ankB null mutant.  Ectopic 
expression of AnkB-AA100 in HEK293T cells results in farnesylation of the 
effector which directs its localization to the plasma membrane and trans-rescues 
the ankB mutant for intracellular replication [110].   
Unlike AnkB AA100, a naturally occurring ankB allele found in the Paris 
strain (AnkB Paris) localizes to the leading edge of lamellipodium formation along 
with α-actinin [98].  The ankB Paris allele contains a mutation at nucleotide 450 
that truncates the C-terminal 18 amino acids, deletes half of the last ankyrin 
repeat, and eliminates the CaaX motif.  This frame shift mutation creates a new 
C-terminus, which resembles a eukaryotic di-lysine motif.  In eukaryotic cells, this 
motif is responsible for trafficking proteins from the Golgi to the ER [115].  
Despite lacking the farnesylation motif essential for function of AnkB AA100, 
AnkB Paris still mediates recruitment of polyubiquitylated proteins to the LCV and 
is essential for intracellular replication and virulence in a mouse model, although 
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to a lesser degree compared to strain AA100/130b [71, 98].  Therefore, AnkB 
Paris likely contains an alternative anchoring mechanism that allows it to localize 
to the ER-derived LCV membrane during infection. 
Except for a single target of AnkB Paris, the proteins ubiquitylated by 
AnkB have not been identified [98].  The primary role of decorating the LCV with 
polyubiquitylated proteins appears to be in the generation of free amino acids to 
power replication, since an ankB mutant can be rescued by a 5-fold excess of 
amino acids [120].  However, this does not exclude the possibility that AnkB may 
target specific host proteins to manipulate specific host pathways.  Identification 
of the specific proteins targeted by AnkB could provide new insights into the 
virulence mechanisms employed by L. pneumophila.   
I hypothesize, that AnkB from the Paris strain contains a eukaryotic-like di-
lysine motif that is critical for directing it to the cytoplasmic face of the ER-derived 
LCV during infection and that, once there, it binds and ubiquitylates specific host 
proteins. 
Specific Aim 1: Determine the mechanism by which AnkB Paris is anchored to 
the cytosolic face of the LCV membrane. 
Specific Aim 2: Determine the residues within the ankyrin domains of AnkB that 
are responsible for binding substrates and promoting their ubiquitylation. 
Specific Aim 3: Identify host and/or L. pneumophila substrate proteins that are 
ubiquitylated by AnkB during infection.
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MATERIALS AND METHODS 
 
Bacterial strains, cell cultures, and infections 
 
 L. pneumophila strain AA100/130b (ATCC BAA-74), its isogenic dotA and 
ankB mutants, and complemented mutants were grown on BCYE agar plates for 
3-4 days at 37⁰C prior to infection as previously described [71].  When required, 
antibiotics were used at a concentration of 50 µg/mL for kanamycin and 5 µg/mL 
for chloramphenicol.  The E. coli strain DH5α was used for cloning.  E. coli was 
grown in Luria-Bertani (LB) and antibiotics were used at a concentration of 100 
µg/mL for ampicillin and 40 µg/mL for chloramphenicol.  HEK293T cell line was 
maintained in DMEM (Gibco, Grand Island, NY) supplemented with 10% FBS.    
Purification and preparation of human monocyte-derived macrophages 
(hMDMs) was performed as previously described.  Monocytes were isolated from 
whole blood of healthy donors and then allowed to adhere to 6 well low 
adherence cell culture plates for 3 days at 37°C and 5% CO2 in RPMI 1640 
supplemented with 20% FBS.  Monocytes were then counted and re-suspended 
RPMI 1640 supplemented with 10% FBS and plated on coverslips at a density of 
2 X 105 cells per well of a 24 well cell culture plate and incubated for a further 2 
days. The cell culture media was then replaced with RPMI 1640 supplemented 
with 5% FBS for one day, and then with RPMI 1640 supplemented with 1% FBS 
for one day.  The resulting hMDMs were then used for infection. 
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All methods were carried out in accordance with relevant guidelines and 
regulations. We confirm that all experimental protocols were approved by the 
Institutional Review Board (IRB) committee (IRB# 04.0358).  We confirm that 
informed consent was obtained from all subjects, as required per our approved 
IRB protocol. 
 Infection of hMDMs was performed as previously described.  Bacteria 
were resuspended in RPMI 1640 with 10% FBS and macrophages were infected 
in triplicate for 1 hour at a multiplicity of infection (MOI) of 10.  Plates were 
centrifuged at 200 g for 5 minutes to synchronize the infection.  Infected cells 
were treated with 50 µg/mL gentamicin for 1 hour to kill extracellular bacteria.  
Following gentamicin treatment, cells were washed three times with Hank’s 
buffered saline solution (HBSS) and then RPMI containing 10% FBS was added.  
At 10 hours post infection, cells were fixed and processed for confocal 
microscopy.  Infection of HEK-293 cells was performed at an MOI of 50 for 1 
hour followed by treatment with gentamicin 50 µg/mL for 1 hour.  At 10 hours 
post infection, cells were fixed and processed for confocal microscopy.   
HEK293T cell transfection and infection 
 To create ankB-Paris and ankB-ParisK149, 151R, ankB from strain 
AA100/130b cloned into the mammalian vector p3XFlag-CMV-10 (Sigma) was 
used as a template for site directed mutagenesis by PCR.  HEK293T cells (85% 
confluent) were re-plated onto poly-L lysine treated coverslips in 24 well plates at 
a density of 5x104 cells/well.  After overnight incubation, cells were transfected 
with 0.625 µg plasmid DNA per well using 1.5 µg polyethylenimine (PEI) per well.  
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After 24 hours, cells were infected with bacteria suspended in DMEM at an MOI 
of 100 for 1 hour at 37⁰C and 5% CO2.  Plates were centrifuged at 200 g for 10 
minutes to synchronize the infection.  Extracellular bacteria were eliminated by 
treatment with gentamicin 50 µg/mL for 1 hour.  At 10 hours post infection, cells 
were fixed and processed for confocal microscopy. 
LCV AnkB localization 
To the determine localization of AnkB on the LCV surface during infection, 
post-nuclear supernatants of infected hMDMs were prepared and then 
differentially labeled as described previously [110].  Briefly, a total of 1 X 106 
hMDMs were infected with L. pneumophila at an MOI of 10 for 2h. Post nuclear 
supernatants were prepared as described previously and LCVs were allowed to 
adhere to poly-L-lysine coated glass coverslips and fixed using 4% 
paraformaldehyde [110].  To differentiate between intact LCVs and extracellular 
bacteria, the LCVs were labeled prior to permeabilization with mouse anti-
Legionella antisera (1/1000 dilution) and rabbit anti-AnkB antisera (1/200 dilution) 
for 1h. LCVs were then permeabilized with -20°C methanol and counter-labeled 
with goat anti-Legionella antisera (1/1000 dilution) for 1h to detect intact LCVs. 
The LCVs were then labeled with Alexa-Fluor conjugated secondary antibodies 
(anti-mouse 488, anti-rabbit 555 and anti-goat 647) following the manufacturers 
recommendations (Invitrogen). 
Confocal microscopy 
 Processing of infected cells for confocal microscopy was performed as we 
described previously [110].  Purification of the LCVs and their labeling prior to 
 32 
 
permeabilization to localize AnkB on the cytosolic side of the LCV membrane 
was performed as we described previously [110]. For antibody labeling, goat 
polyclonal anti-L. pneumophila was used at a dilution of 1:500 and detected by 
Alexa-Fluor 488-conjugated donkey anti-goat IgG (Invitrogen, Carlsbad, CA).  
Poly-ubiquitinated proteins were detected using mouse anti-polyubiquitin FK1 
antibody at a dilution of 1:50 (BIOMOL International/Affiniti, Exeter, United 
Kingdom), followed by Alexa-Fluor 647-conjugated goat anti-mouse IgM 
(Invitrogen, Carlsbad, CA).  For detection of 3X-Flag tagged proteins during 
transfection experiments, mouse monoclonal anti-Flag (Sigma) antibodies were 
used followed by detection with Alexa-Fluor 488-conjugated donkey anti-mouse 
(Invitrogen, Carlsbad, CA).  An Olympus FV1000 laser scanning confocal 
microscope was used to examine cells as we described previously.  On average, 
8-15 0.2 µm serial Z sections of each image were captured and stored for further 
analyses, using Adobe Photoshop CS3. 
Adenylate cyclase and Western blot analysis 
 L. pneumophila strain AA100/130b (ATCC BAA-74) or its isogenic dotA 
mutant harboring pCya-AnkB-Paris, pCya empty vector, or pCya-AnkB-Paris with 
K149R or K151R were grown on BCYE agar plates for 3-4 days at 37⁰C prior to 
infection as previously described [71].  U937 macrophages differentiated with 
PMA at 50 ng/mL were infected at MOI 50 in triplicate and plates were 
centrifuged to synchronize the infection.  After 2 hours at 37°C and 5% CO2, cells 
were washed three times with PBS and lysed by adding 250 µl of 0.1 N HCl 
containing 0.5% Triton X-100 and incubating at room temperature for 20 minutes.  
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Lysates were assayed for cAMP using the Direct Cyclic AMP Enzyme 
Immunoassay kit (Enzo Life Sciences, Inc.).  Aliquots of bacteria used for 
infection (1 x 108 bacteria) were lysed by adding SDS-PAGE loading buffer and 
boiling for 5 minutes.  Fusion protein expression was assessed by Western blot 
using anti-M45 (1:50 dilution) according to standard procedures.  Blots were re-
probed with anti-CAT (1:2000). 
PCR and Sequencing of ankB alleles 
The ankB allele was amplified with the following primers: ankB1F: 5’-
GGATCCCAAGAGATTTTTAG-3’ and ankB1R: 5’ – 
CATTTAACAAACAAGGCACT-3’ using standard PCR conditions. PCR primers 
were located in genes flanking ankB.  Briefly, 25 ng of genomic DNA was used 
as template in a 25 µL PCR reaction containing 1U of Taq polymerase (Midsci, 
St. Louis MO), 150 µM dNTPs, 20 pmol/µl of each primer with the following 
cycling parameters: 94oC-5’ – 1 cycle followed by 30 cycles of 94oC-1’, 55oC-1, 
72oC 1’ and a final 5 min extension at 72oC. DNA sequencing was performed on 
both strands at the University of Washington Sequencing Core, and the 
sequence data was assembled and edited using the DNASTAR suite (DNASTAR 
Inc., Madison, WI). 
Phylogenetic Analysis  
Maximum likelihood (ML) tree was constructed using MEGA version 6 
assuming the TN93 + G substitution model [122]. The percentage of trees in 
which the associated taxa clustered together was determined by a bootstrap 
analysis of 1000 trees. Initial tree for the heuristic search was obtained 
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automatically by applying Neighbor-Joining and BioNJ algorithms to a matrix of 
pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
approach, and then selecting the topology with superior log likelihood value. A 
discrete gamma distribution was used to model evolutionary rate differences 
among sites (5 categories (+G, parameter = 0.2388)). Nucleotide sequence data 
has been submitted to GenBank® and assigned the following accession 
numbers: KM276667-KM276681. 
Analysis of Selection Pressures   
(a) Site Models: To identify the different selective forces, i.e., negative, 
neutral or positive selection, that acted upon ankB codons during its evolutionary 
history we tested the fit of the sequence data to several codon-based models 
implemented in CODEML package of PAML ver 4.7 accessed via its GUI 
interface PAMLX1.2 essentially as described before [123-125].  In brief, we used 
site models to determine selective pressures on each ankB codon by comparing 
the differences in the likelihood score of each model’s fit to the sequence data via 
a series of likelihood ratio tests [LRTs) [123].  To verify or supplement CODEML 
outcomes, we conducted several other alternate tests including GARD (genetic 
algorithms for recombination detection)  to detect recombination among ankB 
sequences, and SLAC (single-likelihood ancestor counting), FEL (fixed effects 
likelihood), IFEL (internal fixed effects likelihood), REL (random effects 
likelihood), and MEME (mixed effects models of evolution), which can each 
detect positive and negatively selected codon in protein coding genes and can 
explicitly account and correct for recombination within sequences. All these 
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methods were accessed and their outcomes analyzed via the 
www.datamonkey.org server [126]. 
(b) Branch Site Models. To determine whether the ankB1 allele branch 
experienced positive selection in its evolutionary history we used two versions of 
the branch-site models A (M2N2) implemented in CODEML: 1) M2N2A1, which 
specifically tested for evidence of positive selection in the clade leading up to 
ankB1 and ankB8; and 2) M2N2A2, which specifically sought evidence for 
positive selection in the ankB1 branch itself. The fit of each model to the data 
was tested via LRTs with 1 degree of freedom and that measured the difference 
in the likelihood score of each model (eg., M2N2A1) with a constrained version 
whereby ω for the branch suspected to be under positive selection was fixed at 1 
(e.g. M2N2A1ωf). It has been suggested that selection of branches of interest to 
test for selection, or testing one branch at a time can sometimes lead to 
statistical instability or acceptance of poorly supported models [126].  Thus to 
confirm the outcomes of our CODEML branch site results, we performed 
supplemental analysis for detecting all branches that may have significantly 
experienced positive selection in their evolutionary history with the GA (genetic 
algorithm) branch method implemented at www.datamonkey.org. 
Infection of A549 GFP-BirA Cells and Effector Complex Isolation 
 To create pBio-ankB and pK/A-ankB, ankB from strain AA100/130b cloned 
into the pICC1544 vector described previously and transformed into WT L. 
pneumophila strain AA100/130b [127].  Bacteria were grown overnight to OD550 
of 1.5-1.7, induced for 1 hour with 1 mM IPTG, and used to infect A549 GFP-BirA 
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cells.  A549 GFP-BirA cells were maintained in G418 at a final concentration of 
800 µg/mL and plated the day before infection at 5.5-5.75 x 106 cells per plate.  
Cells were infected at MOI 50 and centrifuged for 10 minutes at 400 x g at room 
temperature before being placed into the incubator at 37°C and 5% CO2 for 2 
hours.  Plates were washed three times with 1x PBS and returned to the 
incubator for 7 hours.  At the end of the infection, plates were washed twice with 
1x PBS and cross-linked using 10 mL of 1% formaldehyde (in 1x PBS) per plate 
for 30 minutes at room temperature.  Cross-linking was quenched by addition of 
1 mL of 1.25 M glycine and 50 mM cysteine (in 1x PBS) for 15 minutes at room 
temperature.  Cells were washed three times in 1x PBS.  Plates were scraped at 
4°C in 1x PBS, centrifuged for 10 minutes at 500 x g, and stored at -80°C.  Cells 
were lysed for 30 minutes in 50 mM Na2HPO4, 150 mM NaCl, and 1% CHAPS, 
pH 7.3 using 1 mL per plate.  Cellular debris was pelleted at 20,000 x g for 20 
minutes at 4°C.  Sixty µl of equilibrated nickel resin (ThermoFisher 88221) was 
added to each sample and incubated for 2 hours at 4°C.  Resin was washed 5 
times in lysis buffer plus 20 mM imidazole and protease inhibitors.  Bound 
complexes were eluted in lysis buffer plus 250 mM imidazole three times for 10 
minutes each at 4°C with shaking.  Elutions were pooled and 50 µL of 
equilibrated streptavidin agarose (ThermoFisher 20357) was added and samples 
were incubated for 2 hours at 4°C.  Resin was washed 4 times with lysis buffer 
and 4 times with 50 mM ammonium bicarbonate (AMBIC).  Fifty µL AMBIC was 




Cloning, Protein Expression and Purification of AnkB and Skp1 
The human gene Skp1 (residues 1 to 163) was first cloned into 
pRSFDuet-1 between NdeI and AvrII restriction sites. The gene AnkB (lpg2144, 
residues 1 to 168) from Legionella pneumophila strain Philadelphia was then 
cloned into the same vector between BamHI and NotI as a N-terminal His-tagged 
fusion protein. The C-terminal ankyrin domain (residues 54 to 168) was cloned 
into pET15b as a N-terminal His-tagged fusion and pET29a as a C-terminal His-
tagged fusion. Mutagenesis was performed using the QuikChange Multi Site-
Directed Mutagenesis Kit (Agilent Technologies). All constructs were verified by 
DNA sequencing and transformed into a BL21 E. coli strain. The cells were 
grown at 37 ºC in Luria Broth (LB) to an optical density of 0.8, and expression 
was induced with 1 mM isopropyl -D-1-thiogalactopyranoside at 30 ºC for 4 
hours or 16 ºC overnight. After centrifuging the cells, the pellets were 
resuspended in buffer A (50 mM HEPES, 500 mM NaCl, 5% (w/v) glycerol, pH 
7.6), containing 1 mM phenylmethylsulfonyl fluoride and 0.1 mg/ml lysozyme, 
and lysed by sonication. Cell debris was removed by centrifugation, and the 
fusion protein was bound to Ni-NTA Agarose (Qiagen) beads, washed with buffer 
A containing 30 mM imidazole and eluted with buffer A containing 250 mM 
imidazole. The protein was further purified by size-exclusion chromatography on 
a Superdex75 column (GE Healthcare) in buffer B (10 mM HEPES, 100 mM 
NaCl, pH 7.0) before crystallization trials. The His-tag in the pET15b constructs 




For selenomethionine labeling, the plasmid was transformed into a 
methionine auxotroph, E.coli DL41 (DE3), and the cells were grown in LeMaster 
medium supplemented with selenomethionine. For 15N-labeling, the cells were 
grown in M9 minimal medium supplemented with 15N-ammonium chloride as the 
sole source of nitrogen. The expression and purification protocols were the same 
as for the native protein. 
Crystallization and Structure Determination 
Crystallization was performed by the hanging drop vapor diffusion method 
at 293K using the Classics II commercial screen (Qiagen). Native AnkB (54-168) 
concentrated to 7.6 mg/mL crystallized in a 1:1 mixture with the reservoir buffer 
(0.2 M lithium sulfate, 0.1 M HEPES pH 7.5, 25% (w/v) PEG 3350). Crystals of 
the SeMet-labeled C-terminal domain were obtained at 10 mg/mL with the 
mother liquor (0.2 M lithium sulfate, 0.1 M Bis-Tris pH 6.5, 25% (w/v) PEG 3350). 
AnkB (1-168) in complex with Skp1 was concentrated to ~ 4.5 mg/mL and 
crystals were obtained from a condition containing 0.2 M trimethylamine N-oxide, 
0.1 M Tris pH 8.5 and 20% (w/v) PEG 2000 MME.  
The ankyrin domain and complex crystals were cryoprotected with 20% 
glycerol and 20% sucrose, respectively, and flash-cooled in a N2 cold stream. X-
ray diffraction data were collected at beamlines A1 and F1 of Cornell High-
Energy Synchrotron Source (CHESS) using an ADSC Quantum 210 CCD 
detector. Data processing and scaling were performed with HKL-2000 [128]. 
The diffraction data of the ankyrin domain were phased using anomalous signal 
from selenium atoms by the single-wavelength anomalous dispersion method, 
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with the program SHELX [129]. The initial model was built with ARP/wARP and 
refined with Refmac5 [130, 131]. Full length AnkB in complex with Skp1 was 
determined by molecular replacement using Skp1 and F-box from a deposited 
SCF complex structure (PDB code 1LDK) and AnkB (54-168) as the search 
model [132]. The model was built by ARP/wARP, completed with Coot and 
improved by several cycles of refinement using Refmac5 [130, 131, 133]. Water 
molecules were added in the last stage of refinement.  
The refinement statistics are shown in Table 3. The final ankyrin domain 
and complex structures respectively have 0 and 1 outlier in the Ramachandran 
plot computed using MolProbity [134]. 
In vitro Pull-Down 
 AnkB (residues 54-168) was used as bait for the Pierce Pull-Down PolyHis 
Protein:Protein Interaction Kit (ThermoFisher 21277).  Both U937 macrophages 
and HEK293T cells were used as a source of cellular lysate in separate 
experiments.  The protocol was performed per the manufacturer’s instructions.  
Elutions were run on an SDS-PAGE gel and stained with Sypro Ruby.   
HEK293T Transfections and Co-IP 
 Cells were grown to 70% confluence and plated into T-175 flasks at 4 x 
106 cells per flask and incubated overnight.  Cells were transfected using 11 µg 
of plasmid DNA per flask with polyethylenimine as the transfection reagent 
(Polysciences) for 24 hours.  Cells were lysed in 50 mM Tris HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, and 1% Triton X-100 with protease inhibitors.  Flag-tagged or 
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HA-tagged proteins were captured using anti-Flag magnetic beads (Sigma) or 
anti-HA magnetic beads (ThermoFisher) per the manufacturer’s instructions. 
Antibodies and Western Blotting 
 Protein samples were heated to 95°C for 5 minutes in sample buffer, 
separated by SDS-PAGE and transferred to a PVDF membrane.  Anti-Flag 
(Sigma) was used at 1:1000, anti-HA (Bethyl) was used at 1:1000, and anti-AnkB 
was used at 1:30,000 in 6% non-fat milk in PBS+0.05% Tween-20 overnight at 
4°C.  Secondary anti-mouse-HRP was used at 1:50,000 and anti-rabbit-HRP was 
used at 1:100,000.  Blots were developed using chemiluminescent substrate 




IDENTIFICATION OF HOST PROTEIN TARGETS OF ANKB 
 
Results 
In vitro Pull Down 
 Identification of biologically-relevant protein interacting partners can be 
challenging, particularly in the context of proteins involved in bacterial 
pathogenesis.  Approaches include yeast 2-hybrid assays, co-
immunoprecipitations, label transfer interaction analyses, far-Western blots, and 
in vitro pull downs [135, 136].  In vitro pull downs have been successfully used to 
identify novel host interacting partners of bacterial proteins in L. pneumophila and 
Coxiella burnetii [137-139].  We chose an in vitro pull down to identify host 
proteins targeted by AnkB.  Since AnkB is an E3 ubiquitin ligase responsible for 
recruiting K48-linked polyubiquitylated proteins to the LCV, and K48-linked 
proteins are typically targeted for degradation; it is likely that proteins 
ubiquitylated by AnkB will be unstable during a natural infection.  Due to solubility 
issues, we purified a His6 tagged version of the three ankyrin domains of AnkB 
(residues 54-168) from E. coli by nickel affinity chromatography followed by size 
exclusion chromatography.  This purified version of AnkB was used as bait in an 
in vitro pull down with lysates from the U937 macrophage-like cell line or 
HEK293T cells serving as prey.  Columns were washed and interacting partners 
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were eluted.  A column without AnkB was used as a negative control.  Elutions 
were run on an SDS-PAGE gel, stained, and unique bands were excised and 
identified by mass spectrometry (MS).   
The results for both U937 and HEK293T cell lines are shown (Fig. 2).  
Each band indicated was excised from the gel along with the corresponding area 
of the control lane and proteins were identified by MS.  There were five bands 
common to both cell lines of the same apparent molecular weight (MW).  A total 
of 176 proteins were identified among these five bands (Appendices 1 and 2).  
The two to four most abundant proteins in each of the five bands found only in 
the AnkB condition were chosen for confirmatory studies using co-IP (Table 1).  
 To confirm putative AnkB binding partners, HEK293T cells co-expressing 
Flag-tagged AnkB or bacterial alkaline phosphatase (BAP) and hemagglutinin 
(HA)-tagged versions of each candidate substrate were subjected to co-IP using 
anti-Flag magnetic resin followed by Western blot using anti-HA antibodies.  
Overall, none of the 13 candidate proteins was found to interact with AnkB.  Each 
potential interacting partner either non-specifically bound to the anti-Flag resin, 
showed no binding to AnkB or the resin, or was poorly expressed.   
An example of a protein that expressed well but failed to bind either AnkB 
or BAP is also shown in Figure 3.  Expression of PYCR was apparent in both 
AnkB and BAP co-expressing cells, however to a lesser degree in the BAP 
condition.  PYCR did not co-IP with either AnkB or BAP indicating that it is not a 
true binding partner of AnkB under our experimental conditions.  Similar results 
were obtained for ANP32A, ANP32B, ANP32E, CSNK2A1, and SET (data not 
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shown).  Candidate substrates that showed low expression include DBR1, 
TACO1, and UGT8 (Fig. 4 and data not shown).  
A representative example of non-specific binding to the beads is shown in 
Figure 3.  HA-PYCRL co-precipitated with AnkB to a greater degree than with 
BAP.  However, expression of PYCRL in PYCRL/BAP co-expressing cells was 
also lower, which likely accounts for the difference in the intensity of the PYCRL 
band in the AnkB and BAP lanes.  Similar non-specific binding was also 
observed for TBL1XR1, FAM98A, and RACK1 (data not shown).  PIP4k2b 
appeared to specifically bind AnkB as shown in Figure 5a.  PIP4k2b was present 
in the AnkB but not the BAP immunoprecipitate.  However, further investigation 
revealed that PIP4k2b bound non-specifically to the anti-Flag resin to a similar 
degree when co-transfected with either p3x flag empty vector or p3x-ankB (Fig. 
5b compare AnkB/PIP4k2b to p3x/PIP4k2b).  Competition of BAP for PIP4k2b 
binding to anti-Flag resin is one possible explanation for the conflicting results 
observed when empty vector or BAP is used as a negative control.  A positive 
control co-IP using the known AnkB binding partner, Skp1, showed that Skp1 
bound specifically to AnkB under these experimental conditions (Fig. 5b).  
Overall, this indicates that PIP4k2b is not a binding partner for AnkB under our 
































Fig. 2.  In vitro Pull Down His-6 tagged AnkB (54-168) was bound to a nickel 
column and lysates from either the U937 or HEK293T cell line were passed over 
the column.  Columns were washed and eluted.  Elutions were run on an SDS-
PAGE gel and stained with SyproRuby.  Bands that appear to be common to 
both cell lines are labeled with the same number.  Control- no AnkB bound to the 









































Table 1. Candidate AnkB-Interacting Host Proteins  
 
Name Description Band 
*ANP32B Acidic leucine-rich nuclear phosphoprotein B 3 
RACK1 Receptor of activated protein kinase C 3 
ANP32A Acidic leucine-rich nuclear phosphoprotein A 4 
*SET Protein SET 4 
ANP32E Acidic leucine-rich nuclear phosphoprotein E 5 
TACO1 Translational activator of cytochrome c oxidase 5 
PYCRL Pyrroline 5-carboxylate reductase 5 
*CSNK2A1 Casein kinase II subunit alpha 5 
FAM98A Protein FAM98A 6 
*PIP4K2B Phosphatidylinositol 5-phosphate 4-kinase type 2-
beta 
6 




TBL1XR1 F-box-like/WD repeat-containing protein  8 






























Fig. 3. Co-IP of AnkB and either PYCRL or PYCR.  HEK293T cells were 
transfected with Flag-ankB or Flag-BAP and either HA-PYCR or HA-PYCRL as 
indicated.  Cell lysates were incubated with anti-Flag magnetic resin, washed, 
and eluted.  Elutions were run on SDS-PAGE gels and subjected to Western 






















Fig. 4.  Co-IP of AnkB and either UGT8 or ANP32B.  HEK293T cells were 
transfected with flag-ankB or flag-BAP (control) and either ha-ugt8 or ha-anp32b 
as indicated.  Cell lysates were incubated with anti-Flag magnetic resin and 
elutions were run on SDS-PAGE gels and subjected to Western blotting with anti-
HA antibodies.  The expected positions of HA-UGT8 and HA-ANP32B are 
indicated. 
IP: anti-Flag Lysate 




































Fig. 5.  Co-IP of AnkB and PIP4k2b.  (a) HEK293T cells were transfected with 
Flag-ankB or Flag-BAP and HA-PIP4k2b as indicated.  Lysates were incubated 
with anti-Flag magnetic beads and elutions were run on SDS-PAGE gel and 
subjected to Western blotting with anti-HA antibodies. (b) Similar to (a) except 
that an additional negative control using empty p3X flag vector and a positive 
control using HA-Skp1 were also included.  Expected positions of HA-Skp1 and 
HA-PIP4k2b are indicated. 
 
 
IP: anti-Flag Lysate 





Identification of AnkB Substrates by Two-Step Immunoprecipitation 
 The failure of the in vitro pull down to identify AnkB substrates may be due 
to various potential caveats.  E3 ubiquitin ligase substrate identification is 
challenging due to the transient and low affinity nature of E3 ligase-substrate 
interactions and the instability of the resulting ubiquitylated substrates [135, 140].  
Ensminger and colleagues successfully identified a substrate of the L. 
pneumophila F-box protein LegU1 using a two-step enrichment approach [95].  
They ectopically expressed HA-ubiquitin and 3x-flag legU1 in HEK293T cells and 
purified in tandem using anti-Flag resin followed by anti-HA resin.  The resulting 
two-step immunoprecipitate was resolved on an SDS-PAGE gel and proteins 
were identified by MS.  We employed a similar approach whereby HEK293T cells 
were transfected with 3x-flag ankB (or 3x-flag vector as a control) and HA-
ubiquitin and treated with MG132 to inhibit the proteasome.  Treating cells with 
MG132 can result in the stabilization of substrate-F-box protein complexes within 
the cell, which helps facilitate isolation of ubiquitylated substrates [140].  
Ubiquitylated AnkB substrates were purified first using anti-Flag resin followed by 
anti-HA resin.  The resulting two-step immunoprecipiate was resolved on a SDS-
PAGE gel and proteins were identified by MS.   
Three distinct bands on the gel unique to the AnkB condition were 
identified as potential substrates (Fig. 6).  The entire list of proteins identified in 
all the bands is shown in Appendix 3, while a list of proteins identified in at least 2 
of 3 replicates is shown in Table 2 (numbers indicate total spectrum counts).  
Bands 1 and 2 contained the E3 ubiquitin ligase HUWE1 as well as ubiquitin 
 49 
 
itself (Table 2 and Appendix 3).  Region 3 contained no proteins identified from at 
least 2 replicates.  Region 4 contained peptides derived from AnkB and ubiquitin 
which likely represents ubiquitylated AnkB based on the apparent molecular 
weight and the fact that ubiquitylation of AnkB has been described previously 
[141].  To confirm HUWE1 as an AnkB substrate, ha-huwe1 and 3x-flag ankB (or 
3x-flag vector as a control) were co-transfected into HEK293T cells and 
immunoprecipitated with anti-Flag magnetic beads.  The resulting 
immunoprecipitants were subjected to Western blotting using anti-HA antibodies.  
As shown in Figure 7, HA-HUWE1 expressed well but failed to bind AnkB.  Since 
HUWE1 was never detected in the control sample among any of the three 
replicates (Table 2), it is unlikely to non-specifically bind the anti-Flag resin.  As 
the confirmatory co-IP was done using fewer cells than the initial two-step 
enrichment, it is possible that the binding between AnkB and HUWE1 is transient 














































Fig. 6.  SDS-PAGE Gel of Two-Step Immunoprecipitation.  p3x-flag ankB or 
p3x vector was co-transfected with ha-ubiquitin into HEK293T cells.  AnkB was 
purified using anti-Flag resin and elutions were subjected to a second IP with 
anti-HA resin.  Elutions from anti-HA resin were ran on an SDS-PAGE gel and 
stained with Sypro Ruby.  Numbers indicate regions that were excised from the 
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Fig. 7.  Co-IP of HUWE1 and AnkB.  p3x-flag ankB or p3x vector was co-
transfected with ha-huwe1 into HEK293T cells.  AnkB was immunoprecipitated 
with anti-Flag resin.  Elutions were subjected to Western blotting with anti-HA 
antibodies.  SU indicates same µg of DNA used for co-transfection and SM 

























Table 2.  Proteins Appearing in Two or More Replicates from Two-Step 







Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 
Isoform 2 of E3 
ubiquitin-protein ligase 
HUWE1 
480 2 7 
    




Desmoglein-1 114 1 1 
 
2 4 3 
Serum albumin 69 5 
 
2 
   
Immunoglobulin heavy 




   
Band 2 
       
Isoform 2 of E3 
ubiquitin-protein ligase 
HUWE1 
480 4 4 12 




18 3 8 3 
  
1 
Desmoglein-1 114 3 5 1 
   
Band 3 
       
AnkB Legionella 
pneumophila 
18 4 6 6 
   
Ubiquitin-60S 
ribosomal protein L40 
15 3 4 3 1 1 
 
40S ribosomal protein 
S3 












AnkB Substrate Identification by Formaldehyde Cross-linking in vivo 
 As a final attempt to identify substrates of AnkB during infection, we 
modified a method previously described for identification of host protein 
substrates of L. pneumophila effectors [127, 142].  This method takes advantage 
of formaldehyde cross-linking to stabilize transient protein-protein interactions 
and uses a tandem affinity purification of cross-linked effector complexes.  The 
effector of interest is cloned into the pICC1544 plasmid which contains a tag with 
two His-6 epitopes and an E. coli biotinylation site.  L. pneumophila strains 
expressing this fusion construct are used to infect A549 GFP-BirA cells that 
express the E. coli BirA biotin ligase enzyme.  When the effector is translocated, 
it is recognized and biotinylated by the BirA ligase expressed in the host cell.  
Effector-host protein complexes are stabilized via formaldehyde cross-linking and 
purified first on nickel and then on streptavidin.  The negative control for this 
experiment contains a mutation in the biotinylation site such that it no longer 
becomes biotinylated during infection.  In this way, effector complexes containing 
bound host protein targets can be highly purified and the associated host 
proteins identified by MS. 
 AnkB was expressed well from the pICC1544 plasmid (Fig. 8).  In the 
initial experiment, 1.2 x 108 A549 GFP-BirA cells per condition were infected with 
L. pneumophila expressing pBio-ankB or pK/A-ankB (control).  A total of 115 and 
116 host proteins were identified in the Bio and K/A conditions, respectively.  
AnkB was not identified in either condition indicating that the proteins identified 
are contaminants rather than true AnkB interactors.  Samples from this 
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experiment were run on an SDS-PAGE gel and subjected to Western blotting 
with antibodies to AnkB.  As shown in Figure 9, AnkB was undetectable in 
lysates prepared from cells infected with L. pneumophila expressing either pBio-
ankB or pK/A-ankB.  However, AnkB was detected after nickel purification in both 
conditions.  Samples from the unbound fraction after streptavidin purification did 
not show the expected depletion of biotinylated AnkB, which indicates either 
most of the purified AnkB was bacterially derived or failed to become biotinylated 
upon translocation into the host cell.  Since it is possible that more infected cells 
are required for detection of AnkB by MS, a second experiment was done using 




































Fig. 8.  Expression of Bio-AnkB and K/A-AnkB.  L. pneumophila harboring 
pBio-ankB or pK/A-ankB was grown to an OD550 of 1.5 and induced with 1 mM 
IPTG for 1 hour.  1 x 108 bacteria were lysed in SDS-PAGE loading buffer and 














Fig. 9.  Purification of Cross-Linked AnkB-Host Protein Complexes.  AnkB 
complexes were purified from infected A549 GFP-BirA cells first using nickel 
resin and then streptavidin beads.  Bio indicates AnkB purified from A549 cells 
infected with L. pneumophila expressing His6-Biotin-tagged AnkB.  K/A indicates 
the negative control which lacks the biotinylation site.  His unbound indicates a 
sample taken from depleted lysate after His purification.  His E1 indicates the first 
elution from the His purification.  SA unbound indicates a sample taken from the 
material left after SA purification.  Blots were probed with anti-AnkB.
Bio-AnkB 





 AnkB is one of the few of nearly 350 L. pneumophila effectors that is 
required for robust intracellular proliferation [71].  It is an F-box protein that 
substitutes for the host F-box component of the SCF E3 ubiquitin ligase complex 
and mediates the accumulation of K48-linked polyubiquitylated proteins around 
the LCV [99, 120].  The primary purpose of this process is to generate a surplus 
of free host amino acids that drive intracellular replication [120].  AnkB may target 
proteins rich in certain amino acids for which L. pneumophila is auxotrophic, 
however, AnkB may target proteins in specific cellular pathways to modulate 
specific host processes.  The identity of the host proteins targeted by AnkB is 
currently unknown, and their identification likely provide more insight into the role 
of AnkB during infection.  We utilized three approaches to identify host proteins 
targeted for ubiquitylation by AnkB.   
Our first approach employed an in vitro pull-down using AnkB (with the F-
box deleted) as bait and cellular lysates from two different cell lines as prey.  We 
identified 13 potential interacting partners and tested each by co-IP.  None of 
these proteins was confirmed as a true specific interacting partner of AnkB.  
There are several possible explainations for the failure of this approach.  First, 
there was a high background in the in vitro pull down (Fig. 2) possibly owing to 
less than ideal washing conditions.  It is possible that true interacting partners 
were masked by high abundance contaminating proteins which were not 
adequately washed away.  Second, AnkB was recently shown to be post-
translationally modified by hydroxylation within the ankyrin domains [143].  Since 
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the AnkB protein used for the in vitro pull-down was purified from E. coli, it did not 
have this post-translational modification, which could explain why we were 
unable to identify true AnkB interacting partners.  Finally, it is possible that AnkB 
may require L. pneumophila metaeffectors, which are effectors that control the 
activity of other effectors, to properly bind and/or ubiquitylate its target proteins.  
Metaeffectors that target other L. pneumophila effectors for ubiquitylation have 
been described previously [100].   
Our second approach utilized a two-step IP in cells expressing AnkB and 
HA-ubiquitin.  Cells were treated with the proteasome inhibitor, MG132.  From 
cellular lysates, AnkB and bound HA-ubiquitin tagged substrates were 
immunoprecipitated.  In step two, the HA-ubiquitin tagged substrates were 
enriched via anti-HA affinity purification and the results were identified by MS.  
We identified several peptides for ubiquitin as well as the E3 ubiquitin ligase, 
HUWE1.  Our follow-up co-IP in cells expressing Flag-AnkB and HA-HUWE1 
failed to confirm this protein as a true interactor.  Reasons may include that AnkB 
requires specific modifications to its substrates that only occur in the context of 
an infection.  In addition, AnkB-substrate interactions may be too transient and 
low affinity to be identified in a co-IP experiment where the percentage of 
transfected cells is only 20-25%.  Finally, L. pneumophila metaeffectors may be 
required to observe interaction with or ubiquitylation of AnkB substrates.   
Our final approach was to perform the screen for AnkB targets in the 
context of an infection and stabilize protein interactions using formaldehyde 
cross-linking.  This approach also utilized a two-step enrichment strategy that 
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included a biotinylated tag to ensure only AnkB that was translocated into the 
host cell would be purified.  Despite using 2.3 x 108 infected cells, we failed to 
purify detectible amounts of AnkB and did not identify any candidate substrates.   
There are several potential explanations.  It is possible that cross-linked AnkB-
host protein complexes were insoluble under these conditions.  The time of 
infection may impact if AnkB substrates are available for detection by this 
method.  Thus, successful purification of AnkB substrates may require sampling 
at different time points during the infection.  Since AnkB substrates are K48-linked 
and targeted for degradation, their isolation and identification may require 
treating infected cells with a proteasome inhibitor.  In addition, although we 
verified that the tagged version of AnkB is expressed well, translocation 
efficiency of the tagged protein into the host cell may not be optimal.  Finally, the 
N-terminal tag on AnkB may be masked by the host SCF complex cross-linked to 
the F-box domain requiring purification under denaturing conditions. 
 There are two technical considerations that may have impacted two of the 
three approaches we utilized in our search for AnkB targets.  First, it was noted 
during the crystallization studies that AnkB is insoluble when expressed in E. coli 
without its host binding partner, Skp1.  As a result, we used the ankyrin domains 
of AnkB, which are soluble, as bait for the in vitro pull down.  It is possible that 
the entire protein and/or its interacting parter, Skp1, are needed to bind substrate 
proteins.  If this is the case, we would not have been able to detect AnkB targets 
using the in vitro pull down unless we modified our approach by using purified 
AnkB/Skp1 complex as bait.  Second, if binding of AnkB to Skp1 induces a 
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conformational change that allows AnkB to bind substrates, both the in vitro pull 
down as well as the two-step IP approach may have been affected.  Although we 
overexpressed AnkB in HEK293T cells for the two-step IP, there may not have 
been enough endogenous Skp1 protein to promote enough stable AnkB-Skp1-
target protein complexes for successful purification.  Although our first two 
approaches were subject to these limitations, our third approach, being done in 
the context of an infection, should have been unaffected by these technical 













DIVERGENT EVOLUTION OF ER RETENTION VS FARNESYLATION MOTIF-
MEDIATED ANCHORING OF THE ANKB VIRULENCE EFFECTOR TO THE 
LEGIONELLA-CONTAINING VACUOLUAR MEMBRANE1 
 
Results 
Episodic Positive Selection in ankB Evolution  
Compared to strain AA100/130b, the ankB gene of the Paris strain (ankB-
Paris) has a deletion of an adenine at position 450 (ΔA450), which resulted in a 
frame shift mutation (Fig. 10).  This has led to a truncation of the last 18 amino 
acids that included the CaaX farnesylation motif, which is essential for anchoring 
AnkB-AA100/130b into the LCV membrane, which is indispensable for its biologic 
function in decorating the LCV with polyubiquitinated proteins [110, 144].  Despite 
this frame shift mutation and deletion of the C-terminal CaaX farnesylation motif, 
AnkB-Paris is required for decoration of the LCV with polyubiquitinated proteins 
[98].  Concurrently, a unique NKYAP sequence motif is generated at amino acids 
150-154 in AnkB-Paris. To determine whether this frame shift mutation was 
unique to the Paris strain or more widespread among other Legionella isolates, 
                                                          
1 The contents of this chapter are from “Divergent evolution of Di-lysine ER retention vs. farnesylation 
motif-mediated anchoring of the AnkB virulence effector to the Legionella-containing vacuolar 
membrane”, by J.D. Perpich, et al, 2017, Sci Rep, 7(1), p. 5123. Copyright 2017 by Springer Nature. 
Reprinted with permission.  
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we examined the abundance of the ΔA450 mutation in fifty-one isolates of clinical 
(N=25) and environmental (N=26) origin. Analysis of full-length ankB sequences 
revealed 15 distinct ankB alleles (Fig. 10b; Fig. 11).  Interestingly, among the 
15ankB alleles, ankB1 (Paris strain) was the only ankB allele to harbor the 
ΔA450 mutation (Fig. 10b).  The data showed that 19 of 51 isolates (37.25%), of 
which 17 were environmental and 2 were of clinical origin, contained ankB1 allele 
(ank1/ankB-Paris).  We conclude that the ankB1/ankB-Paris allele is wide-spread 
and is predominant among environmental isolates.  To better understand the 
forces that shaped ankB evolution, in particular the maintenance and spread of 
the ankB1 allele in environmental Legionella isolates, we next analyzed the 
selective pressures acting on ankB codons and also on the ankB1 branch using 
CODEML and a variety of other methods (materials and methods). We found 
preponderance of sites that were constrained by either negative selection or 
evolved neutrally.   Comparisons of models M7 and M8 also suggested that at 
least 4 ankB codons had been subject to positive selection. However, we also 
found evidence of recombination in the ankB alignment (Fig. 12). Although the 
M7 vs M8 comparison should be robust to model violations introduced due to 
recombination, we sought additional evidence to verify positive selection using 
REL, FEL, IFEL and MEME methods (materials and methods). Each of these 
methods found significant statistical support for site-specific positive selection in 
ankB codons (data not shown). Branch site tests implemented in CODEML, and 
the GA branch test both provided statistical support for the hypotheses that the 
internal branch leading up to ankB1/ankB-Paris and its branch both had 
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experienced positive selection. Moreover, the NKYAP C-terminal motif itself was 




Fig.  10a: Molecular evolution of ankB.  Representative sequence 
chromatograms indicating the frame shift mutation at nucleotide position 450 
(ΔA) in ankB1 compared to other ankB alleles. This mutation in ankB1 alters the 
reading frame and predicts a prematurely terminated AnkB protein at residue 
154 and generation of a unique NKYAP sequence motif. Arrows mark the 






Fig. 10b. ML analysis of ankB alleles variously from clinical (in black text) and 
environmental (in red text) isolates. All alleles are indicated. Diamonds indicate 
ankB sequence from strains whose complete genomes has been determined. 
Bootstrap values are shown above the branches. The tree is drawn to scale, 








Fig. 11. Sequence polymorphism and divergence in ankB alleles. Polymorphisms unique to each ankB allele are shown. 
Site numbers for each variable position is shown in a vertical format. ankB2 allele sequence was used as a reference. This 









Fig. 12. Two recombination breakpoints were identified in ankB alignment. 
Statistical support for each breakpoint is shown. Breakpoint at position 250 was 
also significant for a Kishino Hasegawa test indicating the presence of 2 or more 






Fig. 13. ankB lineages have experienced variable selective pressures.  An 
unscaled ankB phylogeny indicating the associated selective pressures for each 
branch is shown. This GA Branch analysis indicates a 92.7% and 90.7% support 






Decoration of the LCV with Polyubiquitinated Proteins Independent of the 
ankB Genotype 
We next asked whether the altered C-terminus of AnkB variant encoded 
by ankB1 (Fig.  14a) either modified or significantly reduced the ability of AnkB1 
strains to recruit polyubiquitinated proteins to the LCV. Overall, we found 
extensive variation in the ability of 23 distinct Legionella isolates to recruit 
polyubiquitinated proteins to the LCV (Fig.  14a-14b). Specifically, among AnkB1 
strains, polyubiquitination varied from 30% to 54%. In contrast, six isolates with 
full-length ankB alleles were either similar to the ΔankB mutant or the ΔdotA 
translocation-defective mutant in their ability to recruit polyubiquitinated proteins 
to the LCV (Fig.  14a-14b). However, a comparison of environmental and clinical 
isolates revealed a modest, but statistically significant difference (Student t-test, 
P < 0.05), in their ability to recruit polyubiquitinated proteins (Fig.  15). Thus, 
while the environmental isolates seem less capable than clinical isolates to 
recruit polyubiquitinated proteins to the LCV, the ability to recruit 








Fig.  14a.  AnkB-genotype does not predict the ability to recruit 
polyubiquitinated proteins to the LCV.  Representative confocal microscopy 
images of polyubiquitinated protein recruitment to the LCV among 23 different 
isolates of L. pneumophila expressing various ankB alleles.  Percentages 
indicate the number of LCVs positive for ubiquitin.  Images in the right panel 





Fig 14b.  Distribution of percent polyubiquitin recruitment among 23 different 
isolates of L. pneumophila. Environmental isolates are shown in red and clinical 







Fig. 15. Environmental and clinical isolates showed modest, but significant, 
difference in their ability to recruit polyubiquitinated proteins. Box-plots 
show % polyubquitination (ability to recruit polyubiquitinated proteins to the LCV) 
among 10 environmental and 22 clinical isolates. Statistical significance was 
analyzed via a two tailed Mann-Whitney nonparametric test. The Z-Score was 
2.0111; the p-value is 0.04444. The critical value of U at p≤ 0.05 was 29. 
Therefore, the difference between clinical and environmental isolates is 
















0.01 < p < 0.05 
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Localization of AnkB-Paris to the LCV membrane 
Ectopic expression of AnkB-AA100/130b within amoeba and HEK293T 
cells results in farnesylation-mediated anchoring to the plasma membrane of 
both evolutionarily distinct host cells [110, 111, 144, 145].  In contrast to AnkB-
AA100/130b, AnkB-Paris ectopically expressed within A549 cells is enriched at 
the leading edge of lamellipodium formation and co-localizes with α-actinin [98]. 
Our data showed that in contrast to AnkB-AA100/130b (Fig. 16a), when AnkB-
Paris is ectopically expressed in HEK293T cells, it did not localize to the plasma 
membrane; but it exhibited a punctate appearance and a perinuclear distribution, 
which is characteristic of sub-cellular localization of the ER (Fig. 16c).  This 
perinuclear distribution is distinct from the diffuse cytosolic pattern characteristic 
of AnkB-C169A, which lacks the farnesylation motif (Fig. 16b).  Interestingly, 
mutation of both lysines within the di-lysine motif of AnkB-Paris to arginine 
(AnkB-Paris K149,151R) seemed to alter the distribution upon ectopic expression 
(Fig. 16d).  Ectopically expressed AnkB-Paris tended to localize to the 
perinuclear ER region while AnkB-ParisK149,151R tended to distribute throughout 
the cytoplasm, suggesting the loss of ER localization mediated by the ER 
retention motif (Fig. 16).  Our data clearly show a distinct sub-cellular localization 
of AnkB-Paris and AnkB-AA100/130b.   
While AnkB-AA100/130b is localized to the LCV membrane during 
infection by host-mediated farnesylation, sub-cellular location of AnkB-Paris 
during infection is not known.  Since the farnesylation motif is missing from AnkB-
Paris, we set out to determine sub-cellular localization of AnkB-Paris during 
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infection of hMDMs.  We created an identical ankB-Paris allele and introduced it 
into the isogenic ankB null mutant of strain AA100/130b to determine its potential 
anchoring to the LCV membrane despite the lack of the farnesylation motif.  At 2 
hours post-infection, the LCVs were semi-purified from infected hMDMs.  Prior to 
their permeabilization, the LCVs were labeled with anti-AnkB antibodies to detect 
AnkB on the cytosolic side of the LCV membrane, as we described previously 
[110].  Analyses by confocal microscopy showed that AnkB-AA100/130b was 
anchored to the cytosolic side of the LCV membrane of 80% of WT strain-
containing LCVs (Fig. 17a-17b).  As expected, complementation of the ankB 
mutant of strain AA100/130b with ankB-AA100/130b restored localization of 
AnkB to the LCV membrane similar to the wild type strain [110].  Interestingly, 
despite the lack of the farnesylation motif, complementation of the AA100/130b-
derived ankB mutant with the ankB-Paris allele resulted in anchoring AnkB-Paris 
to the LCV membrane, similar to AnkB-AA100/130b.  Therefore, despite lacking 
the farnesylation motif, which is indispensable for anchoring AnkB-AA00/130b to 
the ER-derived LCV membrane, AnkB-Paris is also anchored to the LCV 











Fig. 16.  Ectopically expressed AnkB-Paris localizes to the cytoplasm with a 
perinuclear distribution.  a-d. Localization of AnkB-AA100, AnkB-Paris, AnkB-
Paris K149,151R, and AnkB-C169A in HEK293T cells transiently transfected with 
3X Flag-tagged versions of each and stained with anti-flag antibodies and DAPI.  







Fig. 17a.  AnkB-Paris localizes to the LCV during infection.  Macrophages 
infected with WT L. pneumophila AA100/130b, ankB mutant, or the ankB mutant 
complemented with either ankB from AA100/130b or ankB from Paris strain were 
fixed at 2 hours post-infection and stained with antibodies to AnkB and Legionella 
(Lpn).  The percentage of bacteria staining positive for AnkB (mean ±1SD) was 
determined by analysis of 100 infected cells in triplicate.  Data are representative 










Fig. 17b.  AnkB-Paris localizes to the LCV during infection.  Representative 
confocal images of LCVs isolated from macrophages infected with the indicated 
strains. To differentiate between intact LCVs and extracellular bacteria, the LCVs 
were labeled prior to permeabilization with mouse anti-Lpn antisera and rabbit 
anti-AnkB antisera for 1h. LCVs were then permeabilized with -20°C methanol 
and counter-labeled with goat anti-Lpn antisera to detect intact LCVs.     
Abbreviations: ankB- (ankB null mutant in AA100/130b strain), dotA (dotA null 
mutant in AA100/130b strain), WT (wild type AA100/130b strain).  Plasmids 







Functional substitution of AnkB-AA100/130b by AnkB-Paris 
Compared to AnkB-AA100/130b, the AnkB-Paris has a truncation of the 
last 18 amino acids.  The crystal structure of AnkB indicates that the C-terminal 
truncation of AnkB-Paris eliminates a large portion of the third ankyrin repeat 
compared to AnkB-AA100/130b (Fig. 18) [146].  To determine if AnkB-Paris can 
functionally substitute for AnkB-AA100/130b strain, we complemented the ankB 
null mutant of the AA100/130b strain with the ankB-Paris allele and assessed 
intracellular replication and decoration of the LCV with polyubiquitinated proteins 
within human monocytes-derived macrophages (hMDMs) [110, 144]. We 
assessed polyubiquitination of the vacuole at 2 hours post-infection by confocal 
microscopy.  The data showed that 20% of ankB mutant-containing LCVs were 
decorated with polyubiquitinated proteins (Fig.  19a). In contrast, approximately 
75% of strain AA100/130b-containing LCVs were decorated with 
polyubiquitinated proteins.  Despite truncation of the third ankyrin domain, the 
ankB-Paris allele fully complemented the AA100/130b isogenic ankB null mutant 
for accumulation of polyubiquitinated proteins, similar to the wild type strain.   
We assessed the ability of AnkB-Paris to restore intracellular replication of 
the ankB mutant of strain AA100/130b by determination of the frequency of 
formation of replicative vacuoles at 10 hours post-infection, by confocal 
microscopy (Fig. 19b).  The majority of cells infected with the ankB mutant 
contained a single bacterium.  In contrast, the majority of cells infected with WT 
bacteria contained 2-4 bacteria per cell and >20% of the LCVs harbored more 
than 5 bacteria per cell.  Similarly, the ankB mutant complemented with the 
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ankB-Paris allele formed replicative vacuoles at a frequency similar to the WT 
strain (Fig. 19b).  Taken together, these results indicate that AnkB-Paris is 
functionally equivalent to AnkB-AA100/130b in its ability to decorate the LCV with 










































Fig. 18.  The crystal structure of AnkB.  a.  The structure of AnkB from the 
Philadelphia strain spanning from Lys2 to Ala168 [146].  The F-box domain near 
the N-terminus is indicated.  Three ankyrin repeats are present rather than the 
predicted two repeats based on the sequence (yellow, cyan, and magenta).  b.  
Predicted structure of AnkB-Paris, which maintains all three ankyrin repeats by 


























Fig. 19.  AnkB-Paris complements the ankB mutant of strain AA100/130b.  a.  Co-localization of polyubiquitinated 
proteins with the LCV at 2 hours post-infection of hMDMs.  Macrophages were infected with either wild type L. 
pneumophila strain AA100/130b, its isogenic ankB or dotA mutant, or the ankB mutant complemented with ankB-Paris or 
ankB-AA100.  Numbers indicate the percentage of LCVs (±1SD) that co-localize with polyubiquitinated proteins.  The data 
are based on analysis of 100 infected cells performed in triplicate and are representative of three independent 
experiments.  b.  At 10 hours post-infection hMDMs were fixed, stained with anti-Lpn, and analyzed by confocal 
microscopy.  The number of bacteria per cell was determined and the data are based on analysis of 100 infected cells 
(mean ±1SD) performed in triplicate and are representative of three independent experiments.  *p<0.05, **p<0.01, 
***p<0.001 compared to corresponding value for ankB null mutant.   
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An indispensable role for the C-terminal Di-lysine Motif of AnkB-Paris in 
biological function  
The C-terminal 5 residues of AnkB strain Paris (K149NK151YAP) resemble 
a eukaryotic di-lysine motif (KxKxx) responsible for ER-to-golgi retrograde protein 
trafficking and retention in the ER [113-115, 147]. The AnkB-AA100/130b is 
anchored to the LCV membrane by host-mediated farnesylation, which is 
essential for biological function.  Therefore, we tested the hypotheses that the 
generated di-lysine ER-retention motif is also required for biological function of 
AnkB-Paris.  We constructed single and double substitutions of lysine149 and 
lysine151 in the ankB-Paris allele with arginine.  Since L. pneumophila effectors 
often have Dot/Icm translocation signals encoded in their C-terminus, we tested 
the ER retention motif AnkB-ParisK149R and AnkB-ParisK151R substitution mutants 
for Dot/Icm-mediated translocation using an adenylate cyclase reporter assay, as 
we described previously [71, 99, 110].  The cya reporter fusions of ankB-Paris, 
ankB-ParisK149R, or ankB-ParisK151R were transformed into either the WT strain 
AA100/130b or its isogenic translocation-deficient dotA mutant.  After 2 hours of 
infection, cells were lysed and cAMP levels were determined via ELISA (Fig. 
20a-20b).  Cells infected with WT bacteria expressing the Cya-AnkB-Paris 
reporter fusion showed robust cAMP production compared to cells infected with 
dotA mutant bacteria expressing the same reporter fusion or cells infected with 
the WT strain expressing the catalytic domain of Cya alone.  This indicates that 
AnkB-Paris is translocated by the AA100/130b strain.  In contrast, substitution of 
either K149 or K151 completely abolished translocation of AnkB-Paris.  These 
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results indicate that the two lysine residues in the putative di-lysine ER-retention 
motif are essential for translocation of AnkB-Paris during infection. 
In eukaryotic cells, the di-lysine motif is recognized by the coatomer 
complex (COPI).  Coatomer is a multiprotein complex composed of two 
subcomplexes that include a trimer of α-COP, β’-COP, and ε-COP and a 
tetramer composed of β-COP, γ-COP, δ-COP, and ζ-COP [148].  The α-COP 
and β’-COP subunits of coatomer are responsible for binding di-lysine motifs.  
We tested for a physical interaction between AnkB-Paris and α-COP or β’-COP 
in vivo by Co-IP but were unable to detect any interaction.  It is possible that 
overexpression of multiple members of the COPI complex is required to detect a 




























Figure 20.  The putative di-lysine motif in the C-terminus of AnkB-Paris is 
essential for translocation by the Dot/Icm system.  a.  Translocation of AnkB-
Paris into U937 cells at 2 hours post-infection by WT or dotA mutant bacteria 
expressing either Cya (negative control) or the indicated Cya::AnkB-Paris 
fusions.  Data represent the mean cAMP concentration of 3 wells (±1SD).  
*p<0.005 compared to dotA harboring Cya::AnkB-Paris. b.  Proteins derived from 
1 x 108 bacteria were loaded onto an SDS-PAGE gel and expression of fusion 
constructs was detected by Western blot using an antibody to the M45 epitope 
present in all Cya fusions.  Blots were re-probed with anti-CAT antibodies.  Lanes 
1: WT Cya, 2: dotA Cya-AnkB-Paris K151R, 3: WT Cya-AnkB-Paris K151R, 4: dotA 
Cya-AnkB-Paris K149R, 5: WT Cya-AnkB-Paris K149R, 6: dotA Cya-AnkB-Paris, 7: 

















The Putative Di-lysine Motif of AnkB-Paris is Required for in-trans Rescue 
of the ankB Mutant 
 Since AnkB-ParisK149R and AnkB-ParisK151R are not translocated by the 
Dot/Icm system, we could not test the potential effect of these mutations on 
intracellular growth or decoration of the LCV with polyubiquitinated proteins.  We 
have previously shown that the ankB null mutant of strain AA100/130b is rescued 
for intra-vacuolar growth within HEK293T ectopically expressing AnkB but not by 
the farnesylation-defective AnkB variant that has a substitution of the cysteine 
within the C-terminal CaaX farnesylation motif [110].  This is due to the ability of 
ectopically expressed AnkB to be farnesylated and anchored to the cytosolic side 
of the plasma membrane where polyubiquitinated proteins are assembled, while 
the farnesylation defective variant of AnkB is defective.  Since this approach 
bypasses the need for translocation, we transfected 3X Flag-tagged versions of 
AnkB-Paris, AnkB-ParisK149R and AnkB-ParisK151R or 3X Flag vector control into 
HEK293T cells and then infected with the ankB mutants.  At 10 hours post-
infection, cells were fixed and examined for formation of replicative vacuoles 
using confocal microscopy.  Our data showed that replication of the ankB mutant 
was efficiently trans-rescued by ectopically-expressed AnkB-Paris compared to 
the vector control (Fig. 21a-21b).  In contrast, replication of the ankB mutant was 
not rescued in cells ectopically expressing AnkB-ParisK149R, AnkB-ParisK151R, or 
AnkB-ParisK149,151R substitution mutants.   Ectopically expressed was localized to 
the perinuclear ER region while the AnkB-ParisK149,151R was distributed 
throughout the cytoplasm (Fig. 16c-16d).  These data indicate that the putative 
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di-lysine ER-retention motif is indispensable for function of AnkB-Paris; likely 









































Figure 21.  Requirement of the putative di-lysine motif in the C-terminus of 
ectopically expressed AnkB-Paris for trans-rescue of the ankB mutant.  a.  
HEK293T cells were first transfected with plasmids encoding 3X-Flag empty 
vector, 3X-Flag AnkB-Paris, 3X-Flag AnkB-Paris K149, 151R, 3X-Flag AnkB-Paris 
K149R, or 3X-Flag AnkB-Paris K151R and then infected with the ankB mutant.  
Intracellular replication was analyzed at 10 hours post infection by confocal 
microscopy. The results are based on examination of 50 infected/transfected 
cells using three biological replicates.  The mean number of bacteria per 
transfected HEK293T cell is shown.  Error bars represent 1 standard deviation.  
*p<0.01 compared to cells transfected with empty vector.  b.  Representative 
confocal microscopy images of cells infected with the ankB mutant and 
expressing the indicated 3X Flag-ankB fusion.  Anti-flag staining is shown in 





Among the more than 300 confirmed and predicted effectors of L. 
pneumophila, very few of them are required for intracellular proliferation and 
AnkB is one the effectors indispensable for intracellular proliferation [59].  These 
have been an emerging common theme of variations in the number of effectors 
and their paralogues among various strains and phenotypic differences between 
various strains associated with these differences [59, 149].  Loss of the AnkB 
AA100/130b effector results in a more severe intracellular defect in macrophage 
and amoeba and in vivo compared to AnkB-Paris, despite the observations that 
both function similarly in decorating the LCV with polyubiquitinated proteins [71, 
98, 99].  Although host proteasomal degradation is essential for intracellular 
replication of the Philadelphia-derived Lp02 strain, its AnkB homologue does not 
contribute to decoration of the LCV with polyubiquitinated proteins or intracellular 
replication [95, 150].  This suggests that other F-box proteins or ubiquitin ligases, 
such as SidE and LubX, are involved in decorating the LCV with 
polyubiquitinated proteins [103, 151-153].  It is also becoming clear that L. 
pneumophila translocate deubiquitinases that remove ubiquitin from the modified 
protein, and variation in translocated deubiquitinases between various L. 
pneumophila isolates is likely to be a contributing factor for differences between 
them in polyubiquitination of the vacuoles and the effectors and metaeffectors 
(effectors of effectors) involved [152].  Whether metaeffectors of AnkB varies 
between various isolates is not known.  In addition, modification of AnkB by K11-
linked polyubiquitination and by asparagine hydroxylation has been shown for 
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AnkB-AA100 but it is not known how that differs between isolates [141, 143]. 
Considering the phenotypic differences between isolates as a consequence of 
the loss of AnkB and the structural differences in AnkB between the two 
characterized strains Paris and AA100/130b, it is important to decipher the 
biological bases of these differences for one of the very few effectors required for 
intracellular proliferation of L. pneumophila.    
Despite the frame shift mutation and deletion of the C-terminal CaaX 
farnesylation motif, AnkB-Paris (AnkB1) is required for decoration of the LCV with 
polyubiquitinated proteins [98]. Concurrently, a unique NKYAP sequence ER 
retention motif is generated at amino acids 150-154 of AnkB-Paris.  The crystal 
structure of AnkB indicates that the third ankyrin repeat is truncated in AnkB-
Paris [146].  Each ankyrin repeat domain is composed of two α-helices 
connected by a β-loop where the substrate binding domain is located [64]. Our 
phylogenetic data show that the ankB1 allele is predominant among 
environmental isolates.  Statistical support for positive selection in ankB codons 
and lineages, and variable effects of ankB genotype on recruitment of 
polyubiquitinated proteins suggest that AnkB may be functionally pleiotropic and 
may engage diverse cellular pathways triggered by various strains to ensure 
survival during intracellular residency.  Other possibilities include differential 
regulation of ankB in different isolates; read through of the stop codon (encoding 
a modified aa in place of stop codon) resulting in a full-length functional AnkB 
similar to AnkB-AA100/130b.  We conclude that positive selection acts on few 
ankB codons; that the ankB1 allele itself is maintained in natural populations by 
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positive selection specifically on the NKYAP ER retention motif; and that the 
relatively high frequency of the ankB1 allele in environmental isolates likely 
reflects a functionally advantageous trait conferred by the ankB1 allele.  The 
selective advantage to harbor the ankB1 allele among environmental isolates of 
L. pneumophila could be due to a more efficient anchoring to the LCV membrane 
through the di-lysine ER retention motif compared to farnesylation in some 
unicellular hosts and/ or the third ankyrin domain that is truncated in AnkB1 does 
not interact with host targets in environmental host but interacts with a specific 
human target.  It is also possible that other effectors expressed by various strains 
may compensate for the loss of the third ankyrin domain in the ankB-Paris allele.  
Identification of the AnkB-interacting targets and their interacting domains in 
AnkB should facilitate deciphering these possibilities. 
Despite the lack of the farnesylation motif, AnkB-Paris is anchored to the 
cytosolic side of the LCV membrane.  However, substitutions of the di-lysine ER 
retention motif results in failure to translocate the effector. This indicates an 
overlap in the signal for membrane anchoring and Dot/Icm-mediated 
translocation of the AnkB-Paris effector.  Unfortunately, it is not possible to 
determine whether the di-lysine ER retention motif of AnkB-Paris was 
responsible for localization to the ER-derived LCV membrane, since the di-lysine 
ER-retention motif substitution in AnkB-Paris resulted in loss of translocation by 
the Dot/Icm system.  In addition, the perinuclear ER-like distribution of 
ectopically-expressed AnkB-Paris is lost upon alternation of the di-lysine ER 
retention motif.  Importantly, the trans-rescue of the ankB mutant within cells 
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ectopically expressing AnkB-Paris and the failure of the ER retention di-lysine 
mutant in trans-rescue clearly shows that the ER retention di-lysine motif is 
essential for the function of AnkB-Paris.  This may not be surprising, since 
substitution of the cysteine within the CaaX farnesylation motif AnkB-AA100 
results in a total loss of function of the effector in trans-rescue of the ankB mutant 
for intra-vacuolar proliferation [110].  We conclude that anchoring of AnkB 
variants to host membranes is essential for function, regardless of the 





STRUCTURAL MIMICRY BY A BACTERIAL F-BOX EFFECTOR HIJACKS THE 
HOST UBIQUITIN-PROTEASOME SYSTEM2 
 
Results 
Structure of AnkB/Skp1 
 The structure of the AnkB effector was determined in complex with its host 
partner, Skp1. It contains one molecule in the asymmetric unit with interpretable 
electron density for Pro2-Cys160 of Skp1 and Lys2-Ala165 of AnkB. The 
structure of AnkB resembles a step stool, with the F-box clasped into a groove 
formed by helices 5 – 8 of Skp1, and the ankyrin domain forming the next step 
(Fig. 23a). The F-box adopts a typical fold, with three α-helices in a right-handed 
superhelical organization. An overlay of the F-box of AnkB with other F-boxes 
reveals high similarity – an RMSD of 0.7 Å over 33 C atoms with a Skp1-Skp2 
complex (PDB code 1FQV) (Fig. 23b) [85].  We also solved the structure of the 
isolated ankyrin domain (residues 54 to 168) to close to 1 Å resolution. The 
                                                          
2 The work in this chapter was done in collaboration with Kathy Wong, Guennadi Kozlov, Miroslaw Cygler, 
and Kalle Gehring.  They solved the crystal structure of AnkB.  My contribution was the design, 
performance, and analysis of the experiments in figures 25 and 26, as well as the writing and editing of 
the manuscript.  The contents of this chapter are from “Structural Mimicry by a Bacterial F Box Effector 
Hijacks the Host Ubiquitin-Proteasome System”, by K. Wong, et al, 2017, Structure, 25(2), p. 376-383.  
Copyright 2017 by Elsevier Ltd.  Reprinted with permission. 
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domain is composed of three ankyrin repeats – one more than originally 
predicted – a short middle repeat (Pro97 to Lys116) flanked by two longer 
repeats (Ile54 to Lys81 and Pro131 to Glu161). Each repeat adopts a helix-turn-
helix fold with connecting loops forming an L-shaped interaction surface typical of 
other ankyrin repeats (Fig. 22b and 23a) [154].  The majority of ankyrin domains 
contain four to seven repeats, while up to 34 repeats have been reported [155].  
The largest sequence differences generally occur in the loop regions and confer 



















































Fig. 22. Domain organization of AnkB a. AnkB is composed of two domains: 
an F-box (pink) and ankyrin repeats (green). b. Sequence alignment of AnkB with 
human proteins containing an F-box [EAW49753.1] and ankyrin repeats 
[AAH11608.2]. The secondary structure elements and important residues in 
AnkB are highlighted: cyan, hydrogen bonds with Skp1; gray, hydrophobic 
interactions with Skp1; yellow, putative substrate binding residues in ankyrin 























Fig. 23. Structure of AnkB as a component of the E3 ubiquitin ligase complex.  a.  Co-crystal of AnkB (pink, F-box; 
green, ankyrin repeats) and Skp1 (cyan). Hydrogen bonds between AnkB and human Skp1 are highlighted. Residues 
involved in the hydrophobic interaction surface between Skp1 and F-box are labeled. In addition to the four AnkB residues 
involved, Pro10 is also shown. Leu9 and Pro10 are highly conserved between F-boxes and abolish binding when mutated 
to alanine [99].  Skp1 secondary structure elements are labeled: H, alpha-helix; S, beta-sheet. AnkB secondary structure 
elements are labeled: α, alpha-helix. b. Comparison of AnkB (pink) and the human F-box protein Skp2 (blue) binding to 




Table 3: Data collection and refinement statistics for AnkB  
Data collection 54-168 1-168/Skp1(1-163) 
Space group C2221 P212121 
Cell dimensions   
a, b, c (Å) 54.32, 80.49, 54.08 53.58, 57.04, 150.90 
α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 50-1.15 (1.17-1.15)1 50-2.85 (2.90-2.85) 
Rsym 0.104 (0.435) 0.113 (0.622) 
I / I 22.3 (3.8) 48.5 (6.42) 
Completeness (%) 98.6 (97.9) 100 (100) 
Redundancy 3.6 (3.6) 14.2 (14.5) 
Refinement   
Resolution (Å) 45.0-1.15 75.45-2.85 
No. reflections 39731 10735 
Rwork / Rfree 0.173/0.191 0.219/0.275 
No. atoms   
Protein 941 2498 
B-factors   
Protein 12.79 40.40 
Water 24.50 48.74 
R.m.s deviations   
Bond lengths (Å) 0.016 0.008 
Bond angles () 1.697 1.253 
Ramachandran statistics (%)   
Most favored regions 100.0 95.7 
Additional allowed regions 0.0 4.3 
1Highest resolution shell is shown in parentheses. 
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Structural basis of AnkB-Skp1 binding 
Full-length AnkB was insoluble when expressed without Skp1. The 
structure of the complex explains this phenomenon as the F-box is unlikely to 
fold without Skp1. A large hydrophobic surface formed by the N-terminal tail and 
helices 1 and 2 of AnkB interacts with helices 5, 6, and 7 of Skp1 (Fig. 23a). 
Multiple hydrogen bonds with helix 7 and its surrounding loops of Skp1 also 
stabilize the interaction. AnkB is insoluble without Skp1 to shield the hydrophobic 
surfaces and provide polar contacts. 
A previous mutagenesis study showed that a mutation in the AnkB F-box 
domain leads to a defect in intracellular bacterial proliferation [99].  The L9A 
P10A mutant is unable to interact with host Skp1 and fails to decorate the LCV 
with polyubiquitinated proteins, a crucial source of carbon and energy for 
intracellular proliferation [99].  The leucine forms part of the hydrophobic 
interaction surface with Skp1, while the proline is responsible for initiating the first 
F-box α-helix (Fig. 23a). Both residues are highly conserved among F-box 
domains and their mutation to alanine likely prevents proper folding of the AnkB 
F-box domain [156].  
Identification of the substrate-binding site on AnkB 
We observed unusually well-ordered crystal contacts between the C-
terminal tail of AnkB and the ankyrin domain of another molecule (Fig. 24a). The 
contacts also occurred in the crystals of the AnkB-Skp1 complex that adopt a 
different space group (data not shown). In the ankyrin domain crystal, a total of 
nine hydrogen bonds are formed between the backbone of the C-terminal tail, 
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Q160EEKI, and the putative AnkB substrate-binding site. Additional side chain 
polar contacts contribute to the structuring of the peptide in the groove formed by 
the first two ankyrin repeats.  
To validate the identification of the substrate-binding site, we 15N-labeled 
the ankyrin domain and acquired NMR 15N-1H correlation spectra following a 
stepwise addition of peptides. Titrations of the ankyrin domain with a 
pentapeptide QEEKI derived from the AnkB C-terminus, resulted in several 
chemical shift changes, indicating weak but significant binding. We also tested 
the effects of N-terminal acetylation and C-terminal amidation and single amino 
acid substitutions to alanine but these had no significant impact on binding. 
Titration with a second peptide, PRLPTL, which binds to the ankyrin domain of 
ANKRA2 showed smaller shifts suggestive of weaker binding (Fig. 24b) [157]. 
Residues within the ankyrin domain of AnkB are essential for recruitment 
of polyubiquitinated proteins to the LCV 
We selected four residues for mutagenesis that are predicted to be 
involved in substrate binding based on the AnkB crystal structure. Tyr91, Leu93 
and Tyr127 form a hydrogen-bonding network connecting and stabilizing the loop 
residues. We also observed Leu134, located on the first helix of the last ankyrin 
repeat, is solvent exposed and potentially provides hydrophobic interactions with 
substrates.  
To validate our structural prediction that Tyr91, Leu93, Tyr127 and Leu134 
are important in the biological function of AnkB during infection, the residues 
were substituted with lysine. To verify that the lysine mutants were still correctly 
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folded, we acquired 1D NMR spectra of the mutants and wild-type ankyrin 
domain. The mutant spectra are similar to that of the native domain, indicating 
proper folding (data not shown). Human monocytes-derived macrophages 
(hMDM) were then infected with the wild-type strain (AA100/130b), the ankB null 
mutant, or the ankB mutant complemented with either a wild-type copy of ankB 
or one of the ankB mutant constructs. At 2 hours post-infection, the function of 
the AnkB variants was evaluated by assessment of recruitment of 
polyubiquitinated proteins using confocal microscopy. The data showed that 
approximately 55% of the LCVs of the wild-type strain-infected cells stained 
positively for polyubiquitin, whereas only 25% of the LCVs harboring the ankB 
null mutant were positive. Complementing the ankB mutant with a wild-type copy 
of ankB fully restored recruitment of polyubiquitinated proteins to the LCV with 
approximately 53% of the LCVs staining positively (Fig. 25a). The single lysine 
ankB mutants and the Y91K L93K double mutant were similarly functional in the 
complementation assay. In contrast, the Y91K L93K Y127K triple mutant and the 
Y91K L93K Y127K L134K quadruple mutant were defective in recruitment of 
polyubiquitinated proteins at levels similar to the ankB null mutant. This confirms 
the importance of the substrate binding site on the ankyrin domain for the 
recruitment of polyubiquitinated proteins to the LCV [141]. 
The ankyrin domain is required for intracellular replication 
We determined if mutations of these four residues resulted in a replication 
defect of the bacteria within the LCV. hMDMs were infected with wild-type L. 
pneumophila, its isogenic dotA or ankB mutants, or the ankB mutant 
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complemented with a wild-type or mutated copy of ankB. At 10 hours post-
infection, the dotA null mutant showed no replication and the ankB null mutant 
was markedly compromised compared to the wild-type strain (Fig. 25b). 
Complementation of the ankB mutant with a wild-type copy of ankB restored 
replication to wild-type levels. The single mutants Y91K, L93K, Y127K, L134K, 
and double mutant Y91K L93K were also effective in restoring growth. In 
contrast, complementation with the triple and quadruple mutations in the ankyrin 
domain showed a significant defect in replication. Similar results were obtained 
with the U937 macrophage cell line (data not shown). These data are in 
agreement with the decreased ubiquitination of the LCV observed in bacteria 
expressing ankB with the same triple and quadruple mutations. Residues Tyr91, 
Leu93, Tyr127, and Leu134 within the ankyrin repeats of AnkB are critical both 
for recruitment of ubiquitinated proteins to the LCV and for replication within 







































Fig. 24. Substrate binding by the ankyrin repeats. a. Crystal contacts in the AnkB ankyrin repeats mimic substrate 
binding. The C-terminal tail (residues 160 to 164, QEEKI) of one molecule (wheat) binds to the ankyrin repeats of another 
(green). Hydrogen bonds are indicated by dashed black lines. Residues involved in contacting the peptide and residues 
that were mutated for further functional studies are labeled in black. An omit map of the substrate is colored and labeled in 
wheat. See also Figure S1. b. Downfield region of HSQC spectra of the 15N-labeled ankyrin domain show chemical shifts 
upon titration with the QEEKI peptide (C-terminal tail) and weaker binding upon titration with the PRLPTL peptide 




























Fig. 25 Replication and Ubiquitylation Defect in hMDMs.  a. Percentage of LCVs colocalizing with polyubiquitinated 
proteins by confocal microscopy at 2 hours post-infection. Human monocytes-derived macrophages (hMDMs) were 
infected with wild type L. pneumophila, ankB mutant, or the ankB mutant complemented with either a wild type copy of 
ankB or ankB containing the indicated single or multiple mutations. The data are representative of three independent 
experiments and are based on analysis of 100 infected cells per strain with each strain analyzed in duplicate. Error bars 
indicate +/- 1 SD. Abbreviations: 3K and 4K refer to Y91K/L93K/Y127K and Y91K/L93K/Y127K/L134K, respectively. 
*p<0.02 compared to ankB mutant complemented with wild type ankB. NS, not significant. See also Figure S2. b. hMDMs 
were infected with wild type, dotA mutant, ankB mutant, or the ankB mutant complemented with either wild type ankB or 
ankB containing the indicated mutations at an MOI of 1 followed by 1 hour treatment with gentamicin to kill extracellular 
bacteria. After 10 h, 100 infected cells were analyzed by confocal microscopy and the number of bacteria per cell was 
determined. The data are representative of two independent experiments with each strain analyzed in duplicate. Error 
bars indicate +/- 1 SD. Abbreviations: 3K, and 4K refer to Y91K/L93K/Y127K and Y91K/L93K/Y127K/L134K, respectively. 










Fig. 26 Mutation of three or more key residues within the Ankyrin domain of AnkB causes a replication defect in 
U937 macrophages U937 cells were infected with wild type, dotA mutant, ankB mutant, or the ankB mutant 
complemented with either wild type ankB or ankB containing the indicated mutations at an MOI of 1 followed by 1 hour 
treatment with gentamicin to kill extracellular bacteria.  After 10 h, 100 infected cells were analyzed by confocal 
microscopy and the number of bacteria per cell was counted.  Each strain was analyzed in duplicate and the results are 
representative of two independent experiments.  Error bars indicate +/- 1 SD.  Abbreviations: 2K, 3K, and 4K refer to ankB 
Y91K L93K, ankB Y91K L93K Y127K, and ankB Y91K L93K Y127K L134K, respectively.  *p <0.05 compared to ankB 




 Here, we present the first structure of a bacterial F-box protein, the 
targeting subunits of SCF ligases. There are close to 70 F-box proteins in 
humans that are involved in a wide range of diseases. These proteins are 
composed of an F-box domain and a variable targeting domain which belongs to 
three main classes: WD40 domains, leucine-rich repeats, and other domains. 
AnkB represents a unique association of an F-box and ankyrin repeats that 
appears to be unique to a small number of lower eukaryotes, bacteria, and 
viruses [158].  Two other F-box effectors exist in the Legionella genome that 
could interact with the host SCF complex, but do not contain an ankyrin domain. 
One has a coiled coil domain (lpp2486) and the other consists of only an F-box 
(lpp0233). Previous mutagenesis studies have shown the importance of the 
AnkB F-box for acquisition of polyubiquitinated proteins to the LCV and bacterial 
proliferation [99].  The ankyrin domain of AnkB is likely involved in recruiting 
substrates for ubiquitination. The structures of a large number of ankyrin protein 
complexes have been determined and reveal a wide range of types of 
interactions. Generally, ankyrin domains use the inter-repeat loops and inner row 
of α-helices to bind other proteins; however, there is no consensus for the 
structure of the bound partner [154].  Ankyrin repeats can bind discontinuous 
protein surfaces, α-helices, and extended strands as observed for AnkB. The 
interactions of AnkB with its C-terminal tail most closely resemble the complex of 
ANKRA2 with a PxLPxI/L motif found in some histone deacetylases and other 
proteins we observed low affinity binding of AnkB to the peptide PRLPTL [157]. 
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The ankyrin domain of AnkB shows broad specificity.  This is typical of 
ankyrin domains that bind unfolded or extended peptide sequences and likely 
reflects the preponderance of AnkB interactions with the backbone atoms in the 
bound peptide. Fitting of the NMR titration curve suggested a dissociation 
constant (Kd) greater than 8 mM for the QEEKI peptide (Fig. 24b). Single amino 
acid substitutions in the peptide did not result in significant changes in the 
titration behavior, which is consistent with low specificity and a distributed binding 
interface.  Similarly, single point mutations in the AnkB ankyrin domain did not 
perturb its function in poly-ubiquitination of LCVs and promoting Legionella 
proliferation (Fig. 25a and 25b). 
In cells, AnkB is unlikely to bind its own tail or that of another AnkB 
molecule.  The QEEKI motif extends from the final helix in the third ankyrin 
repeat and is unable to bind to the first two repeats. The interactions between 
two AnkB molecules is also unlikely as the QEEKI motif is separated by only four 
residues from the AnkB CaaX farnesylation site. The tethering of AnkB to the 
membrane would block access of the QEEKI of one molecule to the ankyrin 
domain of another. Sequence alignment of the AnkB gene between different 
strains reveals that the Paris strain homolog is a truncated version of the AnkB 
structure presented in this paper. While the last α-helix of the last ankyrin repeat 
is absent, the Paris homolog retains the last loop and half of the last repeat.  
From analysis of the crystal structures, this would suggest that the Paris homolog 
would still have a functional substrate-binding interface. 
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To date, two interacting partners of AnkB have been identified. Parvin B 
(ParvB), a target of AnkB ubiquitination was identified by a yeast two-hybrid 
screen and co-immunoprecipitation [98].  ParvB functions in regulating the actin 
cytoskeleton for cell adhesion and migration [159].  Solubility issues prevented us 
from detecting direct binding of ParvB to the purified AnkB ankyrin domain. More 
recently, TRIM21 was identified by coimmunoprecipitation as a partner of AnkB. 
TRIM21 attaches Lys11-linked polyubiquitin chains on Lys76 of AnkB without 
affecting AnkB stability [141]. 
Studies have elucidated two roles of AnkB in Legionella virulence. 
Following phagocytosis, L. pneumophila injects effector proteins into the host cell 
cytosol via the Dot/Icm secretion system. Considerable redundancy exists 
between effectors and loss of the dotA gene (equivalent to a knockout of all 300 
effectors) gives rise to a much stronger ubiquitination and replication deficiency 
than the loss of only ankB (Fig. 25a-25b). Nonetheless, AnkB is effectively 
essential for virulence and acts as a linker to recruit the SCF complex to the LCV. 
Farnesylation of AnkB appears to be essential for its function; however, there is 
strain specificity as AnkB from the Legionella strain Paris lacks the CaaX motif 
but retains function [98, 110, 145].  By co-opting the host SCF complex, AnkB 
redirects host ubiquitination to the LCV and substrates selected by AnkB. We 
have built a model of AnkB in context of the SCF ubiquitination complex and the 
connected UbcH7 (E2 conjugating enzyme), by aligning AnkB onto the F-box of a 
Cul1-Rbx1-Skp1-Skp2 (PDB code 1LDK) and docking UbcH7 onto the Rbx1 
RING domain based on a c-Cbl-UbcH7 structure (PDB code 1FBV) (Fig. 27) 
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[132, 160].  In the model, the active cysteine (Cys86) of the E2 points towards 
the putative substrate-binding site of the AnkB ankyrin repeats, positioning the 
substrate to receive ubiquitin. Lys48-linked poly-ubiquitination of the LCV is a 
critical step in the maturation of the LCV and required to prevent fusion with the 
lysosome.  We observed a strong correlation between loss of ubiquitination 
activity and loss of Legionella proliferation for the AnkB mutations tested. 
Legionella hijacks members of the secretory pathway to fuse endoplasmic 
reticulum (ER)-derived vesicles to the (LCV). As Lys48-linked polyubiquitin chains 
are also associated with recruitment of the autophagy machinery, the reported 
association of AnkB with E3 ligases containing different chain specificities, such 
as TRIM21, is particularly interesting [141]. 
AnkB also plays a role in enriching the cytosolic pool of free amino acids 
through triggering Lys48-linked polyubiquitination and increased protein turnover 
[120].  The levels of amino acids in the infected host cell are insufficient sources 
of carbon, nitrogen and energy for L. pneumophila [161].  AnkB promotes intra-
vacuolar proliferation by ubiquitinating host proteins for their degradation into free 
amino acids [120, 162].  The growth defect of the ankB null mutant in both 
protozoan and eukaryotic cells can be rescued by supplementation with a 
mixture of free amino acids [118, 120].  AnkB likely functions by directly recruiting 
substrate proteins through the ankyrin domain. Mutating either the F-box or the 
ankyrin domain of AnkB results in the same phenotype, suggesting that the 
ability of Legionella to co-opt host E3 ubiquitin ligases through molecular mimicry 






Fig. 27. Model in Context of Ubiquitylation.  Model of AnkB as the F-box 
protein in the SCF E3 ubiquitin ligase complex (PBD code 1LDK) with an E2 
conjugating enzyme (UbcH7) (PDB code 1FBV) docked.  The active cysteine of 
UbcH7 (C86) is labeled.  The color code is as follows: pink and green (F-box and 














CONCLUSIONS AND FUTURE DIRECTIONS 
 
I identified a unique KNKYAP motif present within the C-terminus of AnkB-
Paris that resembles an eukaryotic ER retention di-lysine motif.  I show that this 
allele is predominant among environmental isolates and that the di-lysine motif is 
acted upon by positive selection.  I also demonstrated that AnkB-Paris, like 
AnkB-AA100, is anchored to the cytosolic face of the LCV membrane, albeit by a 
mechanism distinct from farnesylation.  The di-lysine motif is essential for the 
translocation of AnkB-Paris via the Dot/Icm system as mutations in either lysine 
of the motif abrogate translocation.  Because of this, I was unable to determine if 
the di-lysine motif is essential for localization to the cytosolic face of the ER-
derived LCV membrane.  However, I showed the di-lysine motif is essential for 
trans-rescue of the ankB mutant in cells ectopically expressing AnkB-Paris, 
indicating a critical biological function of the motif that is distinct from 
translocation.  The di-lysine motif is, most likely, acting as an ER retention motif 
anchoring AnkB-Paris to the ER-derived LCV membrane.   
There are at least two alternative hypotheses that could explain the failure 
of the di-lysine mutants to trans-rescue the ankB mutant.  First, the KNKYAP 
motif, which is unique to AnkB-Paris, may be crucial for anchoring the protein to 
the LCV surface by interacting with host and/or L. pneumophila proteins present 
on the LCV that are not involved in binding to di-lysine motifs.  Mutation of the 
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lysine residues within C-terminus of AnkB-Paris may disrupt the interactions with 
these proteins resulting in loss of LCV localization and failure to trans-rescue the 
ankB mutant.  Second, the di-lysine motif is contained within the last ankyrin 
repeat.  Therefore, it is possible that substitution of these residues may impact 
the stability of the ankyrin domain and prevent AnkB-Paris from binding to its 
substrates.  This would produce a loss of function in the trans-rescue experiment 
not by disruption of anchoring to the LCV membrane, but by loss of ability to bind 
and ubiquitylate substrates.  Evidence in favor of the di-lysine hypothesis 
includes the striking similarity of the C-terminus of AnkB-Paris to the di-lysine 
consensus, the perinuclear distribution of AnkB-Paris upon ectopic expression, 
and the fact that the LCV is derived from ER and contains coatomer proteins 
known to bind di-lysine motifs.   
Inside eukaryotic cells, the coatomer protein complex is responsible for 
binding di-lysine motifs and trafficking proteins from the Golgi to the ER [163, 
164].  The coatomer complex is composed of a trimer (α-COP, β’-COP, ε-COP) 
and a tetramer (β-COP, γ-COP, δ-COP, and ζ-COP) [148].  I was unable to show 
an interaction between β’-COP and AnkB-Paris by co-IP in cells overexpressing 
both proteins.  However, it is possible that overexpression of all members of the 
trimer subcomplex would be required for binding to AnkB-Paris as was shown for 
the di-lysine motif contained within diphtheria toxin [113].  Alternatively, we could 
test for binding to the coatomer subcomplex in vitro using fragments of AnkB-
Paris fused to GST and immobilized on glutathione beads [147].  Since I have 
established that AnkB-Paris localizes to the ER-derived LCV membrane during 
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infection, we could also assess binding of AnkB-Paris to members of the 
coatomer complex by siRNA knockdown.  In this scenario, cells would be treated 
with siRNA targeting one or more coatomer subunits and then infected with L. 
pneumophila expressing AnkB-Paris.  Localization of AnkB-Paris to the LCV 
would be assessed by confocal microscopy.  In support of this approach, 
coatomer subunits α, β, β’, and γ were all shown to localize to the LCV in a study 
of the complete proteome of the WT LCV [162].  Such studies would provide 
additional evidence that the KNKYAP motif present in AnkB-Paris is functioning 
as a di-lysine motif.    
Overall, I conclude that anchoring of AnkB variants to host membranes is 
essential for function, regardless of the mechanism of membrane anchoring by 
farnesylation or di-lysine ER retention.  It will be interesting to explore the exact 
molecular interactions responsible for tethering the AnkB-Paris to the LCV 
membrane. 
I identified residues within the three ankyrin domains of AnkB that are 
essential for function and likely involved in binding substrates.  The crystal 
structure of AnkB revealed that it has a large hydrophobic surface in its N-
terminus that interacts with helices 5, 6, and 7 of Skp1.  The structure also 
revealed three ankyrin domains within AnkB.  Each repeat adopts a helix-turn-
helix fold with connecting loops in between that is typical of other ankyrin 
repeats.  Three residues, Tyr91, Leu93, and Tyr127, were predicted to form a 
hydrogen-bonding network important for binding substrate proteins and one 
solvent-exposed hydrophobic residue, Leu134, potentially involved in making 
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hydrophobic interactions with substrates.  Single or double substitutions in these 
residues had no effect on AnkB biological function in recruiting ubiquitylated 
proteins to the LCV or promoting intracellular replication.  On the other hand, 
substituting three or four of these residues resulted in a complete loss of 
ubiquitylated protein recruitment and replication similar to an ankB null mutant.  
These data suggest that these residues are likely to be involved in binding to 
AnkB substrates that are ubiquitylated during infection.  Once substrates of AnkB 
are identified, we will be able to confirm these key residues within AnkB are 
responsible for binding to its targets.   
I sought to identify the specific host proteins targeted by AnkB for 
ubiquitylation.  Despite using three different approaches, I was unable to identify 
AnkB-interacting proteins under our experimental conditions.  This knowledge is 
important, as it may confirm the role of AnkB as a virulence factor involved in 
harvesting amino acids from the host.  In this case, identification of substrates 
could reveal that AnkB targets host proteins rich in amino acids that are most 
favorable for energy production via the TCA cycle, such as Ser, Cys, or Ala.  On 
the other hand, identification of specific substrates may reveal that AnkB is 
involved in modulating certain host cell pathways by altering the ubiquitylation 
state of key members.   
Characterization of E3 ubiquitin ligase substrates in mammalian cells is 
challenging [165].  It is estimated that > 80% of the human proteome is subject to 
ubiquitin-mediated degradation, suggesting this process is involved in many 
cellular pathways [166].  There are approximately 600 E3 ligases in the human 
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genome and the substrates of these ligases are largely uncharacterized [140, 
165].  Characterization of substrates is technically challenging for several 
reasons.  First, E3 ligase activity is under tight control and deubiquitylases (DUB) 
act to reverse their activity making the entire process very dynamic [165].  
Interactions between F-box protein and substrate are weak and transient with 
most encounters being unproductive since the dissociation rate is faster than the 
ubiquitylation rate [167].  In addition, there is significant redundancy as any 
particular substrate can be the target of multiple E3 ligases and one ligase can 
target multiple substrates depending on the cellular conditions [165].  Finally, the 
ubiquitylated substrates are rapidly degraded by the proteasome in many cases.  
These factors make isolation of substrates of a given E3 ligase challenging by 
traditional immunoprecipitation methods and may explain why I was unable to do 
so for AnkB. 
A modified immunoprecipitation-based method has been successful in 
identifying F-box protein substrates [168].  Parallel adaptor capture proteomics 
(PAC) utilizes immunoaffinity-based purification of F-box substrates and couples 
it with the Comparative Proteomics Analysis Software Suite (CompPASS) [168].  
The method involves transfecting cells with the F-box protein of interest and 
inhibiting the proteasome to increase the abundance of F-box-substrate 
complexes.  The complexes are purified by immunoprecipitation and interacting 
proteins are identified by MS.  The primary advantage of this approach is the use 
of the CompPASS software to identify high-confidence interacting proteins.  This 
software compares results from an experiment to a table of 174 unrelated bait 
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proteins and calculates a probability that putative substrates are bona fide 
interacting proteins [168].  This approach successfully identified substrates of 19 
different F-box proteins with an overall validation rate of 80% [168].  This 
approach could be readily applied to AnkB without the need for creating new 
constructs. 
An alternative approach that does not rely on purification of F-box-
substrate protein complexes is the BioID-based method, which is a proximity-
based biotinylation method [135].  The E3 ligase of interest is fused to the E. coli 
biotin conjugating enzyme BirA, which can activate biotin but does not bind the 
activated molecule.  As a result, the activated biotin diffuses away and reacts 
with any protein in close proximity, usually physically interacting proteins.  Using 
this method, E3 ligase substrates can be efficiently biotinylated and purified on 
streptavidin under harsh lysis conditions [135].  This method overcomes the 
potential limitation, inherent to immunoaffinity-based methods, for transient low-
affinity interactions encountered when working with E3 ligases and their 
substrates [135].  If AnkB interacts weakly or transiently with its substrate 
proteins, this method could result in identification of AnkB substrates that were 
not detected under our conditions. 
A recently described method, thermophoresis, could be used for 
identification of novel AnkB interacting proteins.  In this method, protein solutions 
are heated with a focused IR laser beam that causes a local movement of 
molecules either away from (positive) or toward (negative) the heating beam 
[169].  These movements are characteristic of the protein and can be altered by 
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changes in the protein’s size, charge, or hydration shell, which can all change in 
response to binding to another protein [169].  This change in thermophoretic 
property can be measured and protein interactions detected at the picomolar 
level [169].  This technique could be applied to discovery of AnkB interacting 
proteins by testing fractions of cellular lysates for their binding to AnkB.  
Fractions could be further divided and purified to a degree that would allow 
identification of the proteins in the mixture that interact with AnkB.  This 
technique could also be used to monitor for changes in binding of substrates to 
mutant versions of AnkB such as the ones described in chapter 3.   
Overall, while I was not able to identify specific substrate proteins targeted 
for ubiquitylation by AnkB, I was able to identify key residues within the ankyrin 
domains that are likely responsible for binding specific substrates and promoting 
their ubiquitylation.  I found that AnkB-Paris, which lacks the farnesylation motif 
found in the AA100/130b strain, contains a putative di-lysine ER retention motif.  I 
show that the lysine residues within this motif are essential for it’s biological 
function during infection.  Similar to AnkB from the AA100/130b strain, AnkB-
Paris localizes to the cytosolic face of the LCV most likely by virtue of its di-lysine 






1. Fraser, D.W., et al., Legionnaires' disease: description of an epidemic of pneumonia. 
N.Engl.J.Med., 1977. 297: p. 1189-1197. 
2. McDade, J.E., et al., Legionnaires' disease: isolation of a bacterium and demonstration of 
its role in other respiratory disease. N.Engl.J.Med., 1977. 297: p. 1197-1203. 
3. Honigsbaum, M., Legionnaires' disease: revisiting the puzzle of the century. Lancet, 
2016. 388(10043): p. 456-7. 
4. Jindal, S.K., Koch's postulates - Pitfalls and relevance in the 21st century. Indian J Tuberc, 
2018. 65(1): p. 6-7. 
5. Den Boer, J.W. and E.P. Yzerman, Diagnosis of Legionella infection in Legionnaires' 
disease. Eur J Clin Microbiol Infect Dis, 2004. 23(12): p. 871-8. 
6. Mercante, J.W. and J.M. Winchell, Current and emerging Legionella diagnostics for 
laboratory and outbreak investigations. Clin Microbiol Rev, 2015. 28(1): p. 95-133. 
7. Rowbotham, T.J., Current views on the relationships between amoebae, legionellae and 
man. Isr.J.Med.Sci., 1986. 22: p. 678-689. 
8. Molofsky, A.B. and M.S. Swanson, Differentiate to thrive: lessons from the Legionella 
pneumophila life cycle. Mol Microbiol, 2004. 53(1): p. 29-40. 
9. Pierre, D.M., et al., Diagnostic testing for Legionnaires' disease. Ann Clin Microbiol 
Antimicrob, 2017. 16(1): p. 59. 
10. Cunha, B.A., A. Burillo, and E. Bouza, Legionnaires' disease. Lancet, 2015. 
11. Phin, N., et al., Epidemiology and clinical management of Legionnaires' disease. The 
Lancet Infectious Diseases, 2014. 14(10): p. 1011-1021. 
12. Legionellosis --- United States, 2000-2009. MMWR Morb Mortal Wkly Rep, 2011. 60(32): 
p. 1083-6. 
13. Fields, B.S., R.F. Benson, and R.E. Besser, Legionella and Legionnaires' disease: 25 years 
of investigation. Clin Microbiol Rev, 2002. 15(3): p. 506-26. 
14. Marston, B.J., H.B. Lipman, and R.F. Breiman, Surveillance for Legionnaires' disease: risk 
factors for mortality and morbidity. Arch.Intern.Med., 1994. 154: p. 2417-2422. 
15. Blatt, S.P., et al., Legionnaires' disease in human immunodeficiency virus-infected 
patients: eight cases and review. Clin Infect Dis, 1994. 18(2): p. 227-32. 
16. Gutierrez Rodero, F., et al., Legionnaires' disease in patients infected with human 
immunodeficiency virus. Clin Infect Dis, 1995. 21(3): p. 712-3. 
17. Glick, T.H., et al., Pontiac fever. An epidemic of unknown etiology in a health 
department: I. Clinical and epidemiologic aspects. Am J Epidemiol, 1978. 107(2): p. 149-
60. 
18. Xu, L. and Z.Q. Luo, Cell biology of infection by Legionella pneumophila. Microbes Infect, 
2013. 15(2): p. 157-67.
 115 
 
19. Mandell, L.A., et al., Infectious Diseases Society of America/American Thoracic Society 
consensus guidelines on the management of community-acquired pneumonia in adults. 
Clin Infect Dis, 2007. 44 Suppl 2: p. S27-72. 
20. Benin, A.L., R.F. Benson, and R.E. Besser, Trends in legionnaires disease, 1980-1998: 
declining mortality and new patterns of diagnosis. Clin Infect Dis, 2002. 35(9): p. 1039-
46. 
21. Heath, C.H., D.I. Grove, and D.F. Looke, Delay in appropriate therapy of Legionella 
pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis, 1996. 
15(4): p. 286-90. 
22. Fliermans, C.B., et al., Ecological distribution of Legionella pneumophila. 
Appl.Environ.Microbiol., 1981. 41: p. 9-16. 
23. Katz, S.M. and J.M. Hammel, The effect of drying, heat, and pH on the survival of 
Legionella pneumophila. Ann.Clin.Lab.Sci., 1987. 17: p. 150-156. 
24. Taylor, M., K. Ross, and R. Bentham, Legionella, protozoa, and biofilms: interactions 
within complex microbial systems. Microb Ecol, 2009. 58(3): p. 538-47. 
25. Bhopal, R.S., et al., Proximity of the home to a cooling tower and risk of non-outbreak 
Legionnaires' disease. BMJ., 1991. 302: p. 378-383. 
26. Atlas, R.M., J.F. Williams, and M.K. Huntington, Legionella contamination of dental-unit 
waters. Appl Environ Microbiol, 1995. 61(4): p. 1208-13. 
27. Bollin, G.E., et al., Aerosols containing Legionella pneumophila generated by shower 
heads and hot-water faucets. Appl.Environ.Microbiol., 1985. 50: p. 1128-1131. 
28. Guyard, C. and D.E. Low, Legionella infections and travel associated legionellosis. Travel 
Med Infect Dis, 2011. 9(4): p. 176-86. 
29. Newton, H.J., et al., Molecular pathogenesis of infections caused by Legionella 
pneumophila. Clin Microbiol Rev, 2010. 23(2): p. 274-98. 
30. Yamamoto, H., et al., Factors stimulating propagation of legionellae in cooling tower 
water. Appl Environ Microbiol, 1992. 58(4): p. 1394-7. 
31. Iervolino, M., B. Mancini, and S. Cristino, Industrial Cooling Tower Disinfection 
Treatment to Prevent Legionella spp. Int J Environ Res Public Health, 2017. 14(10). 
32. George, J.R., et al., Amino acid requirements of Legionella pneumophila. 
J.Clin.Microbiol., 1980. 11: p. 286-291. 
33. Pine, L., et al., Development of a chemically defined liquid medium for growth of 
Legionella pneumophila. J Clin Microbiol, 1979. 9(5): p. 615-26. 
34. Pine, L., et al., Development of a chemically defined liquid medium for growth of 
Legionella pneumophila. J.Clin.Microbiol., 1979. 9: p. 615-626. 
35. Ristroph, J.D., K.W. Hedlund, and S. Gowda, Chemically defined medium for Legionella 
pneumophila growth. J.Clin.Microbiol., 1981. 13: p. 115-119. 
36. Tesh, M.J., S.A. Morse, and R.D. Miller, Intermediary metabolism in Legionella 
pneumophila: utilization of amino acids and other compounds as energy sources. 
J.Bacteriol., 1983. 154: p. 1104-1109. 
37. Eisenreich, W. and K. Heuner, The life stage-specific pathometabolism of Legionella 
pneumophila. FEBS Lett, 2016. 590(21): p. 3868-3886. 
38. Oliva, G., T. Sahr, and C. Buchrieser, The Life Cycle of L. pneumophila: Cellular 
Differentiation Is Linked to Virulence and Metabolism. Frontiers in Cellular and Infection 
Microbiology, 2018. 8(3). 
39. Eylert, E., et al., Isotopologue profiling of Legionella pneumophila: role of serine and 
glucose as carbon substrates. J Biol Chem, 2010. 285(29): p. 22232-43. 
 116 
 
40. Hammer, B.K. and M.S. Swanson, Co-ordination of legionella pneumophila virulence with 
entry into stationary phase by ppGpp. Mol Microbiol, 1999. 33(4): p. 721-31. 
41. James, B.W., et al., Poly-3-hydorxyburyrate in Legionella pneumophila, an energy source 
for survival in low-nutrient environments. Appl.Environ.Microbiol., 1999. 65: p. 822-827. 
42. Gillmaier, N., et al., Growth-related Metabolism of the Carbon Storage Poly-3-
hydroxybutyrate in Legionella pneumophila. J Biol Chem, 2016. 291(12): p. 6471-82. 
43. Horwitz, M.A., Phagocytosis of the Legionnaires' disease bacterium (Legionella 
pneumophila) occurs by a novel mechanism: engulfment within a pseudopod coil. Cell, 
1984. 36: p. 27-33. 
44. Horwitz, M.A. and F.R. Maxfield, Legionella pneumophila inhibits acidification of its 
phagosome in human monocytes. J.Cell.Biol., 1984. 99: p. 1936-1943. 
45. Horwitz, M.A., Formation of a novel phagosome by the Legionnaires' disease bacterium 
(Legionella pneumophila) in human monocytes. J Exp Med, 1983. 158(4): p. 1319-31. 
46. Tilney, L.G., et al., How the parasitic bacterium Legionella pneumophila modifies its 
phagosome and transforms it into rough ER: implications for conversion of plasma 
membrane to the ER membrane. J Cell Sci, 2001. 114(Pt 24): p. 4637-50. 
47. Swanson, M.S. and R.R. Isberg, Association of Legionella pneumophila with the 
macrophage endoplasmic reticulum. Infect.Immun., 1995. 63: p. 3609-3620. 
48. Kagan, J.C. and C.R. Roy, Legionella phagosomes intercept vesicular traffic from 
endoplasmic reticulum exit sites. Nat Cell Biol, 2002. 4: p. 945-954. 
49. Clemens, D.L., B.Y. Lee, and M.A. Horwitz, Deviant expression of rab5 on phagosomes 
containing the intracellular pathogens mycobacterium tuberculosis and legionella 
pneumophila is associated with altered phagosomal fate [In Process Citation]. Infect 
Immun, 2000. 68(5): p. 2671-84. 
50. Berger, K.H. and R.R. Isberg, Two distinct defects in intracellular growth complemented 
by a single genetic locus in Legionella pneumophila. Mol.Microbiol., 1993. 7: p. 7-19. 
51. Marra, A., et al., Identification of a Legionella pneumophila locus required for 
intracellular multiplication in human macrophages. Proc.Natl.Acad.Sci.USA., 1992. 89: p. 
9607-9611. 
52. Ensminger, A.W., Legionella pneumophila, armed to the hilt: justifying the largest 
arsenal of effectors in the bacterial world. Curr Opin Microbiol, 2016. 29: p. 74-80. 
53. Hilbi, H., G. Segal, and H.A. Shuman, Icm/Dot-dependent upregulation of phagocytosis 
by Legionella pneumophila. Mol Microbiol, 2001. 42(3): p. 603-17. 
54. Kirby, J.E., et al., Evidence for pore-forming ability by Legionella pneumophila. 
Mol.Microbiol., 1998. 27: p. 323-336. 
55. Isaac, D.T. and R. Isberg, Master manipulators: an update on Legionella pneumophila 
Icm/Dot translocated substrates and their host targets. Future Microbiology, 2014. 9(3): 
p. 343-359. 
56. O'Connor, T.J., et al., Minimization of the Legionella pneumophila genome reveals 
chromosomal regions involved in host range expansion. Proc Natl Acad Sci U S A, 2011. 
108(36): p. 14733-40. 
57. de Felipe, K.S., et al., Evidence for acquisition of Legionella type IV secretion substrates 
via interdomain horizontal gene transfer. J Bacteriol, 2005. 187(22): p. 7716-26. 
58. Hubber, A. and C.R. Roy, Modulation of host cell function by Legionella pneumophila 
type IV effectors. Annu Rev Cell Dev Biol, 2010. 26: p. 261-83. 
59. Burstein, D., et al., Genomic analysis of 38 Legionella species identifies large and diverse 
effector repertoires. Nat Genet, 2016. 48(2): p. 167-75. 
 117 
 
60. Gomez-Valero, L., et al., Comparative and functional genomics of legionella identified 
eukaryotic like proteins as key players in host-pathogen interactions. Front Microbiol, 
2011. 2: p. 208. 
61. Cazalet, C., et al., Evidence in the Legionella pneumophila genome for exploitation of 
host cell functions and high genome plasticity. Nat Genet, 2004. 36(11): p. 1165-73. 
62. Ghosh, S. and T.J. O'Connor, Beyond Paralogs: The Multiple Layers of Redundancy in 
Bacterial Pathogenesis. Front Cell Infect Microbiol, 2017. 7: p. 467. 
63. So, E.C., et al., Creating a customized intracellular niche: subversion of host cell signaling 
by Legionella type IV secretion system effectors. Can J Microbiol, 2015. 61(9): p. 617-35. 
64. Al-Khodor, S., et al., Functional diversity of ankyrin repeats in microbial proteins. Trends 
Microbiol, 2010. 18(3): p. 132-9. 
65. Mosavi, L.K., et al., The ankyrin repeat as molecular architecture for protein recognition. 
Protein Sci, 2004. 13(6): p. 1435-48. 
66. Voth, D.E., ThANKs for the repeat: Intracellular pathogens exploit a common eukaryotic 
domain. Cell Logist, 2011. 1(4): p. 128-132. 
67. Kohl, A., et al., Designed to be stable: crystal structure of a consensus ankyrin repeat 
protein. Proc Natl Acad Sci U S A, 2003. 100(4): p. 1700-5. 
68. Cazalet, C. and C. Buchrieser, [What do we learn from the genome of Legionella 
pneumophila?]. Med Sci (Paris), 2005. 21(5): p. 455-7. 
69. Habyarimana, F., et al., Molecular characterization of the Dot/Icm-translocated AnkH 
and AnkJ eukaryotic-like effectors of Legionella pneumophila. Infect Immun, 2010. 78(3): 
p. 1123-34. 
70. Habyarimana, F., et al., Role for the Ankyrin eukaryotic-like genes of Legionella 
pneumophila in parasitism of protozoan hosts and human macrophages. Environ 
Microbiol, 2008. 10(6): p. 1460-74. 
71. Al-Khodor, S., et al., A Dot/Icm-translocated ankyrin protein of Legionella pneumophila is 
required for intracellular proliferation within human macrophages and protozoa. Mol 
Microbiol, 2008. 70(4): p. 908-23. 
72. Kerscher, O., R. Felberbaum, and M. Hochstrasser, Modification of proteins by ubiquitin 
and ubiquitin-like proteins. Annu Rev Cell Dev Biol, 2006. 22: p. 159-80. 
73. Qiu, J. and Z.Q. Luo, Hijacking of the Host Ubiquitin Network by Legionella pneumophila. 
Front Cell Infect Microbiol, 2017. 7: p. 487. 
74. Komander, D. and M. Rape, The ubiquitin code. Annu Rev Biochem, 2012. 81: p. 203-29. 
75. Hoege, C., et al., RAD6-dependent DNA repair is linked to modification of PCNA by 
ubiquitin and SUMO. Nature, 2002. 419(6903): p. 135-41. 
76. Haglund, K., et al., Multiple monoubiquitination of RTKs is sufficient for their endocytosis 
and degradation. Nat Cell Biol, 2003. 5(5): p. 461-6. 
77. Kwon, Y.T. and A. Ciechanover, The Ubiquitin Code in the Ubiquitin-Proteasome System 
and Autophagy. Trends Biochem Sci, 2017. 42(11): p. 873-886. 
78. Price, C.T. and Y.A. Kwaik, Exploitation of Host Polyubiquitination Machinery through 
Molecular Mimicry by Eukaryotic-Like Bacterial F-Box Effectors. Front Microbiol, 2010. 1: 
p. 122. 
79. Welchman, R.L., C. Gordon, and R.J. Mayer, Ubiquitin and ubiquitin-like proteins as 
multifunctional signals. Nat Rev Mol Cell Biol, 2005. 6(8): p. 599-609. 
80. Iwai, K., Diverse roles of the ubiquitin system in NF-kappaB activation. Biochim Biophys 
Acta, 2014. 1843(1): p. 129-36. 
81. Spence, J., et al., Cell cycle-regulated modification of the ribosome by a variant 
multiubiquitin chain. Cell, 2000. 102(1): p. 67-76. 
 118 
 
82. Huang, J., et al., RAD18 transmits DNA damage signalling to elicit homologous 
recombination repair. Nat Cell Biol, 2009. 11(5): p. 592-603. 
83. Zheng, N. and N. Shabek, Ubiquitin Ligases: Structure, Function, and Regulation. Annu 
Rev Biochem, 2017. 86: p. 129-157. 
84. Dove, K.K. and R.E. Klevit, RING-Between-RING E3 Ligases: Emerging Themes amid the 
Variations. J Mol Biol, 2017. 429(22): p. 3363-3375. 
85. Schulman, B.A., et al., Insights into SCF ubiquitin ligases from the structure of the Skp1-
Skp2 complex. Nature, 2000. 408(6810): p. 381-6. 
86. Wang, Z., et al., Roles of F-box proteins in cancer. Nat Rev Cancer, 2014. 14(4): p. 233-47. 
87. Skaar, J.R., J.K. Pagan, and M. Pagano, SCF ubiquitin ligase-targeted therapies. Nat Rev 
Drug Discov, 2014. 13(12): p. 889-903. 
88. Skaar, J.R., J.K. Pagan, and M. Pagano, Mechanisms and function of substrate 
recruitment by F-box proteins. Nat Rev Mol Cell Biol, 2013. 14(6): p. 369-81. 
89. Lucas, X. and A. Ciulli, Recognition of substrate degrons by E3 ubiquitin ligases and 
modulation by small-molecule mimicry strategies. Curr Opin Struct Biol, 2017. 44: p. 
101-110. 
90. Kainulainen, M., et al., NSs Virulence Factor of Rift Valley Fever Virus Engages the F-Box 
Proteins FBXW11 and beta-TRCP1 To Degrade the Antiviral Protein Kinase PKR. J Virol, 
2016. 90(13): p. 6140-7. 
91. Wang, C., et al., Identification of FBL2 as a geranylgeranylated cellular protein required 
for hepatitis C virus RNA replication. Mol Cell, 2005. 18(4): p. 425-34. 
92. Yao, I., et al., SCRAPPER-dependent ubiquitination of active zone protein RIM1 regulates 
synaptic vesicle release. Cell, 2007. 130(5): p. 943-57. 
93. Li, Y. and B. Hao, Structural basis of dimerization-dependent ubiquitination by the 
SCF(Fbx4) ubiquitin ligase. J Biol Chem, 2010. 285(18): p. 13896-906. 
94. Zeng, Z., et al., Structural basis of selective ubiquitination of TRF1 by SCFFbx4. Dev Cell, 
2010. 18(2): p. 214-25. 
95. Ensminger, A.W. and R.R. Isberg, E3 ubiquitin ligase activity and targeting of BAT3 by 
multiple Legionella pneumophila translocated substrates. Infect Immun, 2010. 78(9): p. 
3905-19. 
96. Ivanov, S.S. and C.R. Roy, Modulation of ubiquitin dynamics and suppression of DALIS 
formation by the Legionella pneumophila Dot/Icm system. Cell Microbiol, 2009. 11(2): p. 
261-78. 
97. Angot, A., et al., Exploitation of eukaryotic ubiquitin signaling pathways by effectors 
translocated by bacterial type III and type IV secretion systems. PLoS Pathog, 2007. 3(1): 
p. e3. 
98. Lomma, M., et al., The Legionella pneumophila F-box protein Lpp2082 (AnkB) modulates 
ubiquitination of the host protein parvin B and promotes intracellular replication. Cell 
Microbiol, 2010. 12(9): p. 1272-91. 
99. Price, C.T., et al., Molecular mimicry by an F-box effector of Legionella pneumophila 
hijacks a conserved polyubiquitination machinery within macrophages and protozoa. 
PLoS Pathog, 2009. 5(12): p. e1000704. 
100. Kubori, T., et al., Legionella metaeffector exploits host proteasome to temporally 
regulate cognate effector. PLoS Pathog, 2010. 6(12): p. e1001216. 
101. Hsu, F., et al., The Legionella effector SidC defines a unique family of ubiquitin ligases 




102. Puvar, K., et al., Ubiquitin Chains Modified by the Bacterial Ligase SdeA Are Protected 
from Deubiquitinase Hydrolysis. Biochemistry, 2017. 56(36): p. 4762-4766. 
103. Qiu, J., et al., Ubiquitination independent of E1 and E2 enzymes by bacterial effectors. 
Nature, 2016. 533(7601): p. 120-4. 
104. Wright, L.P. and M.R. Philips, Thematic review series: lipid posttranslational 
modifications. CAAX modification and membrane targeting of Ras. J Lipid Res, 2006. 
47(5): p. 883-91. 
105. Ullah, N., M. Mansha, and P.J. Casey, Protein Geranylgeranyltransferase Type 1 as a 
Target in Cancer. Curr Cancer Drug Targets, 2016. 16(7): p. 563-71. 
106. Zhang, F.L. and P.J. Casey, Protein prenylation: molecular mechanisms and functional 
consequences. Annu Rev Biochem, 1996. 65: p. 241-69. 
107. Gelb, M.H., et al., Therapeutic intervention based on protein prenylation and associated 
modifications. Nat Chem Biol, 2006. 2(10): p. 518-28. 
108. Maurer-Stroh, S., S. Washietl, and F. Eisenhaber, Protein prenyltransferases. Genome 
Biol, 2003. 4(4): p. 212. 
109. Wang, M. and P.J. Casey, Protein prenylation: unique fats make their mark on biology. 
Nat Rev Mol Cell Biol, 2016. 17(2): p. 110-22. 
110. Price, C.T., et al., Exploitation of conserved eukaryotic host cell farnesylation machinery 
by an F-box effector of Legionella pneumophila. J Exp Med, 2010. 207(8): p. 1713-26. 
111. Price, C.T., et al., Host-mediated post-translational prenylation of novel dot/icm-
translocated effectors of legionella pneumophila. Front Microbiol, 2010. 1: p. 131. 
112. Ivanov, S.S., et al., Lipidation by the host prenyltransferase machinery facilitates 
membrane localization of Legionella pneumophila effector proteins. J Biol Chem, 2010. 
285(45): p. 34686-98. 
113. Trujillo, C., et al., Essential lysine residues within transmembrane helix 1 of diphtheria 
toxin facilitate COPI binding and catalytic domain entry. Mol Microbiol, 2010. 76(4): p. 
1010-9. 
114. Custer, S.K., et al., Dilysine motifs in exon 2b of SMN protein mediate binding to the COPI 
vesicle protein alpha-COP and neurite outgrowth in a cell culture model of spinal 
muscular atrophy. Hum Mol Genet, 2013. 22(20): p. 4043-52. 
115. Gao, C., et al., Retention mechanisms for ER and Golgi membrane proteins. Trends Plant 
Sci, 2014. 19(8): p. 508-15. 
116. Price, C.T., et al., Indispensable role for the eukaryotic-like ankyrin domains of the 
ankyrin B effector of Legionella pneumophila within macrophages and amoebae. Infect 
Immun, 2010. 78(5): p. 2079-88. 
117. Schroeder, G.N., et al., Legionella pneumophila strain 130b possesses a unique 
combination of type IV secretion systems and novel Dot/Icm secretion system effector 
proteins. J Bacteriol, 2010. 192(22): p. 6001-16. 
118. Bruckert, W.M., C.T. Price, and Y. Abu Kwaik, Rapid nutritional remodeling of the host 
cell upon attachment of Legionella pneumophila. Infect Immun, 2014. 82(1): p. 72-82. 
119. Price, C.T. and Y. Abu Kwaik, Exploitation of Host Polyubiquitination Machinery through 
Molecular Mimicry by Eukaryotic-Like Bacterial F-Box Effectors. Front Microbiol, 2010. 1: 
p. 122. 
120. Price, C.T., et al., Host proteasomal degradation generates amino acids essential for 
intracellular bacterial growth. Science, 2011. 334(6062): p. 1553-7. 
121. Dalebroux, Z.D., R.L. Edwards, and M.S. Swanson, SpoT governs Legionella pneumophila 
differentiation in host macrophages. Mol Microbiol, 2009. 71: p. 640-658. 
 120 
 
122. Tamura, K., et al., MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol 
Evol, 2013. 30(12): p. 2725-9. 
123. Yang, Z., PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol, 2007. 
24(8): p. 1586-91. 
124. Xu, B. and Z. Yang, PAMLX: a graphical user interface for PAML. Mol Biol Evol, 2013. 
30(12): p. 2723-4. 
125. Putty, K., et al., Robustness of Helicobacter pylori infection conferred by context-variable 
redundancy among cysteine-rich paralogs. PLoS One, 2013. 8(3): p. e59560. 
126. Delport, W., et al., Datamonkey 2010: a suite of phylogenetic analysis tools for 
evolutionary biology. Bioinformatics, 2010. 26(19): p. 2455-7. 
127. So, E.C., et al., The Rab-binding profiles of bacterial virulence factors during infection. J 
Biol Chem, 2016. 
128. Otwinowski, Z. and W. Minor, Processing of x-ray diffraction data collected in oscillation 
mode. Meth.Enzymol., 1997. 276: p. 307-326. 
129. Sheldrick, G.M., A short history of SHELX. Acta Crystallogr A, 2008. 64(Pt 1): p. 112-22. 
130. Langer, G., et al., Automated macromolecular model building for X-ray crystallography 
using ARP/wARP version 7. Nat Protoc, 2008. 3(7): p. 1171-9. 
131. Murshudov, G.N., et al., REFMAC5 for the refinement of macromolecular crystal 
structures. Acta Crystallogr D Biol Crystallogr, 2011. 67(Pt 4): p. 355-67. 
132. Zheng, N., et al., Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. 
Nature, 2002. 416(6882): p. 703-9. 
133. Emsley, P. and K. Cowtan, Coot: model-building tools for molecular graphics. Acta 
Crystallogr D Biol Crystallogr, 2004. 60(Pt 12 Pt 1): p. 2126-32. 
134. Chen, V.B., et al., MolProbity: all-atom structure validation for macromolecular 
crystallography. Acta Crystallogr D Biol Crystallogr, 2010. 66(Pt 1): p. 12-21. 
135. Coyaud, E., et al., BioID-based Identification of Skp Cullin F-box (SCF)beta-TrCP1/2 E3 
Ligase Substrates. Mol Cell Proteomics, 2015. 14(7): p. 1781-95. 
136. Rao, V.S., et al., Protein-protein interaction detection: methods and analysis. Int J 
Proteomics, 2014. 2014: p. 147648. 
137. Luhrmann, A., et al., Inhibition of pathogen-induced apoptosis by a Coxiella burnetii type 
IV effector protein. Proc Natl Acad Sci U S A, 2010. 107(44): p. 18997-9001. 
138. Datta, A., A. Kamthan, and M. Kamthan, A simple protocol to detect interacting proteins 
by GST pull down assay coupled with MALDI or LC-MS/MS analysis. 2015. 
139. Shen, X., et al., Targeting eEF1A by a Legionella pneumophila effector leads to inhibition 
of protein synthesis and induction of host stress response. Cell Microbiol, 2009. 11(6): p. 
911-26. 
140. Harper, J.W. and M.K. Tan, Understanding cullin-RING E3 biology through proteomics-
based substrate identification. Mol Cell Proteomics, 2012. 11(12): p. 1541-50. 
141. Bruckert, W.M. and Y. Abu Kwaik, Lysine11-linked polyubiquitination of the AnkB F-Box 
effector of Legionella pneumophila. Infect Immun, 2015. 
142. Mousnier, A., et al., A new method to determine in vivo interactomes reveals binding of 
the Legionella pneumophila effector PieE to multiple rab GTPases. MBio, 2014. 5(4). 
143. Price, C., et al., Host FIH-Mediated Asparaginyl Hydroxylation of Translocated Legionella 
pneumophila Effectors. Front Cell Infect Microbiol, 2017. 7: p. 54. 
144. Al-Quadan, T. and Y.A. Kwaik, Molecular Characterization of Exploitation of the 
Polyubiquitination and Farnesylation Machineries of Dictyostelium Discoideum by the 
AnkB F-Box Effector of Legionella Pneumophila. Front Microbiol, 2011. 2: p. 23. 
 121 
 
145. Al-Quadan, T., et al., Anchoring of bacterial effectors to host membranes through host-
mediated lipidation by prenylation: a common paradigm. Trends Microbiol, 2011. 
19(12): p. 573-9. 
146. Wang, K., et al., Structural Mimicry by a Bacterial F Box Effector Hijacks the Host 
Ubiquitin-Proteasome System. Structure, 2017. doi: 10.1016/j.str.2016.12.015(In Press). 
147. Ma, W. and J. Goldberg, Rules for the recognition of dilysine retrieval motifs by 
coatomer. The EMBO Journal, 2013. 32(7): p. 926-937. 
148. Popoff, V., et al., COPI budding within the Golgi stack. Cold Spring Harb Perspect Biol, 
2011. 3(11): p. a005231. 
149. Shi, X., et al., Direct targeting of membrane fusion by SNARE mimicry: Convergent 
evolution of Legionella effectors. Proc Natl Acad Sci U S A, 2016. 113(31): p. 8807-12. 
150. Dorer, M.S., et al., RNA interference analysis of Legionella in Drosophila cells: 
exploitation of early secretory apparatus dynamics. PLoS Pathog, 2006. 2(4): p. e34. 
151. Quaile, A.T., et al., Molecular Characterization of LubX: Functional Divergence of the U-
Box Fold by Legionella pneumophila. Structure, 2015. 23(8): p. 1459-69. 
152. Urbanus, M.L., et al., Diverse mechanisms of metaeffector activity in an intracellular 
bacterial pathogen, Legionella pneumophila. Mol Syst Biol, 2016. 12(12): p. 893. 
153. Speir, M., et al., Legionella pneumophila strain 130b evades macrophage cell death 
independent of the effector SidF in the absence of flagellin. Front. Cell. Infect. Microbiol., 
2017. doi: 10.3389/fcimb.2017.00035. 
154. Parra, R.G., et al., Structural and Energetic Characterization of the Ankyrin Repeat 
Protein Family. PLoS Comput Biol, 2015. 11(12): p. e1004659. 
155. Li, J., A. Mahajan, and M.D. Tsai, Ankyrin repeat: a unique motif mediating protein-
protein interactions. Biochemistry, 2006. 45(51): p. 15168-78. 
156. Kipreos, E.T. and M. Pagano, The F-box protein family. Genome Biol, 2000. 1(5): p. 
REVIEWS3002. 
157. Xu, C., et al., Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat 
tumbler lock. Sci Signal, 2012. 5(226): p. ra39. 
158. Herbert, M.H., C.J. Squire, and A.A. Mercer, Poxviral ankyrin proteins. Viruses, 2015. 
7(2): p. 709-38. 
159. Legate, K.R., et al., ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell 
Biol, 2006. 7(1): p. 20-31. 
160. Zheng, N., et al., Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-
protein ligases. Cell, 2000. 102(4): p. 533-9. 
161. Price, C.T., A.M. Richards, and Y. Abu Kwaik, Nutrient generation and retrieval from the 
host cell cytosol by intra-vacuolar Legionella pneumophila. Front Cell Infect Microbiol, 
2014. 4: p. 111. 
162. Bruckert, W.M. and Y. Abu Kwaik, Complete and ubiquitinated proteome of the 
Legionella-containing vacuole within human macrophages. J Proteome Res, 2015. 14(1): 
p. 236-48. 
163. Letourneur, F., et al., Coatomer is essential for retrieval of dilysine-tagged proteins to the 
endoplasmic reticulum. Cell, 1994. 79(7): p. 1199-207. 
164. Cosson, P. and F. Letourneur, Coatomer interaction with di-lysine endoplasmic reticulum 
retention motifs. Science, 1994. 263(5153): p. 1629-31. 
165. Iconomou, M. and D.N. Saunders, Systematic approaches to identify E3 ligase 
substrates. Biochem J, 2016. 473(22): p. 4083-4101. 
166. Yen, H.C., et al., Global protein stability profiling in mammalian cells. Science, 2008. 
322(5903): p. 918-23. 
 122 
 
167. Pierce, N.W., et al., Detection of sequential polyubiquitylation on a millisecond 
timescale. Nature, 2009. 462(7273): p. 615-9. 
168. Tan, M.K., et al., Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in 
NRF2 activation via BACH1 repressor turnover. Mol Cell, 2013. 52(1): p. 9-24. 
169. Seidel, S.A., et al., Microscale thermophoresis quantifies biomolecular interactions under 
previously challenging conditions. Methods, 2013. 59(3): p. 301-15. 
 123 
 
 APPENDIX 1 
 










































Table 4.  Proteins identified in band 3 in HEK293T 
Protein Name Accession Norm 
IBAQ 
MW MW on 
gel 
Isoform 2 of Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
OS=Homo sapiens GN=ANP32B 
sp|Q92688-2|AN32B_HUMAN (+1) 1.78E+07 22 kDa 25 kDa 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 PE=1 
SV=6 
sp|P13645|K1C10_HUMAN 9.64E+06 59 kDa 25 kDa 
Ankyrin-repeat protein B OS=Legionella 
pneumophila GN=ankB PE=4 SV=1 
tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN 6.81E+06 20 kDa 25 kDa 
Cluster of Amino-terminal enhancer of 
split OS=Homo sapiens GN=AES PE=1 
SV=4 (sp|Q08117|AES_HUMAN) 
sp|Q08117|AES_HUMAN 3.48E+06 22 kDa 25 kDa 
TATA box-binding protein-like protein 1 
OS=Homo sapiens GN=TBPL1 PE=1 
SV=1 
sp|P62380|TBPL1_HUMAN 3.44E+06 21 kDa 25 kDa 
ER membrane protein complex subunit 
8 OS=Homo sapiens GN=EMC8 PE=1 
SV=1 
sp|O43402|EMC8_HUMAN (+1) 1.57E+06 24 kDa 25 kDa 
Cluster of Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 PE=1 
SV=4 (sp|P02533|K1C14_HUMAN) 
sp|P02533|K1C14_HUMAN 1.37E+06 52 kDa 25 kDa 
Isoform 2 of 60S ribosomal protein L15 
OS=Homo sapiens GN=RPL15 
sp|P61313-2|RL15_HUMAN (+3) 1.01E+06 17 kDa 25 kDa 
Protein SETSIP OS=Homo sapiens 
GN=SETSIP PE=1 SV=1 
sp|P0DME0|SETLP_HUMAN (+6) 7.66E+05 35 kDa 25 kDa 
Cytochrome c1, heme protein, 
mitochondrial OS=Homo sapiens 
GN=CYC1 PE=1 SV=3 








protein 1 OS=Homo sapiens 
GN=PRADC1 PE=1 SV=1 
sp|Q9BSG0|PADC1_HUMAN 7.18E+05 21 kDa 25 kDa 
Transducin-like enhancer protein 1 
OS=Homo sapiens GN=TLE1 PE=1 
SV=2 
sp|Q04724|TLE1_HUMAN (+2) 4.61E+05 83 kDa 25 kDa 
     
DDB1- and CUL4-associated factor 7 
OS=Homo sapiens GN=DCAF7 PE=1 
SV=1 
sp|P61962|DCAF7_HUMAN 4.18E+05 39 kDa 25 kDa 
Proteasome subunit beta type-3 
OS=Homo sapiens GN=PSMB3 PE=1 
SV=2 
sp|P49720|PSB3_HUMAN (+1) 3.21E+05 23 kDa 25 kDa 
28 kDa heat- and acid-stable 
phosphoprotein OS=Homo sapiens 
GN=PDAP1 PE=1 SV=1 
sp|Q13442|HAP28_HUMAN 2.11E+05 21 kDa 25 kDa 
Isoform 2 of Coronin-1C OS=Homo 
sapiens GN=CORO1C 
sp|Q9ULV4-2|COR1C_HUMAN (+3) 1.61E+05 54 kDa 25 kDa 
Casein kinase I isoform epsilon 
OS=Homo sapiens GN=CSNK1E PE=1 
SV=1 
sp|P49674|KC1E_HUMAN 1.37E+05 47 kDa 25 kDa 
Isoform 2 of Paraspeckle component 1 
OS=Homo sapiens GN=PSPC1 
sp|Q8WXF1-2|PSPC1_HUMAN (+2) 1.35E+05 46 kDa 25 kDa 
Isoform 2 of Myc-associated zinc finger 
protein OS=Homo sapiens GN=MAZ 
sp|P56270-2|MAZ_HUMAN 1.24E+05 51 kDa 25 kDa 
GTP-binding nuclear protein Ran 
OS=Homo sapiens GN=RAN PE=1 
SV=3 







40S ribosomal protein S4, X isoform 
OS=Homo sapiens GN=RPS4X PE=1 
SV=2 
sp|P62701|RS4X_HUMAN 6.47E+04 30 kDa 25 kDa 
Isoform 2 of Oxidation resistance protein 
1 OS=Homo sapiens GN=OXR1 
sp|Q8N573-2|OXR1_HUMAN (+5) 4.65E+04 94 kDa 25 kDa 
Isoform 2 of Heat shock 70 kDa protein 
1A OS=Homo sapiens GN=HSPA1A 
sp|P0DMV8-2|HS71A_HUMAN (+2) 4.29E+04 64 kDa 25 kDa 
Isoform 2 of Heat shock cognate 71 kDa 
protein OS=Homo sapiens GN=HSPA8 
sp|P11142-2|HSP7C_HUMAN (+6) 3.78E+04 54 kDa 25 kDa 
Isoform 2 of Keratin, type II cytoskeletal 
78 OS=Homo sapiens GN=KRT78 
sp|Q8N1N4-2|K2C78_HUMAN (+1) 7310 45 kDa 25 kDa 
 
 
Table 5.  Proteins identified in band 4 from HEK293T cells 
Protein Name Accession Norm IBAQ MW MW 
on gel 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
OS=Homo sapiens GN=ANP32A PE=1 
SV=1 
sp|P39687|AN32A_HUMAN (+1) 5.37E+07 29 kDa 30 kDa 
Isoform 2 of Protein SET OS=Homo 
sapiens GN=SET 
sp|Q01105-2|SET_HUMAN (+4) 1.64E+07 32 kDa 30 kDa 
Small acidic protein OS=Homo sapiens 
GN=SMAP PE=1 SV=1 
sp|O00193|SMAP_HUMAN 4.05E+06 20 kDa 30 kDa 
Putative RNA-binding protein Luc7-like 2 
OS=Homo sapiens GN=LUC7L2 PE=1 
SV=2 
sp|Q9Y383|LC7L2_HUMAN 2.37E+06 47 kDa 30 kDa 
Cluster of Isoform Long of Proteasome 
subunit alpha type-1 OS=Homo sapiens 









Isoform 2 of Nucleophosmin OS=Homo 
sapiens GN=NPM1 
sp|P06748-2|NPM_HUMAN (+1) 1.34E+06 29 kDa 30 kDa 
WD repeat-containing protein 82 
OS=Homo sapiens GN=WDR82 PE=1 
SV=1 
sp|Q6UXN9|WDR82_HUMAN 9.71E+05 35 kDa 30 kDa 
Isoform 2 of Protein FAM76A OS=Homo 
sapiens GN=FAM76A 
sp|Q8TAV0-2|FA76A_HUMAN (+5) 9.45E+05 32 kDa 30 kDa 
Isoform 2 of Protein FAM64A OS=Homo 
sapiens GN=FAM64A 
sp|Q9BSJ6-2|FA64A_HUMAN (+2) 6.62E+05 26 kDa 30 kDa 
Malonyl-CoA-acyl carrier protein 
transacylase, mitochondrial OS=Homo 
sapiens GN=MCAT PE=1 SV=2 
sp|Q8IVS2|FABD_HUMAN 6.28E+05 43 kDa 30 kDa 
RWD domain-containing protein 2B 
OS=Homo sapiens GN=RWDD2B PE=1 
SV=1 
sp|P57060|RWD2B_HUMAN 4.58E+05 36 kDa 30 kDa 
Proteasome subunit alpha type-4 
OS=Homo sapiens GN=PSMA4 PE=1 
SV=1 
sp|P25789|PSA4_HUMAN (+3) 3.76E+05 29 kDa 30 kDa 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L3 OS=Homo sapiens 
GN=UCHL3 PE=1 SV=1 
sp|P15374|UCHL3_HUMAN (+2) 3.76E+05 26 kDa 30 kDa 
Zinc finger BED domain-containing 
protein 3 OS=Homo sapiens 
GN=ZBED3 PE=1 SV=1 
sp|Q96IU2|ZBED3_HUMAN 3.54E+05 25 kDa 30 kDa 
Geminin OS=Homo sapiens GN=GMNN 
PE=1 SV=1 







WD repeat-containing protein 61 
OS=Homo sapiens GN=WDR61 PE=1 
SV=1 
sp|Q9GZS3|WDR61_HUMAN 3.41E+05 34 kDa 30 kDa 
Isoform 2 of ER membrane protein 
complex subunit 3 OS=Homo sapiens 
GN=EMC3 
sp|Q9P0I2-2|EMC3_HUMAN (+1) 2.99E+05 25 kDa 30 kDa 
Isoform 2 of Mitogen-activated protein 
kinase 1 OS=Homo sapiens 
GN=MAPK1 
sp|P28482-2|MK01_HUMAN (+1) 2.86E+05 36 kDa 30 kDa 
Isoform 2 of Ribonuclease P protein 
subunit p30 OS=Homo sapiens 
GN=RPP30 
sp|P78346-2|RPP30_HUMAN (+2) 2.60E+05 36 kDa 30 kDa 
Elongation factor 1-beta OS=Homo 
sapiens GN=EEF1B2 PE=1 SV=3 
sp|P24534|EF1B_HUMAN 2.39E+05 25 kDa 30 kDa 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial OS=Homo sapiens 
GN=C1QBP PE=1 SV=1 
sp|Q07021|C1QBP_HUMAN (+2) 2.20E+05 31 kDa 30 kDa 
Isoform 2 of Na(+)/H(+) exchange 
regulatory cofactor NHE-RF2 OS=Homo 
sapiens GN=SLC9A3R2 
sp|Q15599-2|NHRF2_HUMAN (+2) 1.85E+05 36 kDa 30 kDa 
TP53-regulating kinase OS=Homo 
sapiens GN=TP53RK PE=1 SV=2 
sp|Q96S44|PRPK_HUMAN 1.55E+05 28 kDa 30 kDa 
Glutamate dehydrogenase 1, 
mitochondrial OS=Homo sapiens 
GN=GLUD1 PE=1 SV=2 
sp|P00367|DHE3_HUMAN 1.51E+05 61 kDa 30 kDa 
Isoform 2 of Cleavage and 
polyadenylation specificity factor subunit 
7 OS=Homo sapiens GN=CPSF7 







COP9 signalosome complex subunit 7a 
OS=Homo sapiens GN=COPS7A PE=1 
SV=1 
sp|Q9UBW8|CSN7A_HUMAN (+4) 1.36E+05 30 kDa 30 kDa 
Isoform 2 of 2,4-dienoyl-CoA reductase, 
mitochondrial OS=Homo sapiens 
GN=DECR1 
sp|Q16698-2|DECR_HUMAN (+4) 1.29E+05 35 kDa 30 kDa 
Isoform 2 of Mitotic checkpoint protein 
BUB3 OS=Homo sapiens GN=BUB3 
sp|O43684-2|BUB3_HUMAN (+2) 1.01E+05 37 kDa 30 kDa 
Isoform 3 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma 
OS=Homo sapiens GN=PIP4K2C 
sp|Q8TBX8-3|PI42C_HUMAN (+1) 7.76E+04 45 kDa 30 kDa 
Isoform 2 of Inhibitor of growth protein 4 
OS=Homo sapiens GN=ING4 
sp|Q9UNL4-2|ING4_HUMAN (+7) 7.01E+04 28 kDa 30 kDa 
Isoform 2 of Plasminogen activator 
inhibitor 1 RNA-binding protein 
OS=Homo sapiens GN=SERBP1 
sp|Q8NC51-2|PAIRB_HUMAN (+3) 4.61E+04 44 kDa 30 kDa 
Pre-rRNA-processing protein TSR1 
homolog OS=Homo sapiens GN=TSR1 
PE=1 SV=1 
sp|Q2NL82|TSR1_HUMAN 3.74E+04 92 kDa 30 kDa 
 
Table 6.  Proteins identified in band 5 from HEK293T cells 
Protein Name Accession Norm 
IBAQ 
MW MW on 
gel 
Translational activator of cytochrome c 
oxidase 1 OS=Homo sapiens 
GN=TACO1 PE=1 SV=1 
sp|Q9BSH4|TACO1_HUMAN 5.42E+06 32 kDa 33 kDa 
Isoform 3 of Acidic leucine-rich nuclear 
phosphoprotein 32 family member E 
OS=Homo sapiens GN=ANP32E 







Pyrroline-5-carboxylate reductase 3 
OS=Homo sapiens GN=PYCRL PE=1 
SV=3 
sp|Q53H96|P5CR3_HUMAN (+1) 1.90E+06 29 kDa 33 kDa 
Cluster of Isoform 2 of Mitogen-
activated protein kinase 1 OS=Homo 
sapiens GN=MAPK1 (sp|P28482-
2|MK01_HUMAN) 
sp|P28482-2|MK01_HUMAN [2] 6.24E+05 36 kDa 33 kDa 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
sp|P08865|RSSA_HUMAN (+3) 5.69E+05 33 kDa 33 kDa 
Casein kinase II subunit alpha 
OS=Homo sapiens GN=CSNK2A1 
PE=1 SV=1 
sp|P68400|CSK21_HUMAN (+2) 4.75E+05 45 kDa 33 kDa 
Splicing factor U2AF 35 kDa subunit-
like protein OS=Homo sapiens 
GN=U2AF1L5 PE=3 SV=1 
sp|P0DN76|U2AF5_HUMAN 3.23E+05 28 kDa 33 kDa 
Multiple myeloma tumor-associated 
protein 2 OS=Homo sapiens 
GN=MMTAG2 PE=1 SV=1 
sp|Q9BU76|MMTA2_HUMAN 3.22E+05 29 kDa 33 kDa 
Transcription initiation factor IIA subunit 
1 OS=Homo sapiens GN=GTF2A1 
PE=1 SV=1 
sp|P52655|TF2AA_HUMAN (+1) 2.78E+05 42 kDa 33 kDa 
Isoform 3 of Protein FRA10AC1 
OS=Homo sapiens GN=FRA10AC1 
sp|Q70Z53-3|F10C1_HUMAN 2.62E+05 37 kDa 33 kDa 
Regulation of nuclear pre-mRNA 
domain-containing protein 1B 
OS=Homo sapiens GN=RPRD1B PE=1 
SV=1 
sp|Q9NQG5|RPR1B_HUMAN 2.50E+05 37 kDa 33 kDa 
Developmentally-regulated GTP-
binding protein 1 OS=Homo sapiens 
GN=DRG1 PE=1 SV=1 







Isoform 2 of Elongation factor 1-delta 
OS=Homo sapiens GN=EEF1D 
sp|P29692-2|EF1D_HUMAN (+14) 1.99E+05 71 kDa 33 kDa 
Isoform 2 of F-actin-capping protein 
subunit beta OS=Homo sapiens 
GN=CAPZB 
sp|P47756-2|CAPZB_HUMAN (+3) 1.95E+05 31 kDa 33 kDa 
Pre-mRNA-splicing factor 38A 
OS=Homo sapiens GN=PRPF38A 
PE=1 SV=1 
sp|Q8NAV1|PR38A_HUMAN 1.91E+05 37 kDa 33 kDa 
Peptidyl-prolyl cis-trans isomerase-like 
4 OS=Homo sapiens GN=PPIL4 PE=1 
SV=1 
sp|Q8WUA2|PPIL4_HUMAN 1.73E+05 57 kDa 33 kDa 
Translin-associated protein X 
OS=Homo sapiens GN=TSNAX PE=1 
SV=1 
sp|Q99598|TSNAX_HUMAN 1.69E+05 33 kDa 33 kDa 
Enhancer of mRNA-decapping protein 
3 OS=Homo sapiens GN=EDC3 PE=1 
SV=1 
sp|Q96F86|EDC3_HUMAN 1.59E+05 56 kDa 33 kDa 
Isoform 2 of Endonuclease III-like 
protein 1 OS=Homo sapiens 
GN=NTHL1 
sp|P78549-2|NTH_HUMAN (+3) 1.29E+05 34 kDa 33 kDa 
Isoform 2 of RNA pseudouridylate 
synthase domain-containing protein 3 
OS=Homo sapiens GN=RPUSD3 
sp|Q6P087-2|RUSD3_HUMAN (+1) 1.27E+05 37 kDa 33 kDa 
BTB/POZ domain-containing protein 
KCTD12 OS=Homo sapiens 
GN=KCTD12 PE=1 SV=1 
sp|Q96CX2|KCD12_HUMAN 1.20E+05 36 kDa 33 kDa 
Heterogeneous nuclear 
ribonucleoprotein A0 OS=Homo 
sapiens GN=HNRNPA0 PE=1 SV=1 







Cluster of Serine/threonine-protein 
phosphatase PP1-beta catalytic subunit 
OS=Homo sapiens GN=PPP1CB PE=1 
SV=3 (sp|P62140|PP1B_HUMAN) 
sp|P62140|PP1B_HUMAN 1.10E+05 37 kDa 33 kDa 
Isoform 2 of 60S acidic ribosomal 
protein P0 OS=Homo sapiens 
GN=RPLP0 
sp|P05388-2|RLA0_HUMAN (+2) 1.02E+05 27 kDa 33 kDa 
Isoform 2 of V-type proton ATPase 
subunit E 1 OS=Homo sapiens 
GN=ATP6V1E1 
sp|P36543-2|VATE1_HUMAN (+2) 1.01E+05 24 kDa 33 kDa 
Isoform 2 of Septin-2 OS=Homo 
sapiens GN=SEPT2 
sp|Q15019-2|SEPT2_HUMAN (+3) 8.81E+04 45 kDa 33 kDa 
Ribose-5-phosphate isomerase 
OS=Homo sapiens GN=RPIA PE=1 
SV=3 
sp|P49247|RPIA_HUMAN 8.18E+04 33 kDa 33 kDa 
Isoform 2 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 alpha 
OS=Homo sapiens GN=PIP4K2A 
sp|P48426-2|PI42A_HUMAN (+1) 7.86E+04 40 kDa 33 kDa 
Isoform 1 of RNA demethylase 
ALKBH5 OS=Homo sapiens 
GN=ALKBH5 
sp|Q6P6C2-1|ALKB5_HUMAN (+1) 5.33E+04 52 kDa 33 kDa 
Ribonucleoprotein PTB-binding 1 




4.61E+04 78 kDa 33 kDa 
FACT complex subunit SSRP1 
OS=Homo sapiens GN=SSRP1 PE=1 
SV=1 
sp|Q08945|SSRP1_HUMAN (+1) 4.54E+04 81 kDa 33 kDa 
Casein kinase II subunit alpha' 
OS=Homo sapiens GN=CSNK2A2 
PE=1 SV=1 







ATP synthase subunit gamma, 
mitochondrial OS=Homo sapiens 
GN=ATP5C1 PE=1 SV=1 
sp|P36542|ATPG_HUMAN 3.53E+04 33 kDa 33 kDa 
Isoform 2 of Pre-B-cell leukemia 
transcription factor-interacting protein 1 
OS=Homo sapiens GN=PBXIP1 
sp|Q96AQ6-2|PBIP1_HUMAN (+1) 3.30E+04 78 kDa 33 kDa 
Isoform 2 of Transducin-like enhancer 
protein 3 OS=Homo sapiens GN=TLE3 
sp|Q04726-2|TLE3_HUMAN (+12) 2.96E+04 82 kDa 33 kDa 
Erythrocyte band 7 integral membrane 
protein OS=Homo sapiens GN=STOM 
PE=1 SV=3 
sp|P27105|STOM_HUMAN (+1) 2.37E+04 32 kDa 33 kDa 
Isoform 3 of Ubiquitin carboxyl-terminal 
hydrolase 7 OS=Homo sapiens 
GN=USP7 
sp|Q93009-3|UBP7_HUMAN (+1) 2.11E+04 126 
kDa 
33 kDa 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 
sp|Q86YZ3|HORN_HUMAN 1.43E+04 282 
kDa 
33 kDa 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 
sp|P02768|ALBU_HUMAN (+1) 7190 69 kDa 33 kDa 
 
Table 7.  Proteins identified in band 6 from HEK293T cells 
Protein Name Accession Norm IBAQ MW MW 
on gel 
Pyrroline-5-carboxylate reductase 2 
OS=Homo sapiens GN=PYCR2 PE=1 
SV=1 
sp|Q96C36|P5CR2_HUMAN 7.62E+06 34 kDa 39 kDa 
Isoform 3 of Pyrroline-5-carboxylate 
reductase 1, mitochondrial OS=Homo 
sapiens GN=PYCR1 







Isoform 2 of RNA-binding protein with 
serine-rich domain 1 OS=Homo sapiens 
GN=RNPS1 
sp|Q15287-2|RNPS1_HUMAN (+6) 7.88E+05 32 kDa 39 kDa 
Splicing factor 3B subunit 4 OS=Homo 
sapiens GN=SF3B4 PE=1 SV=1 
sp|Q15427|SF3B4_HUMAN 6.44E+05 44 kDa 39 kDa 
Isoform 2 of Pyrroline-5-carboxylate 
reductase 3 OS=Homo sapiens 
GN=PYCRL 
sp|Q53H96-2|P5CR3_HUMAN (+2) 5.93E+05 26 kDa 39 kDa 
Isoform 2 of Protein FAM98A OS=Homo 
sapiens GN=FAM98A 
sp|Q8NCA5-2|FA98A_HUMAN (+1) 5.77E+05 55 kDa 39 kDa 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 beta OS=Homo sapiens 
GN=PIP4K2B PE=1 SV=1 
sp|P78356|PI42B_HUMAN 5.44E+05 47 kDa 39 kDa 
60S ribosomal protein L5 OS=Homo 
sapiens GN=RPL5 PE=1 SV=3 
sp|P46777|RL5_HUMAN (+1) 4.32E+05 34 kDa 39 kDa 
Zinc finger and SCAN domain-containing 
protein 26 OS=Homo sapiens 
GN=ZSCAN26 PE=1 SV=2 
sp|Q16670|ZSC26_HUMAN (+2) 4.17E+05 55 kDa 39 kDa 
Casein kinase I isoform alpha OS=Homo 
sapiens GN=CSNK1A1 PE=1 SV=2 
sp|P48729|KC1A_HUMAN 3.94E+05 39 kDa 39 kDa 
Isoform 3 of Ubiquitin carboxyl-terminal 
hydrolase 46 OS=Homo sapiens 
GN=USP46 
sp|P62068-3|UBP46_HUMAN (+3) 3.22E+05 42 kDa 39 kDa 
Isoform 2 of Eukaryotic peptide chain 
release factor subunit 1 OS=Homo 
sapiens GN=ETF1 
sp|P62495-2|ERF1_HUMAN (+2) 2.93E+05 45 kDa 39 kDa 
Isoform 3 of Serine 
hydroxymethyltransferase, mitochondrial 
OS=Homo sapiens GN=SHMT2 







Crk-like protein OS=Homo sapiens 
GN=CRKL PE=1 SV=1 
sp|P46109|CRKL_HUMAN 2.54E+05 34 kDa 39 kDa 
Isoform 2 of Microtubule-associated 
protein RP/EB family member 2 
OS=Homo sapiens GN=MAPRE2 
sp|Q15555-2|MARE2_HUMAN (+6) 2.47E+05 29 kDa 39 kDa 
Inositol hexakisphosphate kinase 2 
OS=Homo sapiens GN=IP6K2 PE=1 
SV=2 
sp|Q9UHH9|IP6K2_HUMAN 2.40E+05 49 kDa 39 kDa 
Isoform 2 of Isovaleryl-CoA 
dehydrogenase, mitochondrial 
OS=Homo sapiens GN=IVD 
sp|P26440-2|IVD_HUMAN (+2) 2.37E+05 43 kDa 39 kDa 
Aurora kinase A OS=Homo sapiens 
GN=AURKA PE=1 SV=2 
sp|O14965|AURKA_HUMAN 2.14E+05 46 kDa 39 kDa 
RNA-binding protein NOB1 OS=Homo 
sapiens GN=NOB1 PE=1 SV=1 
sp|Q9ULX3|NOB1_HUMAN 2.06E+05 47 kDa 39 kDa 
Isoform 2 of Probable RNA-binding 
protein 23 OS=Homo sapiens 
GN=RBM23 
sp|Q86U06-2|RBM23_HUMAN (+4) 1.96E+05 47 kDa 39 kDa 
Isoform 4 of Casein kinase I isoform 
gamma-3 OS=Homo sapiens 
GN=CSNK1G3 
sp|Q9Y6M4-4|KC1G3_HUMAN 1.33E+05 49 kDa 39 kDa 
Isoform 2 of ATP-dependent RNA 
helicase DDX42 OS=Homo sapiens 
GN=DDX42 
sp|Q86XP3-2|DDX42_HUMAN (+2) 1.30E+05 90 kDa 39 kDa 
Lactadherin OS=Homo sapiens 
GN=MFGE8 PE=1 SV=2 
sp|Q08431|MFGM_HUMAN 1.10E+05 43 kDa 39 kDa 
Isoform 2 of Poly(rC)-binding protein 2 
OS=Homo sapiens GN=PCBP2 
sp|Q15366-2|PCBP2_HUMAN (+10) 1.02E+05 39 kDa 39 kDa 
Zinc finger protein 696 OS=Homo 
sapiens GN=ZNF696 PE=2 SV=2 









OS=Homo sapiens GN=TRMT61B PE=1 
SV=2 
sp|Q9BVS5|TR61B_HUMAN 9.83E+04 53 kDa 39 kDa 
E3 ubiquitin-protein ligase RING2 
OS=Homo sapiens GN=RNF2 PE=1 
SV=1 
sp|Q99496|RING2_HUMAN (+1) 9.62E+04 38 kDa 39 kDa 
Phenylalanine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=FARS2 PE=1 SV=1 
sp|O95363|SYFM_HUMAN 9.49E+04 52 kDa 39 kDa 
26S proteasome non-ATPase regulatory 
subunit 7 OS=Homo sapiens 
GN=PSMD7 PE=1 SV=2 
sp|P51665|PSMD7_HUMAN 6.47E+04 37 kDa 39 kDa 
Isoform 2 of ATP synthase subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=ATP5A1 
sp|P25705-2|ATPA_HUMAN (+1) 6.04E+04 54 kDa 39 kDa 
Isoform 2 of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3 
OS=Homo sapiens GN=PFKFB3 
sp|Q16875-2|F263_HUMAN (+6) 5.80E+04 59 kDa 39 kDa 
AMME syndrome candidate gene 1 
protein OS=Homo sapiens 
GN=AMMECR1 PE=1 SV=1 
sp|Q9Y4X0|AMMR1_HUMAN 5.56E+04 35 kDa 39 kDa 
Isoform 2 of DNA replication licensing 
factor MCM3 OS=Homo sapiens 
GN=MCM3 
sp|P25205-2|MCM3_HUMAN (+1) 5.46E+04 96 kDa 39 kDa 
Isoform C1 of Heterogeneous nuclear 
ribonucleoproteins C1/C2 OS=Homo 
sapiens GN=HNRNPC 
sp|P07910-2|HNRPC_HUMAN (+8) 4.65E+04 32 kDa 39 kDa 
Lupus La protein OS=Homo sapiens 
GN=SSB PE=1 SV=2 







Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
sp|P19338|NUCL_HUMAN (+1) 4.46E+04 77 kDa 39 kDa 
Protein KTI12 homolog OS=Homo 
sapiens GN=KTI12 PE=1 SV=1 
sp|Q96EK9|KTI12_HUMAN 4.42E+04 39 kDa 39 kDa 
Isoform 2 of Multifunctional protein ADE2 
OS=Homo sapiens GN=PAICS 
sp|P22234-2|PUR6_HUMAN (+2) 4.11E+04 48 kDa 39 kDa 
T-complex protein 1 subunit beta 
OS=Homo sapiens GN=CCT2 PE=1 
SV=4 
sp|P78371|TCPB_HUMAN (+2) 3.95E+04 57 kDa 39 kDa 
Isoform 2 of Septin-7 OS=Homo sapiens 
GN=SEPT7 
sp|Q16181-2|SEPT7_HUMAN (+5) 3.46E+04 51 kDa 39 kDa 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
sp|P49411|EFTU_HUMAN 2.06E+04 50 kDa 39 kDa 
Isoform 2 of Polypeptide N-
acetylgalactosaminyltransferase 2 
OS=Homo sapiens GN=GALNT2 
sp|Q10471-2|GALT2_HUMAN (+1) 2.00E+04 30 kDa 39 kDa 
Isoform 1 of Growth factor receptor-
bound protein 10 OS=Homo sapiens 
GN=GRB10 
sp|Q13322-2|GRB10_HUMAN (+3) 1.49E+04 62 kDa 39 kDa 
Isoform 2 of DnaJ homolog subfamily B 
member 1 OS=Homo sapiens 
GN=DNAJB1 
sp|P25685-2|DNJB1_HUMAN (+1) 1.06E+04 27 kDa 39 kDa 
DDB1- and CUL4-associated factor 13 
OS=Homo sapiens GN=DCAF13 PE=1 
SV=2 
sp|Q9NV06|DCA13_HUMAN (+1) 6180 51 kDa 39 kDa 
Isoform 2 of Sentrin-specific protease 6 
OS=Homo sapiens GN=SENP6 











Table 8.  Proteins identified in band 8 from HEK293T cells 




sapiens GN=UGT8 PE=2 SV=2 
sp|Q16880|CGT_HUMAN 1.55E+06 61 kDa 54 kDa 
Lariat debranching enzyme OS=Homo 
sapiens GN=DBR1 PE=1 SV=2 
sp|Q9UK59|DBR1_HUMAN 1.16E+06 62 kDa 54 kDa 
F-box-like/WD repeat-containing 
protein TBL1XR1 OS=Homo sapiens 
GN=TBL1XR1 PE=1 SV=1 
sp|Q9BZK7|TBL1R_HUMAN 1.00E+06 56 kDa 54 kDa 
Isoform 2 of Creatine kinase U-type, 
mitochondrial OS=Homo sapiens 
GN=CKMT1A 
sp|P12532-2|KCRU_HUMAN (+1) 8.59E+05 50 kDa 54 kDa 
Isoform 2 of Replication initiator 1 
OS=Homo sapiens GN=REPIN1 
sp|Q9BWE0-4|REPI1_HUMAN (+3) 8.18E+05 70 kDa 54 kDa 
Zinc finger protein ZIC 2 OS=Homo 
sapiens GN=ZIC2 PE=1 SV=2 
sp|O95409|ZIC2_HUMAN (+1) 7.29E+05 55 kDa 54 kDa 
Isoform 2 of Adenylosuccinate lyase 
OS=Homo sapiens GN=ADSL 
sp|P30566-2|PUR8_HUMAN (+1) 6.93E+05 48 kDa 54 kDa 
Cluster of Pyrroline-5-carboxylate 
reductase 2 OS=Homo sapiens 
GN=PYCR2 PE=1 SV=1 
(sp|Q96C36|P5CR2_HUMAN) 
sp|Q96C36|P5CR2_HUMAN 6.04E+05 34 kDa 54 kDa 
Cluster of Isoform 2 of Transducin-like 
enhancer protein 3 OS=Homo sapiens 
GN=TLE3 (sp|Q04726-
2|TLE3_HUMAN) 
sp|Q04726-2|TLE3_HUMAN [9] 5.83E+05 82 kDa 54 kDa 
Coronin-1B OS=Homo sapiens 
GN=CORO1B PE=1 SV=1 







Isoform 2 of H/ACA ribonucleoprotein 
complex non-core subunit NAF1 
OS=Homo sapiens GN=NAF1 
sp|Q96HR8-2|NAF1_HUMAN (+1) 3.95E+05 42 kDa 54 kDa 
Desmoglein-1 OS=Homo sapiens 
GN=DSG1 PE=1 SV=2 
sp|Q02413|DSG1_HUMAN 3.94E+05 114 
kDa 
54 kDa 
LanC-like protein 2 OS=Homo sapiens 
GN=LANCL2 PE=1 SV=1 
sp|Q9NS86|LANC2_HUMAN 3.87E+05 51 kDa 54 kDa 
Isoform 2 of Myc proto-oncogene 
protein OS=Homo sapiens GN=MYC 
sp|P01106-2|MYC_HUMAN (+3) 3.13E+05 51 kDa 54 kDa 
Suppressor of fused homolog 
OS=Homo sapiens GN=SUFU PE=1 
SV=2 
sp|Q9UMX1|SUFU_HUMAN 2.89E+05 54 kDa 54 kDa 
Isoform 2 of Dynactin subunit 4 
OS=Homo sapiens GN=DCTN4 
sp|Q9UJW0-2|DCTN4_HUMAN (+2) 2.82E+05 46 kDa 54 kDa 
Myotubularin-related protein 9 
OS=Homo sapiens GN=MTMR9 PE=1 
SV=1 
sp|Q96QG7|MTMR9_HUMAN 2.58E+05 63 kDa 54 kDa 
Isoform 3 of Src substrate cortactin 
OS=Homo sapiens GN=CTTN 
sp|Q14247-3|SRC8_HUMAN (+1) 2.28E+05 57 kDa 54 kDa 
Microfibrillar-associated protein 1 
OS=Homo sapiens GN=MFAP1 PE=1 
SV=2 
sp|P55081|MFAP1_HUMAN 2.11E+05 52 kDa 54 kDa 
Isoform 1 of Rab-3A-interacting protein 
OS=Homo sapiens GN=RAB3IP 
sp|Q96QF0-2|RAB3I_HUMAN (+2) 1.84E+05 51 kDa 54 kDa 
Isoform 2 of Signal recognition particle 
54 kDa protein OS=Homo sapiens 
GN=SRP54 
sp|P61011-2|SRP54_HUMAN (+2) 1.78E+05 50 kDa 54 kDa 
Isoform 2 of Bifunctional arginine 
demethylase and lysyl-hydroxylase 
JMJD6 OS=Homo sapiens GN=JMJD6 







Isoform 2 of Nucleolar and spindle-
associated protein 1 OS=Homo 
sapiens GN=NUSAP1 
sp|Q9BXS6-2|NUSAP_HUMAN (+6) 1.50E+05 49 kDa 54 kDa 
Probable asparagine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=NARS2 PE=1 SV=3 
sp|Q96I59|SYNM_HUMAN 1.48E+05 54 kDa 54 kDa 
7SK snRNA methylphosphate capping 
enzyme OS=Homo sapiens 
GN=MEPCE PE=1 SV=1 
sp|Q7L2J0|MEPCE_HUMAN 1.46E+05 74 kDa 54 kDa 
DNA primase large subunit OS=Homo 
sapiens GN=PRIM2 PE=1 SV=2 
sp|P49643|PRI2_HUMAN 1.29E+05 59 kDa 54 kDa 
Isoform 2 of U4/U6.U5 tri-snRNP-
associated protein 2 OS=Homo 
sapiens GN=USP39 
sp|Q53GS9-2|SNUT2_HUMAN (+4) 1.08E+05 54 kDa 54 kDa 
Isoform 2 of Protein SMG8 OS=Homo 
sapiens GN=SMG8 
sp|Q8ND04-2|SMG8_HUMAN (+1) 7.63E+04 113 
kDa 
54 kDa 
Parafibromin OS=Homo sapiens 
GN=CDC73 PE=1 SV=1 
sp|Q6P1J9|CDC73_HUMAN 7.00E+04 61 kDa 54 kDa 
Isoform 2 of Brain-specific 
angiogenesis inhibitor 1-associated 
protein 2 OS=Homo sapiens 
GN=BAIAP2 
sp|Q9UQB8-2|BAIP2_HUMAN (+7) 6.87E+04 59 kDa 54 kDa 
Isoform 2 of Myotubularin-related 
protein 12 OS=Homo sapiens 
GN=MTMR12 
sp|Q9C0I1-2|MTMRC_HUMAN (+2) 5.16E+04 80 kDa 54 kDa 
Suprabasin OS=Homo sapiens 
GN=SBSN PE=1 SV=2 
sp|Q6UWP8|SBSN_HUMAN 3.76E+04 61 kDa 54 kDa 
Isoform 3 of RNA polymerase II-
associated factor 1 homolog OS=Homo 
sapiens GN=PAF1 







Isoform DPII of Desmoplakin 
OS=Homo sapiens GN=DSP 
sp|P15924-2|DESP_HUMAN (+2) 1.62E+04 260 
kDa 
54 kDa 
Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 




































Table 9.  Proteins identified in band 1 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Isoform 2 of Nucleophosmin OS=Homo 
sapiens GN=NPM1 
sp|P06748-2|NPM_HUMAN (+2) 4.15E+06 29 kDa 17 kDa 
40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 
sp|P62269|RS18_HUMAN 9.80E+05 18 kDa 17 kDa 
Casein kinase II subunit alpha OS=Homo 
sapiens GN=CSNK2A1 PE=1 SV=1 
sp|P68400|CSK21_HUMAN (+3) 4.65E+05 45 kDa 17 kDa 
Nucleoplasmin-3 OS=Homo sapiens 
GN=NPM3 PE=1 SV=3 
sp|O75607|NPM3_HUMAN 3.75E+05 19 kDa 17 kDa 
Isoform SM-B of Small nuclear 
ribonucleoprotein-associated proteins B 
and B' OS=Homo sapiens GN=SNRPB 
sp|P14678-2|RSMB_HUMAN (+1) 3.50E+05 24 kDa 17 kDa 
60S ribosomal protein L12 OS=Homo 
sapiens GN=RPL12 PE=1 SV=1 
sp|P30050|RL12_HUMAN 2.97E+05 18 kDa 17 kDa 
Isoform 2 of Peptidyl-prolyl cis-trans 
isomerase H OS=Homo sapiens 
GN=PPIH 
sp|O43447-2|PPIH_HUMAN (+2) 1.85E+05 14 kDa 17 kDa 
40S ribosomal protein S15 OS=Homo 
sapiens GN=RPS15 PE=1 SV=2 
sp|P62841|RS15_HUMAN (+7) 1.10E+05 17 kDa 17 kDa 
Isoform 2 of 60S ribosomal protein L18 
OS=Homo sapiens GN=RPL18 
sp|Q07020-2|RL18_HUMAN (+5) 9.76E+04 18 kDa 17 kDa 
Isoform 1 of Growth factor receptor-bound 
protein 10 OS=Homo sapiens 
GN=GRB10 
sp|Q13322-2|GRB10_HUMAN (+3) 6.66E+04 62 kDa 17 kDa 
Isoform 2 of DNA-3-methyladenine 
glycosylase OS=Homo sapiens GN=MPG 
sp|P29372-2|3MG_HUMAN (+4) 1.22E+04 32 kDa 17 kDa 
Isoform 2 of Paraspeckle component 1 
OS=Homo sapiens GN=PSPC1 







Isoform 2 of Obg-like ATPase 1 
OS=Homo sapiens GN=OLA1 
sp|Q9NTK5-2|OLA1_HUMAN (+2) 8430 28 kDa 17 kDa 
 
Table 10.  Proteins identified in band 2 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Isoform 2 of Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
OS=Homo sapiens GN=ANP32B 
sp|Q92688-2|AN32B_HUMAN (+1) 5.94E+06 22 kDa 19 kDa 
Nucleoplasmin-3 OS=Homo sapiens 
GN=NPM3 PE=1 SV=3 
sp|O75607|NPM3_HUMAN 1.98E+06 19 kDa 19 kDa 
Isoform 2 of U1 small nuclear 
ribonucleoprotein 70 kDa OS=Homo 
sapiens GN=SNRNP70 
sp|P08621-2|RU17_HUMAN (+1) 6.30E+05 51 kDa 19 kDa 
Ankyrin-repeat protein B OS=Legionella 
pneumophila GN=ankB PE=4 SV=1 
tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN 4.42E+05 20 kDa 19 kDa 
Isoform 2 of Malignant T-cell-amplified 
sequence 1 OS=Homo sapiens 
GN=MCTS1 
sp|Q9ULC4-2|MCTS1_HUMAN (+2) 2.88E+05 19 kDa 19 kDa 
Isoform 2 of 60S ribosomal protein L18 
OS=Homo sapiens GN=RPL18 
sp|Q07020-2|RL18_HUMAN (+5) 1.09E+05 18 kDa 19 kDa 
Protein SETSIP OS=Homo sapiens 
GN=SETSIP PE=1 SV=1 
sp|P0DME0|SETLP_HUMAN (+6) 9.91E+04 35 kDa 19 kDa 
Isoform 2 of ELAV-like protein 1 
OS=Homo sapiens GN=ELAVL1 
sp|Q15717-2|ELAV1_HUMAN 9.07E+04 39 kDa 19 kDa 
Isoform 2 of DNA replication licensing 
factor MCM3 OS=Homo sapiens 
GN=MCM3 







Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
sp|P49411|EFTU_HUMAN 6.94E+04 50 kDa 19 kDa 
Isoform 2 of E3 ubiquitin-protein ligase 
Hakai OS=Homo sapiens GN=CBLL1 
sp|Q75N03-2|HAKAI_HUMAN (+1) 4.37E+04 54 kDa 19 kDa 
Mitochondrial assembly of ribosomal 
large subunit protein 1 OS=Homo 
sapiens GN=MALSU1 PE=1 SV=1 
sp|Q96EH3|MASU1_HUMAN 3.74E+04 26 kDa 19 kDa 
Casein kinase II subunit beta OS=Homo 
sapiens GN=CSNK2B PE=1 SV=1 
sp|P67870|CSK2B_HUMAN (+2) 3.25E+04 25 kDa 19 kDa 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
sp|P19338|NUCL_HUMAN 2.64E+04 77 kDa 19 kDa 
Pre-mRNA-splicing factor ATP-
dependent RNA helicase DHX15 
OS=Homo sapiens GN=DHX15 PE=1 
SV=2 
sp|O43143|DHX15_HUMAN 2.52E+04 91 kDa 19 kDa 
Zinc finger and BTB domain-containing 
protein 45 OS=Homo sapiens 
GN=ZBTB45 PE=2 SV=1 
sp|Q96K62|ZBT45_HUMAN 2.07E+04 54 kDa 19 kDa 
Mothers against decapentaplegic 
homolog 3 OS=Homo sapiens 
GN=SMAD3 PE=1 SV=1 
sp|P84022|SMAD3_HUMAN 1.63E+04 48 kDa 19 kDa 
Isoform 2 of RNA-binding protein 26 
OS=Homo sapiens GN=RBM26 













Table 11.  Proteins identified in band 3 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Casein kinase II subunit beta OS=Homo 
sapiens GN=CSNK2B PE=1 SV=1 
sp|P67870|CSK2B_HUMAN (+2) 7.17E+05 25 kDa 25 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein A3 OS=Homo sapiens 
GN=HNRNPA3 
sp|P51991-2|ROA3_HUMAN (+1) 3.94E+05 37 kDa 25 kDa 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
sp|P08865|RSSA_HUMAN (+2) 3.85E+05 33 kDa 25 kDa 
Protein SETSIP OS=Homo sapiens 
GN=SETSIP PE=1 SV=1 
sp|P0DME0|SETLP_HUMAN (+6) 2.25E+05 35 kDa 25 kDa 
Cluster of Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 PE=1 
SV=4 (sp|P02533|K1C14_HUMAN) 
sp|P02533|K1C14_HUMAN 1.82E+05 52 kDa 25 kDa 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
sp|P19338|NUCL_HUMAN (+1) 1.56E+05 77 kDa 25 kDa 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
sp|P49411|EFTU_HUMAN 9.69E+04 50 kDa 25 kDa 
Lupus La protein OS=Homo sapiens 
GN=SSB PE=1 SV=2 
sp|P05455|LA_HUMAN (+2) 8.48E+04 47 kDa 25 kDa 
Proteasome subunit alpha type-5 
OS=Homo sapiens GN=PSMA5 PE=1 
SV=3 
sp|P28066|PSA5_HUMAN 7.78E+04 26 kDa 25 kDa 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 







Isoform A1-A of Heterogeneous nuclear 
ribonucleoprotein A1 OS=Homo sapiens 
GN=HNRNPA1 
sp|P09651-2|ROA1_HUMAN (+4) 7.26E+04 34 kDa 25 kDa 
Splicing factor U2AF 35 kDa subunit-like 
protein OS=Homo sapiens 
GN=U2AF1L5 PE=3 SV=1 
sp|P0DN76|U2AF5_HUMAN 3.81E+04 28 kDa 25 kDa 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 OS=Homo sapiens 
GN=SLC9A3R1 PE=1 SV=4 
sp|O14745|NHRF1_HUMAN (+1) 1.37E+04 39 kDa 25 kDa 
sp|DHE3_BOVIN| sp|DHE3_BOVIN| (+3) 9410 62 kDa 25 kDa 
Isoform 2 of DNA replication licensing 
factor MCM3 OS=Homo sapiens 
GN=MCM3 
sp|P25205-2|MCM3_HUMAN (+2) 0 96 kDa 25 kDa 
 
Table 12.  Proteins identified in band 4 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Cluster of Protein SET OS=Homo sapiens 
GN=SET PE=1 SV=3 
(sp|Q01105|SET_HUMAN) 
sp|Q01105|SET_HUMAN [2] 1.65E+07 33 kDa 34 kDa 
Casein kinase II subunit alpha OS=Homo 
sapiens GN=CSNK2A1 PE=1 SV=1 
sp|P68400|CSK21_HUMAN (+3) 1.53E+06 45 kDa 34 kDa 
Cluster of Isoform 2 of Nucleosome 
assembly protein 1-like 1 OS=Homo 
sapiens GN=NAP1L1 (sp|P55209-
2|NP1L1_HUMAN) 
sp|P55209-2|NP1L1_HUMAN [11] 1.48E+06 43 kDa 34 kDa 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
sp|P08865|RSSA_HUMAN (+2) 7.86E+05 33 kDa 34 kDa 
Casein kinase II subunit alpha' OS=Homo 
sapiens GN=CSNK2A2 PE=1 SV=1 







Isoform 2 of Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo sapiens 
GN=GAPDH 
sp|P04406-2|G3P_HUMAN (+2) 3.68E+05 32 kDa 34 kDa 
Eukaryotic translation initiation factor 2 
subunit 1 OS=Homo sapiens GN=EIF2S1 
PE=1 SV=3 
sp|P05198|IF2A_HUMAN 3.64E+05 36 kDa 34 kDa 
Isoform 2 of Transducin-like enhancer 
protein 3 OS=Homo sapiens GN=TLE3 
sp|Q04726-2|TLE3_HUMAN (+11) 2.72E+05 82 kDa 34 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein R OS=Homo sapiens 
GN=HNRNPR 
sp|O43390-2|HNRPR_HUMAN (+2) 2.47E+05 71 kDa 34 kDa 
WD repeat-containing protein 5 
OS=Homo sapiens GN=WDR5 PE=1 
SV=1 
sp|P61964|WDR5_HUMAN 1.39E+05 37 kDa 34 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein Q OS=Homo sapiens 
GN=SYNCRIP 
sp|O60506-2|HNRPQ_HUMAN (+4) 1.38E+05 66 kDa 34 kDa 
Obg-like ATPase 1 OS=Homo sapiens 
GN=OLA1 PE=1 SV=2 
sp|Q9NTK5|OLA1_HUMAN (+1) 8.51E+04 45 kDa 34 kDa 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
sp|P19338|NUCL_HUMAN 8.07E+04 77 kDa 34 kDa 
X-ray repair cross-complementing protein 
6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 
sp|P12956|XRCC6_HUMAN 5.33E+04 70 kDa 34 kDa 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 
sp|P54577|SYYC_HUMAN (+1) 3.94E+04 59 kDa 34 kDa 
Beta-adrenergic receptor kinase 1 
OS=Homo sapiens GN=ADRBK1 PE=1 
SV=2 







Cluster of Beta-actin-like protein 2 
OS=Homo sapiens GN=ACTBL2 PE=1 
SV=2 (sp|Q562R1|ACTBL_HUMAN) 
sp|Q562R1|ACTBL_HUMAN [2] 3.33E+04 42 kDa 34 kDa 
Isoform 2 of Arf-GAP with GTPase, ANK 
repeat and PH domain-containing protein 
2 OS=Homo sapiens GN=AGAP2 
sp|Q99490-2|AGAP2_HUMAN (+3) 2.32E+04 91 kDa 34 kDa 
Cluster of Casein kinase I isoform 
gamma-2 OS=Homo sapiens 
GN=CSNK1G2 PE=1 SV=1 
(sp|P78368|KC1G2_HUMAN) 
sp|P78368|KC1G2_HUMAN 2.23E+04 47 kDa 34 kDa 
DNA replication licensing factor MCM5 
OS=Homo sapiens GN=MCM5 PE=1 
SV=5 
sp|P33992|MCM5_HUMAN (+1) 1.62E+04 82 kDa 34 kDa 
Isoform 3 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma 
OS=Homo sapiens GN=PIP4K2C 
sp|Q8TBX8-3|PI42C_HUMAN (+1) 1.16E+04 45 kDa 34 kDa 
Isoform 2 of Splicing factor 1 OS=Homo 
sapiens GN=SF1 
sp|Q15637-2|SF01_HUMAN (+6) 1.09E+04 69 kDa 34 kDa 
Isoform 2 of Exosome component 10 
OS=Homo sapiens GN=EXOSC10 
sp|Q01780-2|EXOSX_HUMAN (+1) 7480 98 kDa 34 kDa 
Isoform 2 of Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 1 
OS=Homo sapiens GN=INPP5D 
sp|Q92835-2|SHIP1_HUMAN (+3) 5880 133 kDa 34 kDa 
RNA-binding protein 33 OS=Homo 
sapiens GN=RBM33 PE=1 SV=3 












Table 13.  Proteins identified in band 5.1 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Cluster of Protein SET OS=Homo sapiens 
GN=SET PE=1 SV=3 
(sp|Q01105|SET_HUMAN) 
sp|Q01105|SET_HUMAN [2] 2.05E+07 33 kDa 35 kDa 
Casein kinase II subunit alpha OS=Homo 
sapiens GN=CSNK2A1 PE=1 SV=1 
sp|P68400|CSK21_HUMAN (+3) 6.46E+06 45 kDa 35 kDa 
Casein kinase II subunit alpha' OS=Homo 
sapiens GN=CSNK2A2 PE=1 SV=1 
sp|P19784|CSK22_HUMAN 2.75E+06 41 kDa 35 kDa 
Isoform 2 of Nucleosome assembly 
protein 1-like 1 OS=Homo sapiens 
GN=NAP1L1 
sp|P55209-2|NP1L1_HUMAN (+13) 1.19E+06 43 kDa 35 kDa 
Cluster of Isoform 2 of Heterogeneous 
nuclear ribonucleoprotein R OS=Homo 
sapiens GN=HNRNPR (sp|O43390-
2|HNRPR_HUMAN) 
sp|O43390-2|HNRPR_HUMAN [3] 4.83E+05 71 kDa 35 kDa 
Ankyrin-repeat protein B OS=Legionella 
pneumophila GN=ankB PE=4 SV=1 
tr|A0A0A1EKG7|A0A0A1EKG7_LEGPN 4.33E+05 20 kDa 35 kDa 
Eukaryotic translation initiation factor 2 
subunit 1 OS=Homo sapiens GN=EIF2S1 
PE=1 SV=3 
sp|P05198|IF2A_HUMAN 4.02E+05 36 kDa 35 kDa 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
sp|P08865|RSSA_HUMAN (+3) 3.37E+05 33 kDa 35 kDa 
Isoform 2 of Nucleosome assembly 
protein 1-like 4 OS=Homo sapiens 
GN=NAP1L4 
sp|Q99733-2|NP1L4_HUMAN (+5) 3.23E+05 44 kDa 35 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein L OS=Homo sapiens 
GN=HNRNPL 







Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
sp|P49411|EFTU_HUMAN 2.31E+05 50 kDa 35 kDa 
LanC-like protein 2 OS=Homo sapiens 
GN=LANCL2 PE=1 SV=1 
sp|Q9NS86|LANC2_HUMAN 1.73E+05 51 kDa 35 kDa 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 
sp|P54577|SYYC_HUMAN 1.64E+05 59 kDa 35 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein D0 OS=Homo sapiens 
GN=HNRNPD 
sp|Q14103-2|HNRPD_HUMAN (+7) 1.52E+05 36 kDa 35 kDa 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 
sp|P19338|NUCL_HUMAN 1.11E+05 77 kDa 35 kDa 
DDB1- and CUL4-associated factor 7 
OS=Homo sapiens GN=DCAF7 PE=1 
SV=1 
sp|P61962|DCAF7_HUMAN 1.10E+05 39 kDa 35 kDa 
Phosphatidylinositol 5-phosphate 4-kinase 
type-2 beta OS=Homo sapiens 
GN=PIP4K2B PE=1 SV=1 
sp|P78356|PI42B_HUMAN 1.08E+05 47 kDa 35 kDa 
Isoform 2 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 alpha 
OS=Homo sapiens GN=PIP4K2A 
sp|P48426-2|PI42A_HUMAN (+1) 9.98E+04 40 kDa 35 kDa 
Casein kinase I isoform gamma-2 
OS=Homo sapiens GN=CSNK1G2 PE=1 
SV=1 
sp|P78368|KC1G2_HUMAN 9.57E+04 47 kDa 35 kDa 
Obg-like ATPase 1 OS=Homo sapiens 
GN=OLA1 PE=1 SV=2 
sp|Q9NTK5|OLA1_HUMAN (+1) 8.26E+04 45 kDa 35 kDa 
Isoform 2 of Methylmalonate-
semialdehyde dehydrogenase [acylating], 







mitochondrial OS=Homo sapiens 
GN=ALDH6A1 
DNA replication licensing factor MCM5 
OS=Homo sapiens GN=MCM5 PE=1 
SV=5 
sp|P33992|MCM5_HUMAN (+1) 5.73E+04 82 kDa 35 kDa 
Probable asparagine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=NARS2 PE=1 SV=3 
sp|Q96I59|SYNM_HUMAN 5.05E+04 54 kDa 35 kDa 
Eukaryotic translation initiation factor 5B 
OS=Homo sapiens GN=EIF5B PE=1 
SV=4 
sp|O60841|IF2P_HUMAN (+1) 3.92E+04 139 kDa 35 kDa 
Isoform 2 of Homer protein homolog 3 
OS=Homo sapiens GN=HOMER3 
sp|Q9NSC5-2|HOME3_HUMAN (+3) 2.56E+04 39 kDa 35 kDa 
Isoform 2 of Splicing factor 1 OS=Homo 
sapiens GN=SF1 
sp|Q15637-2|SF01_HUMAN (+6) 1.73E+04 69 kDa 35 kDa 
Mothers against decapentaplegic 
homolog 4 OS=Homo sapiens 
GN=SMAD4 PE=1 SV=1 
sp|Q13485|SMAD4_HUMAN (+1) 1.53E+04 60 kDa 35 kDa 
Isoform 3 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma 
OS=Homo sapiens GN=PIP4K2C 
sp|Q8TBX8-3|PI42C_HUMAN (+1) 1.48E+04 45 kDa 35 kDa 
X-ray repair cross-complementing protein 
6 OS=Homo sapiens GN=XRCC6 PE=1 
SV=2 
sp|P12956|XRCC6_HUMAN (+1) 1.10E+04 70 kDa 35 kDa 
E3 ubiquitin-protein ligase CBL OS=Homo 
sapiens GN=CBL PE=1 SV=2 









Table 14.  Proteins identified in band 5.2 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Cluster of Protein SET OS=Homo sapiens 
GN=SET PE=1 SV=3 
(sp|Q01105|SET_HUMAN) 
sp|Q01105|SET_HUMAN [2] 1.74E+07 33 kDa 37 kDa 
Putative RNA-binding protein Luc7-like 2 
OS=Homo sapiens GN=LUC7L2 PE=1 
SV=2 
sp|Q9Y383|LC7L2_HUMAN 9.32E+06 47 kDa 37 kDa 
Elongation factor 1-alpha 1 OS=Homo 
sapiens GN=EEF1A1 PE=1 SV=1 
sp|P68104|EF1A1_HUMAN (+1) 7.53E+06 50 kDa 37 kDa 
sp|TRYP_PIG| sp|TRYP_PIG| 6.08E+06 24 kDa 37 kDa 
Cluster of Isoform 2 of Nucleosome 
assembly protein 1-like 1 OS=Homo 
sapiens GN=NAP1L1 (sp|P55209-
2|NP1L1_HUMAN) 
sp|P55209-2|NP1L1_HUMAN [11] 2.22E+06 43 kDa 37 kDa 
sp|K1C9_HUMAN| sp|K1C9_HUMAN| (+1) 1.98E+06 62 kDa 37 kDa 
Casein kinase II subunit alpha OS=Homo 
sapiens GN=CSNK2A1 PE=1 SV=1 
sp|P68400|CSK21_HUMAN (+3) 1.73E+06 45 kDa 37 kDa 
Non-POU domain-containing octamer-
binding protein OS=Homo sapiens 
GN=NONO PE=1 SV=4 
sp|Q15233|NONO_HUMAN 1.09E+06 54 kDa 37 kDa 
Splicing factor 3A subunit 1 OS=Homo 
sapiens GN=SF3A1 PE=1 SV=1 
sp|Q15459|SF3A1_HUMAN 6.26E+05 89 kDa 37 kDa 
Isoform Short of Splicing factor, proline- 
and glutamine-rich OS=Homo sapiens 
GN=SFPQ 
sp|P23246-2|SFPQ_HUMAN (+1) 5.98E+05 72 kDa 37 kDa 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1 OS=Homo sapiens 
GN=SLC9A3R1 PE=1 SV=4 







Glutamate dehydrogenase 1, 
mitochondrial OS=Homo sapiens 
GN=GLUD1 PE=1 SV=2 
sp|P00367|DHE3_HUMAN 3.60E+05 61 kDa 37 kDa 
40S ribosomal protein SA OS=Homo 
sapiens GN=RPSA PE=1 SV=4 
sp|P08865|RSSA_HUMAN (+2) 2.92E+05 33 kDa 37 kDa 
Isoform 2 of Methylmalonate-
semialdehyde dehydrogenase [acylating], 
mitochondrial OS=Homo sapiens 
GN=ALDH6A1 
sp|Q02252-2|MMSA_HUMAN (+1) 2.24E+05 56 kDa 37 kDa 
Chitinase-3-like protein 1 OS=Homo 
sapiens GN=CHI3L1 PE=1 SV=2 
sp|P36222|CH3L1_HUMAN 2.12E+05 43 kDa 37 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein D0 OS=Homo sapiens 
GN=HNRNPD 
sp|Q14103-2|HNRPD_HUMAN (+7) 2.02E+05 36 kDa 37 kDa 
Fructose-bisphosphate aldolase A 
OS=Homo sapiens GN=ALDOA PE=1 
SV=2 
sp|P04075|ALDOA_HUMAN (+2) 1.65E+05 39 kDa 37 kDa 
Isoform 2 of Isovaleryl-CoA 
dehydrogenase, mitochondrial OS=Homo 
sapiens GN=IVD 
sp|P26440-2|IVD_HUMAN (+2) 9.23E+04 43 kDa 37 kDa 
DNA replication licensing factor MCM5 
OS=Homo sapiens GN=MCM5 PE=1 
SV=5 
sp|P33992|MCM5_HUMAN (+1) 9.15E+04 82 kDa 37 kDa 
Elongation factor Tu, mitochondrial 
OS=Homo sapiens GN=TUFM PE=1 
SV=2 
sp|P49411|EFTU_HUMAN 9.06E+04 50 kDa 37 kDa 
Isoform 2 of Mitotic checkpoint protein 
BUB3 OS=Homo sapiens GN=BUB3 
sp|O43684-2|BUB3_HUMAN (+2) 8.85E+04 37 kDa 37 kDa 
Nucleolin OS=Homo sapiens GN=NCL 
PE=1 SV=3 







NAD-dependent malic enzyme, 
mitochondrial OS=Homo sapiens 
GN=ME2 PE=1 SV=1 
sp|P23368|MAOM_HUMAN 6.84E+04 65 kDa 37 kDa 
Obg-like ATPase 1 OS=Homo sapiens 
GN=OLA1 PE=1 SV=2 
sp|Q9NTK5|OLA1_HUMAN (+1) 6.35E+04 45 kDa 37 kDa 
Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 
sp|P60709|ACTB_HUMAN (+1) 6.01E+04 42 kDa 37 kDa 
Isoform 1 of Growth arrest-specific protein 
7 OS=Homo sapiens GN=GAS7 
sp|O60861-1|GAS7_HUMAN (+2) 5.74E+04 47 kDa 37 kDa 
Isoform MBP-1 of Alpha-enolase 
OS=Homo sapiens GN=ENO1 
sp|P06733-2|ENOA_HUMAN (+1) 5.69E+04 37 kDa 37 kDa 
LanC-like protein 1 OS=Homo sapiens 
GN=LANCL1 PE=1 SV=1 
sp|O43813|LANC1_HUMAN (+1) 5.57E+04 45 kDa 37 kDa 
LanC-like protein 2 OS=Homo sapiens 
GN=LANCL2 PE=1 SV=1 
sp|Q9NS86|LANC2_HUMAN 5.29E+04 51 kDa 37 kDa 
Isoform 10 of Abl interactor 1 OS=Homo 
sapiens GN=ABI1 
sp|Q8IZP0-10|ABI1_HUMAN (+12) 5.20E+04 43 kDa 37 kDa 
Isoform 2 of NAD kinase OS=Homo 
sapiens GN=NADK 
sp|O95544-2|NADK_HUMAN (+3) 4.89E+04 63 kDa 37 kDa 
Probable asparagine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=NARS2 PE=1 SV=3 
sp|Q96I59|SYNM_HUMAN 4.70E+04 54 kDa 37 kDa 
Isoform 2 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 alpha 
OS=Homo sapiens GN=PIP4K2A 
sp|P48426-2|PI42A_HUMAN (+1) 4.59E+04 40 kDa 37 kDa 
Isoform 2 of Interferon regulatory factor 2-
binding protein 2 OS=Homo sapiens 
GN=IRF2BP2 







U3 small nucleolar RNA-associated 
protein 18 homolog OS=Homo sapiens 
GN=UTP18 PE=1 SV=3 
sp|Q9Y5J1|UTP18_HUMAN 3.96E+04 62 kDa 37 kDa 
DNA polymerase beta OS=Homo sapiens 
GN=POLB PE=1 SV=3 
sp|P06746|DPOLB_HUMAN (+2) 3.94E+04 38 kDa 37 kDa 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 
sp|P54577|SYYC_HUMAN (+1) 2.53E+04 59 kDa 37 kDa 
Beta-adrenergic receptor kinase 1 
OS=Homo sapiens GN=ADRBK1 PE=1 
SV=2 
sp|P25098|ARBK1_HUMAN 2.48E+04 80 kDa 37 kDa 
Isoform 3 of Bifunctional lysine-specific 
demethylase and histidyl-hydroxylase 
MINA OS=Homo sapiens GN=MINA 
sp|Q8IUF8-3|MINA_HUMAN (+1) 2.09E+04 24 kDa 37 kDa 
Tyrosyl-DNA phosphodiesterase 1 
OS=Homo sapiens GN=TDP1 PE=1 
SV=2 
sp|Q9NUW8|TYDP1_HUMAN (+2) 1.89E+04 68 kDa 37 kDa 
Paired amphipathic helix protein Sin3a 
OS=Homo sapiens GN=SIN3A PE=1 
SV=2 
sp|Q96ST3|SIN3A_HUMAN (+1) 1.88E+04 145 
kDa 
37 kDa 
Isoform 2 of Septin-2 OS=Homo sapiens 
GN=SEPT2 
sp|Q15019-2|SEPT2_HUMAN (+3) 9780 45 kDa 37 kDa 
Phosphatidylinositol 5-phosphate 4-
kinase type-2 beta OS=Homo sapiens 
GN=PIP4K2B PE=1 SV=1 












Table 15.  Proteins identified in band 6 from U937 cells 
Protein Name Accession Norm iBAQ MW MW on 
gel 
Protein SET OS=Homo sapiens GN=SET 
PE=1 SV=3 
sp|Q01105|SET_HUMAN 1.42E+07 33 kDa 43 kDa 
Isoform 2 of Cleavage and 
polyadenylation specificity factor subunit 
6 OS=Homo sapiens GN=CPSF6 
sp|Q16630-2|CPSF6_HUMAN (+3) 3.14E+06 63 kDa 43 kDa 
Isoform 2 of Nucleosome assembly 
protein 1-like 1 OS=Homo sapiens 
GN=NAP1L1 
sp|P55209-2|NP1L1_HUMAN (+10) 2.99E+06 43 kDa 43 kDa 
Cluster of Nucleolin OS=Homo sapiens 
GN=NCL PE=1 SV=3 
(sp|P19338|NUCL_HUMAN) 
sp|P19338|NUCL_HUMAN 1.36E+06 77 kDa 43 kDa 
Tyrosine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=YARS PE=1 
SV=4 
sp|P54577|SYYC_HUMAN 1.07E+06 59 kDa 43 kDa 
Isoform 2 of Nucleosome assembly 
protein 1-like 4 OS=Homo sapiens 
GN=NAP1L4 
sp|Q99733-2|NP1L4_HUMAN (+3) 9.00E+05 44 kDa 43 kDa 
Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein L OS=Homo sapiens 
GN=HNRNPL 
sp|P14866-2|HNRPL_HUMAN (+3) 7.06E+05 51 kDa 43 kDa 
Probable cysteine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=CARS2 PE=1 SV=1 
sp|Q9HA77|SYCM_HUMAN 3.95E+05 62 kDa 43 kDa 
Lupus La protein OS=Homo sapiens 
GN=SSB PE=1 SV=2 








mitochondrial OS=Homo sapiens 
GN=FARS2 PE=1 SV=1 
sp|O95363|SYFM_HUMAN 2.75E+05 52 kDa 43 kDa 
Probable asparagine--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=NARS2 PE=1 SV=3 
sp|Q96I59|SYNM_HUMAN 2.39E+05 54 kDa 43 kDa 
Eukaryotic translation initiation factor 5B 
OS=Homo sapiens GN=EIF5B PE=1 
SV=4 
sp|O60841|IF2P_HUMAN (+1) 2.03E+05 139 kDa 43 kDa 
Isoform 2 of Methyltransferase-like 
protein 17, mitochondrial OS=Homo 
sapiens GN=METTL17 
sp|Q9H7H0-2|MET17_HUMAN (+3) 1.86E+05 50 kDa 43 kDa 
Isoform 3 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma 
OS=Homo sapiens GN=PIP4K2C 
sp|Q8TBX8-3|PI42C_HUMAN (+1) 1.85E+05 45 kDa 43 kDa 
E3 ubiquitin-protein ligase CBL 
OS=Homo sapiens GN=CBL PE=1 SV=2 
sp|P22681|CBL_HUMAN (+2) 1.20E+05 100 kDa 43 kDa 
Coiled-coil domain-containing protein 6 
OS=Homo sapiens GN=CCDC6 PE=1 
SV=2 
sp|Q16204|CCDC6_HUMAN 1.15E+05 53 kDa 43 kDa 
Tyrosyl-DNA phosphodiesterase 1 
OS=Homo sapiens GN=TDP1 PE=1 
SV=2 
sp|Q9NUW8|TYDP1_HUMAN (+2) 1.03E+05 68 kDa 43 kDa 
Isoform 4 of Squamous cell carcinoma 
antigen recognized by T-cells 3 
OS=Homo sapiens GN=SART3 
sp|Q15020-4|SART3_HUMAN (+2) 9.59E+04 106 kDa 43 kDa 
Eukaryotic initiation factor 4A-III 
OS=Homo sapiens GN=EIF4A3 PE=1 
SV=4 







Beta-adrenergic receptor kinase 1 
OS=Homo sapiens GN=ADRBK1 PE=1 
SV=2 
sp|P25098|ARBK1_HUMAN 7.56E+04 80 kDa 43 kDa 
Nucleolar protein 58 OS=Homo sapiens 
GN=NOP58 PE=1 SV=1 
sp|Q9Y2X3|NOP58_HUMAN 7.28E+04 60 kDa 43 kDa 
Isoform 5 of Protein disulfide-isomerase 
A6 OS=Homo sapiens GN=PDIA6 
sp|Q15084-5|PDIA6_HUMAN 4.56E+04 53 kDa 43 kDa 
Coronin-1A OS=Homo sapiens 
GN=CORO1A PE=1 SV=4 
sp|P31146|COR1A_HUMAN (+3) 3.44E+04 51 kDa 43 kDa 
Endoplasmic reticulum resident protein 
44 OS=Homo sapiens GN=ERP44 PE=1 
SV=1 
sp|Q9BS26|ERP44_HUMAN 0 47 kDa 43 kDa 
 
Table 16.  Proteins identified in band 8 from U937 cells 
Protein Name Accession Norm 
iBAQ 
MW MW on 
gel 
X-ray repair cross-complementing 
protein 5 OS=Homo sapiens 
GN=XRCC5 PE=1 SV=3 
sp|P13010|XRCC5_HUMAN 6.68E+05 83 kDa 65 kDa 
Aspartate--tRNA ligase, mitochondrial 
OS=Homo sapiens GN=DARS2 PE=1 
SV=1 
sp|Q6PI48|SYDM_HUMAN 2.54E+05 74 kDa 65 kDa 
Replication protein A 70 kDa DNA-
binding subunit OS=Homo sapiens 
GN=RPA1 PE=1 SV=2 
sp|P27694|RFA1_HUMAN 1.01E+05 68 kDa 65 kDa 
Squamous cell carcinoma antigen 
recognized by T-cells 3 OS=Homo 
sapiens GN=SART3 PE=1 SV=1 








containing protein 1 OS=Homo sapiens 
GN=SND1 PE=1 SV=1 
sp|Q7KZF4|SND1_HUMAN 6.43E+04 102 kDa 65 kDa 
X-ray repair cross-complementing 
protein 6 OS=Homo sapiens 
GN=XRCC6 PE=1 SV=2 
sp|P12956|XRCC6_HUMAN (+1) 5.32E+04 70 kDa 65 kDa 
Bromodomain-containing protein 4 
OS=Homo sapiens GN=BRD4 PE=1 
SV=2 
sp|O60885|BRD4_HUMAN 3.72E+04 152 kDa 65 kDa 
Stress-70 protein, mitochondrial 
OS=Homo sapiens GN=HSPA9 PE=1 
SV=2 
sp|P38646|GRP75_HUMAN 2.37E+04 74 kDa 65 kDa 
Asparagine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=NARS PE=1 
SV=1 
sp|O43776|SYNC_HUMAN 1.85E+04 63 kDa 65 kDa 
Ubiquitin-associated protein 2 OS=Homo 
sapiens GN=UBAP2 PE=1 SV=1 








































Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 
Desmoglein-1 114 1 1 
 
2 4 3 
Cluster of Actin, cytoplasmic 1 42 
  
8 
   
Isoform 2 of E3 ubiquitin-protein 
ligase HUWE1  
480 2 7 
    
Alpha-2-macroglobulin  163 12 
     
Complement C3  187 8 
     
Serum albumin  69 5 
 
2 
   









   
Isoform DSPIa of Desmoplakin  279 
    
1 
 
Serotransferrin  77 3 
     
Isoform 2 of Fibrinogen alpha chain  70 2 
     
Isoform 2 of Glyceraldehyde-3-




   
Immunoglobulin kappa constant  12 2 
     
Immunoglobulin heavy constant 
gamma 1  
36 3 
     
Isoform 2 of Haptoglobin  38 1 
     
Isoform 2 of Gelsolin  81 
  
2 
   
Isoform 2 of Immunoglobulin heavy 
constant mu  
52 3 
     
Hemoglobin subunit beta  16 
  
2 
   
Apolipoprotein A-I  31 1 












Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 
Filaggrin-2  248 1      
Isoform H14 of Myeloperoxidase  74   2    
Alpha-enolase  47   1    
Annexin A1  39   2    
Isoform Gamma-A of Fibrinogen 
gamma chain  
49 1      
Fibrinogen beta chain  56 1      
Immunoglobulin lambda-like 
polypeptide  
23 1      
Cluster of Isoform 2 of Semenogelin-
1  
45      1 
Isoform 2 of Transketolase  69   2    
Immunoglobulin heavy constant 
gamma 2  

















Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 
Isoform 2 of E3 ubiquitin-protein 
ligase HUWE1  
480 4 4 12 
   
Ubiquitin-40S ribosomal protein 
S27a  
18 3 8 3 
  
1 
Isoform DSPIa of Desmoplakin  279 
 
7 
    
Desmoglein-1  114 3 5 1 
   
Junction plakoglobin  82 
 
6 
    
Isoform 1B of Desmocollin-1  94 1 3 
    
Isoform 2 of Glyceraldehyde-3-




    
Hornerin  282 
 
2 
    
POTE ankyrin domain family 




    
 




Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 
Isoform 12 of Titin  3816 
   
1 
  
Isoform 2 of Protein piccolo  531 1 




    
Isoform 2 of Methylosome protein 50  30 
    
2 
 
Desmoglein-1  114 














Rep 1 Rep 2 Rep 3 Rep 1 Rep 2 Rep 3 








Ubiquitin-60S ribosomal protein L40  15 3 4 3 1 1 
 
AnkB of L. pneumophila 35 4 6 6 
   




Junction plakoglobin  82 
  
11 
   
Isoform 1B of Desmocollin-1  94 
  
5 
   





    
Isoform 2 of Glyceraldehyde-3-




   
Isoform 1 of Plakophilin-1  80 
  
4 
   
U1 small nuclear ribonucleoprotein A  31 
     
3 
Isoform 2 of Annexin A2  40 
  
2 
   
Corneodesmosin  52 
  
2 
   
Filaggrin-2  248 1 
     
Protein-glutamine gamma-




   
Hornerin  282 
  
2 
   
Isoform 2 of Extracellular matrix 




   
Bleomycin hydrolase  53 
  
1 
   
Isoform 3 of Protein KIAA0100  45 












































2. Divergent evolution of Di-lysine ER retention vs. farnesylation motif 
mediated anchoring of the AnkB virulence effector to the Legionella-
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Houston, TX 
 
2011 – 2012  Oncology Pharmacist 
 Norton Cancer Institute; Louisville, KY 
TEACHING EXPERIENCE _____                                  
1999 – 2001  Teaching Assistant 
Hematology Laboratory for Medical Technology 
undergraduates 
   Medical Technology Program 
   Michigan State University; East Lansing, MI 
 
June-Aug 2000 Teaching Assistant 
   Molecular Biology Laboratory for international scholars 
   Michigan State University; East Lansing, MI 
 
Jan-April 2007 Group Tutor 
   Biochemistry for Doctor of Pharmacy candidates 
   Medical University of South Carolina; Charleston, SC 
 
2014 – 2015  Graduate Teaching Academy 
Participated in nine 2-hour workshops to enhance teaching 
skills 
   University of Louisville; Louisville, KY 
 
2016 - 2017  Guest Lecturer  
Research Methods course for doctoral students 
   Department of Microbiology and Immunology 
   University of Louisville; Louisville, KY 
 
2017 – 2018  Active Learning Sessions 
Developed and facilitated active learning in General 
Microbiology 
   Teaching Innovation Learning Lab (TILL) 




PRESENTATIONS           
 
May 2006  Potentially Inappropriate Prescribing in the Elderly 
Physician In-service. University of Louisville Hospital; 
Louisville, KY  
 
June 2006 Utility of Stimulant Medications in the Surgical Intensive 
Care Unit 
Nursing In-service.   
University of Louisville Hospital; Louisville, KY  
 
August 2006 Use of 90Y-ibritumomab tiuxetan, Zevalin®, in the 
Treatment of Non-Hodgkin’s Lymphoma  
Grand Rounds, Medical University of South Carolina; 
Charleston, SC 
 
August 2006 Quadrivalent Human Papilloma Virus (HPV) Vaccine, 
Gardasil®, for the Prevention of HPV-Associated 
Cancers 
Monograph Presentation to the Pharmacy and Therapeutics 
Committee.  Medical University of South Carolina; 
Charleston, SC  
 
October 2007 Sitagliptin (Januvia®) for Type 2 Diabetes 
Prepared and Presented a Drug Monograph to the 
Pharmacy and Therapeutics Committee, Intermountain 
Health Care, PGY-1 Residency; Salt Lake City, UT 
 
April 2008  Review of Immunology 
Professional development seminar at Intermountain Medical 
Center; 
Salt Lake City, UT 
 
March 2009  Management of bcr-abl+ Leukemias 
ACPE Continuing Education Seminar, M. D. Anderson 
Cancer Center; Houston, TX   
 
2016 – 2018   Host Protein Targets of the AnkB Effector of Legionella  
   pneumophila 
Department of Microbiology and Immunology Seminar 
Series, University of Louisville; Louisville, KY 
